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Abstract;
The aim o f the project was to synthesise a novel small peptide containing an ether 
linkage between two side chains. Computer modelling had shown the structure was 
likely to form a stable p turn in solution and would therefore be a good candidate to 
study this class o f protein secondary structure. To do this a differentially protected 
bis-amino acid containing the ether linkage was retrosynthesised to chiral pool 
synthons L-aspartic acid and L-methionine. Many attempts were then made to 
differentially protect and manipulate the respective acid and sulfide side chains into 
synthons that would participate in Williamson ether synthesis. Techniques explored 
included N-chlorosuccinimide hemithioacetal formation, sulfonium salt displacement, 
bismuth trichloride and silver salt induced etherifications.
Using molecules made during this research we then worked towards making a 
similarly constrained peptide containing a homolanthionine bridge, a thioether 
analogue o f the anti-tryptic reactive site loop o f Bowman Birk Inhibitor, a proteinase 
inhibitor protein.
Chapter 1 contains a review of peptides constrained through bridging o f side chains 
and the effects that this has upon them.
Chapters 2 and 3 outline the synthetic steps that were used in the process of 
synthesising an ether linked bis-amino acid. Subchapter 2.2 shows the synthesis of
3
protected homoserine, a nucleophile for ether reactions. Subchapter 2.3 highlights the 
difficulty in making differentially protected electrophilic amino acids and coupling 
reactions between the two synthons. In chapter 3 the protected electrophilic 
homoserine is coupled with cysteine to make a homolanthionine bridge which is then 
integrated into a short peptide.
Chapter 6 contains the experimental procedures for the reactions carried out and the 
spectral data for isolated compounds.
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1.0 Introduction - Enforcing Protein Secondary Structure In Peptides Through 
Side-Chain Modifications
Protein secondary structure primarily consists of three different motifs, a  helices, p 
sheets and reverse turns1. When they are found within the hydrophobic interiors of 
proteins they act as structure-stabilizing templates and aid in protein folding. Their 
presence within enzyme active sites imparts vast functionality and when present on 
the surfaces o f proteins they play a key role in interacting with RNA, DNA and other 
proteins. The ubiquitous array of roles that these motifs play has sparked a great deal 
of interest in their specific nature2. Protein architecture is too complex to study motifs 
individually and therefore they must be expressed in small molecules and peptides3. 
New techniques for stabilizing short peptide motifs are valuable in drug therapy, 
studying protein folding, modeling proteins, creating artificial proteins, and may aid 
the design o f inhibitors or mimics o f protein function.
The helical structure is dependent on the backbone conformation o f the polypeptide 
chain. The values of torsion angles co, \j/ and <|> are affected by the types of amino 
acids that make up the sequence and the side chains that they possess (Figure l)4.
R-i H O 
Figure 1: The torsion angles co, \|/ and <j> o f a peptide
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Values of <j> = -57° and \j/ = -47° result in the backbone adopting an a  helical structure. 
Hydrogen bonds occur between the carbonyl groups and amide protons that are found 
between one turn of the helix, the i and (i+4) positions, representing 3.6 residues per 
complete turn which stabilise the structure (Figure 2).
Figure 2: The i and (i+4) sites of an a-helix5
Natural a  helices are right-handed because of the chirality of the amino acids and are 
not capable of forming left-handed types. The majority o f helical structures found in
17
proteins are a  helices but there are other types, of these the most notable is the 3io 
helix. This is a more tightly wound helix with hydrogen bonds occurring between the 
i and (i+3) residues and torsion angles of § = -70° and \|/ = -5°.
p turns consist o f a loop o f two to six amino acid residues which link peptide strands 
together6. The most common contain two amino acids in the loop, i+1 and i+2, with 
the i and i+3 residues forming the first hydrogen bond between the strands (Figure 
3)7.
Figure 3: The hydrogen bonding of a (Mura and the i and (i+3) positions
There are many different types of loop known but there are six major categories 
classified by the bond angles co, \j/ and (Figure 4, Table l ) 8.
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HN
y  Peptide
O "
Peptide
Figure 4: Diagram showing the torsion angles important to assign fi-turn type
Table 1: The torsion angles important to assign p-turn type
Turn Type
Dihedral Angle I I’ II II' III nr
<i>i -60 60 -60 60 -60 60
Vi -30 30 120 -120 -30 30
^2 -90 90 80 -80 -60 60
V2 0 0 0 0 -30 -30
p turns are generally found within proteins as reverse turns for antiparallel p sheet 
propagation. Here they act to alternate the direction o f a peptide strand and if  found in 
series can produce antiparallel p sheets. The peptide chains in these motifs run in 
opposite directions a consequence o f this is creation o f a hydrogen bonding network 
between the carbonyl group and amide proton which are found opposite each other 
(Figure 5 & 6)9.
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Peptide Backbone
Figure 5: The build up of an antiparallel p-sheet by p-turns 
u n p w n p w n p
O R H O R H O R H p
Figure 6: Hydrogen bonding found within antiparallel p-sheets
Parallel p sheets are less common, this is believed to be due to their folding motifs 
which involve bringing strands together from different parts o f the peptide chain that 
are not close in sequence (crossover connections). Here the opposite strands run in the 
same direction to one another and create a non-planar hydrogen bonding network 
(Figure 7)6.
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Figure 7: The hydrogen bonding found within parallel p-sheets
The study o f secondary structure within small molecules has been wide ranging. 
Peptidomimetics have been targeted as specific drug molecules10. Molecules are 
made to copy the local topography about the amide bond by synthesis o f amide bond 
isosteres, pyrrolinones or short portions of secondary structure. Generally these 
molecules such as l 11 and 2 12 both factor Xa inhibitors look nothing like peptides but 
contain groups positioned in such a way that they either mimic the secondary 
structure of a peptide or the arrangement of the side-chains o f the peptide being 
imitated (Figure 8).
HOOC HN
HN
NH O
HoN
OH
NH
Figure 8: Two peptidomimetic drugs 1 and 2
These molecules tell us little about the shape o f the secondary structure o f proteins. 
To study the structure of proteins small peptides have been synthesized that adopt
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helices13, turns14 and sheets15. These peptides generally rely on either sequences that 
are specific to the motif16 or artificial constraints being applied to the backbone or 
side chains17. This is extremely limiting as only certain amino acids can be included 
in the sequence18. This hinders the development o f possible applications for example, 
synthesis of artificial enzymes, as the structure should be constant while amino acids 
are changed to achieve selectivity.
A route which is becoming more popular involves replacement o f natural 
conformational constraints, such as disulfide bridges, by closely related mimics19. 
Performing this often leads to molecules with a defined three-dimensional shape and 
increased metabolic stability. Limiting the flexibility o f short peptides in this way has 
also been found to increase the affinity for receptors by reducing the unfavorable 
entropy loss upon binding20. The relatively stable secondary structure formed by these 
molecules can be studied and give insights into protein folding, aggregation and bond
9 1angles . This review aims to highlight the different ways in which this can be done 
using aliphatic bridges as well as covering syntheses o f bridged bis amino acids.
1.1 Carbon Side-Chain Bridged Peptides
Carba analogues o f several hormones were synthesized in the early 1970’s22, 23. The 
first o f these mimicked the disulfide bridge using a molecule of 1,6-aminosuberic 
acid 3 (Figure 9). This was incorporated into the peptide and then cyclised onto the N  
terminus to form an amide (Figure 10). Although not a linkage between two side
22
chains, the synthesized peptides 4 and 5 successfully mimicked and were denatured 
slower than the natural hormones although they did exhibit a drop in potency.
Q
H2N O
Figure 9 : 1,6-aminosuberic acid 3
c o n h 2
4 - [1,6-aminosuberic acid]-8-lysine-vasopressin
CONH2
5 - [1,6-aminosuberic acid]-8-lysine-vasotocin
Figure 10: Synthetic mimics of vasopressin 4 and vasotocin 5
Similar work was completed on the peptidal release inhibiting factor somatostatin 6 
(Figure 11). Again 1,6-diaminosuberic acid was used to cyclise the two ends o f the 
peptide instead o f a disulfide found in the natural peptide24.
23
HN COOH
X -Y
6 = X, Y = S = Somatostatin
7 = X, Y = CH2
Figure 11: Natural somatostatin 5 and synthetic mimic 7
Synthesizing 7 was important to determine whether it was the dithiol linear form or 
the cyclised disulfide o f the parent peptide which caused activity in vivo. Upon 
testing, 7 was found to show significant biological activity. In gastric secretion 
studies the authors found that 7 maintained the same inhibitory effect 30 minutes after 
the infusion had stopped, whereas somatostatin lost activity immediately. This 
highlights the increased stability that can result upon enforcing structural features 
found within natural peptides and shows that it is the dithiol form of the hormone 
which causes activity. Further analogues of somatostatin were synthesized some 
containing two carba bridges25. These molecules could not be synthesized using the 
standard peptide synthesis techniques used previously. An orthogonal strategy for the 
integration o f the dicarba analogues into the peptide had to be used. First LL-a,a’- 
diaminosuberic acid 8 had to be synthesized in optically pure form containing 
orthogonal groups to those that were to be used in the peptide synthesis (Figure 12).
24
BocHN O 
8
Figure 12: L L -a,a’-Diaminosuberic acid
This was achieved by Kolbe electrolysis o f two differentially protected glutamic 
acids26. Acids 9 and 10 were stirred together in a solution o f sodium in methanol and 
pyridine and this was then treated electrolytically (Scheme 1). The close running 
fractions by flash column chromatography of homo coupled products 12 and 13 and 
desired bis amino acid 11 were separated by saponifying the methyl esters and 
resubjecting the diacid and monoacid to column chromatography.
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OMe
CbzHN'
Ot-Bu
BocHN
11
OH
Ot-Bu
BocHN '
O
OH
OMe
O
OMe
CbzHN'
OMe
CbzHN
12
Ot-Bu
BocHN'
19% Overall
Ot-Bu
BocHN
13
OH
CbzHN-
Ot-Bu
BocHN
a) Na, MeOH, pyridine, electrolysis, 20° - 25°C b) i) NaOH, dioxane ii) flash column
chromatography
Scheme 1: Synthesis o f protected L L -a,a’-diaminosuberic acid 8
The integrity of both the chiral centers remained throughout the synthesis and a 19 % 
yield was achieved. Although low yielding, the synthesis uses cheap and readily 
available starting materials producing chiral material without the need for asymmetric 
synthesis. The bis amino acid was then integrated into an analogue o f somatostatin as 
shown in Scheme 2 .
26
o
n h 2
t-BuO.
NHBoc NHiNoc
O O
15 c 14 b 0Bz 16
Scheme 2: Synthesis of butyl side-chain bridged cyclic peptide 17
The free acid o f 14 is coupled with the amine of previously synthesized tetrapeptide 
16 (a). The Boc and lbutyl groups were then removed and the methyl ester was 
converted to the acyl azide via the hydrazide before the peptide was cyclised (b). 
Condensation of protected aminosuberic acid amine 15 with the free acid o f the 
cyclised peptide was achieved using diphenylphosphoryl azide (c). Cbz deprotection 
and azide cyclisation (d) followed by hydrogenation to remove side chain protecting 
groups gave analogue 17 (Figure 13). When tested in vivo analogue 17 was found to 
have an increased duration o f action with respect to somatostatin but was not as 
effective at inhibiting the release o f growth hormone. This highlighted the difficulty 
in designing structurally more stable analogues of natural peptides.
27
HN
NH
HOOC1
rOH
17
Figure 13: Synthetic mimic of somatostatin 17, with butyl side-chain bridge
A similar route was more recently employed by Tabor et al28’29. to study the shape of 
small peptides. Using chiral auxiliaries which differed in the conditions required to 
remove them it was possible to synthesize a differentially protected hexyl bridged bis 
amino acid (Scheme 3).
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o
x
HN O
21
l \ ^ - ^ / COOSiMe2tBu
5
19
OEt
OEt
OEt
Y  OH 
NHFmocOEt
24
OEt
OEt
20
OEt
►
OH
OEt
23
NHAIoc
AIIO Y  OH 
NHFmoc
25
a) i) nBuLi ii) CuCN 3) 19 b) i) TBAF ii) Et3 N, 'Butyl Chloroformate iii) 21 c) i) KHMDS ii) Trisyl 
Azide iii) KOAc, HOAc iv) LiOH, H2 0 2 d) i) PPh3  ii) H2 O iii) Fmoc Chloroformate e) i) HCI ii) 
NaHC03  iii) Allyl Chloroformate iv) DBU, Allyl Bromide, LiBr.
Scheme 3: Synthesis of orthogonally protected hexyl bridged bis-amino acid 25
T A
Alkylation of Schollkopf s bis lactam 18 by iodide 19 produced intermediate 20. 
After acid deprotection the Evans31 oxazolidinone chiral auxiliary 21 was coupled to 
the alkyl chain. Asymmetric animation was achieved using the electrophilic trisyl 
azide before the Evan’s oxazolidinone was removed from 23 with LiOH and H2O2 . 
Staudinger reduction of the azide 23 using triphenylphosphine produced amino acid 
24. Protection o f the amine as an Fmoc carbamate allowed the bis lactam to be 
removed without producing equivalent amines. Allyl chloroformate protection o f the
29
free amine and base catalysed transesterification o f the ethyl ester for an allyl ester 
produced acid and orthogonally protected bis amino acid 25.
25 NHAIoc
AIIO
26
AlocHN 
AIIO
COOH 
NHFmoc
Incorporation into performed SPPS
FmocHN—(Xaa)m— COHN CONH— (Xaa)n-C O O
Deprotection and cyclisation
27
H2 N ^ C O H N —(Xaa)m-C O H N  CONH-— (Xaa)n-C O O —Q
Continuation of SPPS and cleavage from 
the resin
28
H2 N— (Xaa)p— COHN COHN— (Xaa)m-C O H N  CONH— (Xaa)n COOH
Scheme 4: Synthesis of hexyl side-chain peptide 28
The differential protecting groups of the molecule meant that it could be incorporated 
into a peptide by SPPS in the following way (Scheme 4). Iterative SPPS is started on 
resin and after the required C-terminus amount of amino acids are added the acid 
moiety of 25 is coupled to the free amine terminus. The Fmoc group is then removed 
and SPPS continues. After addition of the requisite amount o f protected amino acids 
the allyl groups are selectively deprotected and the Fmoc removed and the peptide
30
cyclised on resin (27). Amino acids are then added via SPPS and the peptide cleaved 
from the resin when complete to give 28. Using this technique it is possible to insert 
any number of unnatural side-chain linkers between two groups in a peptide. The 
method is hugely advantageous as the whole synthesis can be performed on resin and 
therefore many purification steps can be removed. Creating linkers between amino 
acid side-chains often relies on post synthetic modifications o f the peptide and 
therefore limits the presence of amino acids that may interfere with the reacting 
species. Using this technique allows for any amino acids to be used as it relies on 
protecting group deprotection and cyclisation, the side-chain linker being synthesized 
before the SPPS. The final peptide was found to exhibit a stabilized type II (3 turn 
(Figure 14).
AcHN
CONH
Figure 14: Hexyl side-chain bridged peptide
The most flexible method developed for introducing dicarba bridges to peptides 
within recent years is by RCM. Many groups have performed RCM both to create bis 
amino acids and to cross-link side-chains o f synthesised peptides32,33. It has allowed 
for previously very difficult transformations to be carried out in one facile step and is 
highly amenable to create libraries o f peptides. The group o f Grubbs were first to 
perform RCM within a peptide scaffold34. A tetrapeptide previously shown to create a
31
(3 turn when two terminal cysteine residues formed a disulfide bridge was synthesised 
with the cysteine replaced by racemic allyl glycine units (Scheme 5).
Ph
Ph
BocHN HN
H NMe
BocHN HN
NMe
29
Scheme 5: Synthesis of alkene side-chain bridged tetrapeptide 31
Upon exposure o f 29 to the ruthenium RCM catalyst 30 only the (S,S) isomer ring 
closed, thus creating diastereomerically pure product 31 which was found to replicate 
the hydrogen bonding network found within natural p turns. The group then went on 
to perform solid phase peptide synthesis incorporating allyl glycine residues which 
they subsequently ring closed on resin (Scheme 6 )35. The resultant hexapeptide 34 
was produced in 65 % overall yield and highlights the power o f the method.
32
F" ^ k $ 7 $ v ) ^
30
FmocHN
FmocHN
Cleavage
32
33
v ^ - c o o n h 2
34
65%
Scheme 6 : Synthesis o f alkene side-chain bridge peptide 34 via SPPS
A larger octyl side-chain linker was installed in a small tripeptide mimic protease 
inhibitor as a post synthetic modification using RCM 36 (Scheme 7). After asymmetric 
synthesis of the two alkene containing species they were coupled to either side o f a 
valine residue to give 35. The side-chains were then cyclised by RCM in good yield 
before the remaining double bond was hydrogenated (36).
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OHOBn BocHNBocHN
3635
a) i) 30 ii) Na, NH3  iii) Pd-C, H2.
Scheme 7: Synthesis o f octyl side-chain bridged tripeptide 36
'KHRecently much progress has been achieved in the area o f RCAM ’ . Alkyne amino 
acids39 have been successfully synthesised and undergo RCAM in good yield39. This 
can be performed both to make bis amino acids40 and also as a post synthetic 
modification41. Progress towards the synthesis o f an alkyne carba analogue of 
antibiotic nisin was achieved by using RCAM to successfully synthesise a mimic of 
the A ring41,42 (38) (Scheme 8 ).
34
Scheme 8 : Synthesis of akyne side-chain bridged pentapeptide 38
The unnatural tetrapeptide 40 was synthesised and subjected to RCAM catalyst 39 to 
study the effects o f alkyne analogues o f disulfide bridges in (3 turns (Scheme 9)43. 
After cyclisation structural analysis by NMR indicated that the presence of the 
acetylene bridge in 41 rendered the cyclic peptide more rigid than a disulfide, 
showing stronger intrastrand proton-proton interactions than the natural linkage.
oN
H HN
OMe
O
BocHN
(62%)
O
N
H HN
OMeO
BocHN
41
Scheme 9: Synthesis o f akyne side-chain bridged tetrapeptide 41 
1.1.1 Carbon Bridged Bis Amino Acids
Coverage in this section will be focused on a selection o f syntheses that have used 
different methods to make carba bridged bis amino acids but for one reason or 
another the final molecules have not been incorporated into peptides.
Synthesis of propyl and butyl linked bis amino acids was reported by Williams et al, 44 
(Scheme 10). Using commercially available lactone 42 as an asymmetric inducer they 
were able to prepare bis amino acids such as 47 enantiopure as either (R,R) or (S,S) 
diastereoisomers.
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a) i) LiHMDS ii) O3  iii) Me2S c) radical deoxygenation d) H2, PdCI2  
Scheme 10: Synthesis of propyl bridged bis-amino acid 47
The synthesized molecules were being prepared as antibiotics so no effort was made 
to make orthogonally protected derivatives.
Schollkopf s bis lactam ether was employed by Vederas et a t 5, to synthesise an 
inhibitor o f diaminopimelic acid epimerase (Scheme 11).
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Scheme 11: Synthesis o f 1-fluroro propyl bridged bis-amino acid 54
Protected glutamate semialdehyde 49 is reacted with the chiral glycine equivalent 48. 
This gives the alcohols 50 and 51 in a 3:1 ratio respectively in favour of the desired 
product. The unwanted alcohol when subjected to fluorination with DAST eliminates 
to give alkene 52 and thus allows for easy separation o f the alkyl fluoride 53. The 
protecting groups are then cleaved with strong acid to yield 54. The final material is 
required fully deprotected but if different protecting groups were used an
38
orthogonally protected derivative of this interesting class o f bis amino acids could be 
produced.
A thorough study of the Kolbe electrolysis reaction was performed by Hiebl et al.Ae 
(Scheme 12). Yields as high as 38% were reported for homo coupled glutamic acids. 
Aspartic acid was also coupled using this technique to give protected 2,5- 
diaminoadipic acid (56) in low 17 to 25 % yields depending on the protecting groups 
used.
O O
X  B o c H N ^ J l
^ O H  OBn: un  Kolbe i
B ^ N H B o c  electrolysis /
O BnCX
NHBoc 
O
55 56
Scheme 12: Synthesis of ethyl bridged bis-amino acid 56
Although low yielding the reaction does show how complex bis amino acids can be 
synthesized using cheap starting materials, avoiding the high cost o f metathesis 
catalysts.
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58 59
HNNH
60 n = 0
61 n = 2
62 n = 3
a) DBN b) H2, [(COD)Rh(S,S)-Et-DuPHOS]OTf.
Scheme 13: Synthesis of propyl, butyl and pentyl bis-amino acids 60 ,61  and 62
Winkler et al.41, 48. more recently used asymmetric catalytic hydrogenation to install 
the stereocenters o f bis amino acids (Scheme 13). This allowed them to produce a 
range o f differing linkers between the protected amino acids such as 60, 61 and 62. 
Although these molecules were produced without orthogonal protecting groups the 
yields and ee’s were good.
Using an approach based on the palladium mediated allylation o f Schiff bases derived 
from glycine, Najera et al.49. were able to make some highly novel bis amino acids 
such as 67 and 6 8  (Scheme 14).
40
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a) i) LiHMDS ii) 64, Pd(PPh3 ) 4  b) H20
H 0 2C
NH2  i i  C 02H
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h 2n
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c o 2h
67 68
Scheme 14: Synthesis of novel alkene containing bis-amino acids 6 6 ,6 7  and 6 8
Reaction o f two equivalents of Schiff base (63) with aliphatic dihalide 64 in the 
presence o f tetrakis(triphenylphosphine) palladium (0 ) and base produces the bis 
imino ester 65. Upon hydrolysis o f this intermediate the bis amino acid 6 6  was 
produced in good yields. The major drawback to this approach is the synthesis o f a 
mixture of stereoisomers, as the alkylation reactions were not performed 
asymmetrically. Isolating the correct stereoisomer would be difficult and time 
consuming.
A very powerful method for the synthesis of unnatural amino acids was used to 
synthesise propyl linked bis amino acid 75 by Walsh et a l 50 (Scheme 15).
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Scheme 15: Synthesis of propyl bridged bis-amino acid 75
An enantioselective and catalytic vinylation of benzaldehyde leads to allylic alcohol 
72 that can then be transformed into allylic amine 73 via conversion to an imidate and 
subsequent [3,3]-sigmatropic rearrangement. Oxidative cleavage o f allylic amine 73 
furnishes amino acid 74 in good yields and excellent ee’s. Using this approach bis 
amino acid 75 was produced in an excellent 89% yield from a bis allyl amine. 
However a drawback to this methodology would be the difficulty in installing 
orthogonal protecting groups.
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The RCM methodology has also been used to prepare orthogonally protected bis 
amino acids51. Starting from allylglycine, 2,7-diaminosuberic acid derivative 82 was 
prepared using a dibenzyl ester protection strategy (Scheme 16).
OH
HO
NHBoc
O
76
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O
BocHN O
O
79 Ar = C6 H4 N 0 2
BocHN BocHN
N. . 0
80 81
h o 2 c .  ,
Y "
NHBoc
NH2A' C 02Ph
82
a) i) EDCI, DMAP, 77 ii) 78, ‘Pr2EtN b) 76, jPr2EtN c) Ru-cat d) H2 -Pd, p-TsOH.
Scheme 16: Synthesis of orthogonally protected butyl bridged bis-amino acid 82
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The metathesis reaction provided the alkene 81 which was then hydrogenated to yield 
the final molecule 82 which could be easily incorporated into an amino acid via 
SPPS.
Synthesis of alkene and alkyne equivalents of diaminosuberic acid was performed 
using RCAM by first cyclising two equivalents of alkyne 84 tethered together with an 
ethyl ester using tungsten-alkylidyne 39 in a good 84 % yield40 (Scheme 17).
NHBoc NHBoc
NHBoc
BocHN’
NHBoc O' 'NHBoc
NHBoc
NHBoc NHBoc
a) i) HOCH2 CH2 OH, DCC, DMAP ii) 92, DCC, DMAP b) 39 c) i) H2) Lindlar cat. ii)
LiOH d) LiOH
Scheme 17: Synthesis o f propyne bridged bis-amino acid 87
Removal o f the ethyl ester protection produces alkyne bis amino acid 87. Reduction 
of the alkyne before ethyl ester removal with Lindlar’s catalyst gives a cis alkene 
which is then saponified to 8 6 .
44
1.2 Oxygen Side-Chain Bridged Peptides.
A post synthetic RCM was performed on a peptide that contained allyl ether residues 
and therefore produced a diether bridge52 (Scheme 18).
88
a) i) 30 ii) H2  Pd-C 
Scheme 18: Synthesis of diether side-chain bridged peptides 89 and 90
Using the sequence o f a peptide that was shown to form a stable a  helix in solution 
the bridge was formed between the i, (i+4) residues, sites that represent one complete 
turn of the helix. This was performed by allylating serine or homoserine side-chains 
found within the peptide. The allyl ethers were then subjected to RCM to yield the 
alkene. The double bond was then subjected to catalytic hydrogenation to give an 
unsaturated diether bridge. The bridge formed in 89 and 90 was shown to form a 3io 
helix by both CD spectra and crystal structures.
A further side-chain linked ether was synthesised by Fairlie et al52. to mimic the 
shape of (3 strands (Scheme 19). After synthesis of tripeptide 91 the primary alcohol
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was derivatized as an iodide. The introduction o f a weak base then led to ring closure 
and ether 92.
B o c H N ^ A NI i N ^ A OMe
r H .
BocHN
OMe
OH
HO
9291
a) i) PPh3l CBr4  ii) Nal iii) K2 C 03, DMF 
Scheme 19: Synthesis of ether side-chain bridged tripeptide 92
The presence of orthogonal protecting groups gives the possibility of peptide chain 
extension.
1.3 Nitrogen Side-Chain Bridged Peptides.
Inouye et al54. used a post synthetic modification o f the lysine residue o f a peptide to 
stabilise a  helical structures (Figure 15).
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Figure 15: Succinimidyl esters used to bridge to lysine residues of a peptide
After each peptide was synthesised it was incubated with one of the cross-linking 
agent shown in Figure 15. The lysine residues were placed at the i and i+4 positions 
o f one peptide and at the i and i+7 of the other chain to encourage a helical structure. 
The primary amine o f the lysine residue reacted with the succinimide esters o f the 
cross-linking agents to produce a bridged diamide. The reactions were performed in 
very dilute concentrations and no peptide dimers were observed. The propensity of 
the natural peptide to form a  helical structures was found to greatly increase when 
acetylenic bridges 93 and 95 were introduced. The thermal stability o f the bridged 
peptide was also very surprising with diacetylene 95 producing a 15% helical 
structure at 70°C. These molecules have possible applications as stable mimics of 
alpha helices for drug or artificial enzyme applications. The majordraw back is the 
requirement o f the peptide backbone to contain no residues that are likely to be 
nucleophilic enough to react with the succinimidyl esters.
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An ambitious mimic o f somatostatin was synthesized by Smith et al. as an efficacious 
hormone inhibitor (Scheme 20)55. The synthesis relied on three pairs o f triply 
orthogonal protecting groups to form three macrocycles by regiospecific side-chain 
cross-linking. After attachment of the aspartic acid side-chain to the solid phase the 
peptide 100 was synthesized via SPPS.
48
NHTrt
FmocHN,
FmocHN,Dpr
DprAlocHN'
HN
COOt-Bu
COOt-Bu
HN 0 = 1•OAI NHBoc HN
NHBocNHCbz
NHCbz
Dpr
Dpr
Ot-Bu
Ot-Bu
O
FmocHN,
Dpr
HN
0 = 1
HN
NH
NHCbz
Dpr
OH
Dpr
HN
C = 0
0=1
HN
NH
NH
Dpr
OH
99 100
a) i) 0.75% TFA in CH2CI2 ii) DPPA iii) Pd(PPh3)4 iv) DPPA b) i) 50% 
TFA in CH2CI2 ii) DPPA c) i) Piperidine ii) H2 Pd-C
Scheme 20: Synthesis of diamide side-chain bridged decapeptide 100
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Figure 16: (S)-2,3-Diaminopropionic acid
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Cleavage of 97 from the resin using a very low concentration of TFA resulted in 
concomitant deprotection o f the previously trityl protected Dpr (Figure 16) residue 
(Scheme 23). The two free side-chains were then coupled using DPPA to give 99. 
Next the allyl ester and carbamate were deprotected using Pd(PPh3)4 and the acid and 
amine coupled with DPPA to cyclise the termini of the peptide with a backbone 
linked octanoic acid. A more concentrated solution of TFA was then used to remove 
the t-butyl protecting groups and the Dpr and aspartic acid residues coupled with 
DPPA (116). The final two deprotection steps, removal o f Fmoc from one lysine and 
Cbz from another, brought the total number o f orthogonal protecting groups used to 
5. The final molecule 100 was found to be only a moderately active mimic of 
somatostatin.
Simpler side chain amides have been widely reported. These tend to involve a post 
synthetic modification o f lysine and either glutamic56 or aspartic57 acid to encourage 
stability o f secondary structure (Figure 17).
NH
Figure 17: Example of an amide side-chain bridged peptide form ing an a-helix
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1.4 Sulfur Side-Chain Bridged Peptides.
The use of sulfur as a linking moiety in side-chains as a stable means o f mimicking 
disulfide bonds has seen much interest. Primarily this is due to research into a class of 
natural product antibiotics containing lanthionine bridges58,59 (Figure 18).
COOH NH2  
112
Figure 18: Lanthionine 112
There are many syntheses where these residues have been incorporated into peptides. 
Most have relied on either a post peptide synthesis modifications o f the side-chains or 
synthesis o f an orthogonally protected lanthionine derivative for iterative 
incorporation into a peptide. Notable syntheses include those by Harpp et a f Q where 
sulfur extrusion o f a protected cysteine moiety such as 113 by (Et2N)3P was used to 
produce non orthogonally protected lanthionine bridge 114 (Scheme 21). This 
technique was also used in the only total synthesis o f the antibiotic nisin. Disulfide 
bridges were formed before sulfur extrusion to form lanthionine bridges occurred as a 
post synthetic modification61.
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Scheme 21: Synthesis of lanthionine 114 via sulfur extrusion
Work by Goodman et al.62 produced a differentially protected lanthionine bridge by 
opening p-lactone 116 derived from serine with cysteine derivative 115 (Scheme 22).
SH xNHCbz
i— 1 a M e O O C ^ ^ \  .NHCbz
M e 0  NHBoc ° A  ----------- *  T  S rNHBoc NHBoc COOH
O
115 116 117
a) Cs2 C 03, DMF
Scheme 22: Synthesis of orthogonally protected lanthionine 117 via P-lactone opening
Tabor et al. synthesised orthogonally protected lanthionine 120 by reaction of 
cysteine 119 with iodo alanine in the presence o f CS2CO3 (Scheme 23)63,64. The 
product 120 was then incorporated into a peptide in the same way as Scheme 4.
TrtHN FmocHN
H H
a A lo c H N ^ -^ ^ ^ /-\- /(X )O t-B u
Ot-Bu "  I S T
COOAI NHFmoc
120
a) Cs2 C 0 3l DMF
Scheme 23: Synthesis o f orthogonally protected lanthionine 120 via iodo alanine and cysteine
coupling
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Bradley et al.65 developed a method using a post synthetic modification of a 
synthesised peptide containing cysteine and dehydroalanine (Scheme 24). Exposure 
of peptide 121 to DBU resulted in a Michael reaction to generate the ring B of 
antibiotic nisin 122 with a single chiral centre being formed at the a  carbon.
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Scheme 24: Synthesis of ring B o f nisin by intramolecular M ichael reaction
Recently a side-chain sulfur coupling methodology was developed to stabilise helical 
peptides as an alternative to lactam bridges by Dawson et al.66 (Scheme 25). 
Synthesis of peptide 123 was performed by SPPS, containing lysine and cysteine 
residues protected as their Fmoc carbamate and /?ara-methoxybenzyl sulfide 
respectively. Deprotection of the Fmoc group by piperidine and reaction o f the 
primary amine with bromoacetic acid 124 using DIC produces 125. Concomitant 
deprotection of the sulfide protecting group and cleavage o f the peptide from the resin 
is achieved with HF. The free thiol is then cyclised by reaction with the alkyl bromide
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in a basic buffer to give cyclic sulfide 126. In the peptides tested the presence o f the 
sulfide bridge yielded greater helicity than those with lactam bridges and those 
without.
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Scheme 25: Synthesis of amide and sulfide side-chain bridged peptide 126
Vinyl sulfide 128 was produced when cysteine was reacted in the presence o f acid 
with a side-chain acetal by Hallberg et al.61 in the synthesis towards angiotensin 
agonists (Scheme 26). These exhibited similar conformations and activity to the 
natural peptides.
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Scheme 26: Synthesis of vinyl sulfide side-chain bridged peptide 128
In conclusion it has been shown that there are many different side-chain linkers that 
can be introduced into peptides to constrain and encourage secondary structure. The 
most common ways to incorporate these into peptides is either via an orthogonal 
protection strategy or synthesis of side-chains that can be reacted once the peptide is 
made. Another method involving linkage between two natural side-chains present in 
the peptide is also common but is limited by the amino acids that can be used in the 
peptide chain and the compatibility of the side chain-forming chemistry with the 
underlying peptide.
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2.0 Results and Discussion
2.1 Introduction
Computer modelling highlighted some small peptides that were envisaged to form 
stable P turns1. The modelled peptides were constrained by a variety o f linkages 
between two side-chains o f amino acids. The m otif that appeared to be most 
promising in enforcing secondary structure was ether linkage 129 (Figure 19). It was 
decided to pursue a synthesis o f these peptides to study the structures formed.
peptide
—  peptide ]— N
O H H
peptide
129
Figure 19: Ether side-chain bridged peptide 129
Synthesising peptides with unnatural side chains is a topic that has been well 
researched within the group2,3,4. Lanthionine bridged (130, Figure 20) and alkyl 
bridged (9) side chain linked peptides have been made using a proven methodology.
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N— peptide — N
peptide —  O
130
Figure 20: Lanthionine side chain bridged peptide 130
Initially a double headed amino acid 25 is synthesised with orthogonal protecting 
groups. This is then integrated into a peptide in the following way (Scheme 27).
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NHAIoc
AIIO COOH
NHFmoc
131
OAII
O
«<XXX>0
132
b FmocHN COOH
133
N
134
HO
135
d FmocHN COOH
H2N
136
COOH
a) I) PyOAP, HOAt ii) Piperidine b) several rounds of synthesis c) i) Pd(PPh3 ) 4  ii) 
PyOAP, HOAt d) i)several rounds of synthesis ii) TFA
i = Amino Acid 
Scheme 27: Synthesis of hexyl side-chain peptide 136
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The C-terminus o f the peptide is synthesised using standard Fmoc SPPS5 up until the 
point where the first residue o f the unnatural amino acid 25 is to be added. This is 
then coupled via the free carboxylic acid group to the amine o f the resin-bound, 
protected peptide 131. The Fmoc group is then deprotected and further amino acids 
are added via iterative SPPS until the second residue o f the unnatural side chain is to 
be added to the linear peptide chain. The Aloe and Allyl groups are selectively 
deprotected with Pd(PPh3)46 and the peptide is cyclised on resin via coupling o f the 
free acid with the amine terminus o f the linear peptide. Amino acids are then added to 
the free carboxylic acid group o f 134 until the peptide is complete. It is then cleaved 
from the resin to yield an unnatural side chain constrained peptide 136.
The synthetic target for our synthesis was therefore a double headed amino acid (137) 
bearing a two carbon chain at either end bonded by an ether linkage (Scheme 28). It 
was also essential that the two amino acid groups were protected with orthogonal 
protecting groups. For peptide synthesis the Tabor group have found the combination 
o f Fmoc and allyl groups ideal, as they can be deprotected with mild reagents that 
will not attack the peptide and can also be deprotected without removing the 
permanent acid labile side-chain protecting groups. Often these protecting groups are 
not compatible with the synthetic route to the final double headed amino acid. In 
these cases different orthogonal groups are used throughout the synthesis, these are 
then sequentially removed and replaced by the preferred Fmoc and allyl protecting 
groups before SPPS is commenced.
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140 141
L-Aspartic Acid L-Methionine
LG = I, Br, OMs, OTs.
Scheme 28: Retrosyntheis o f ether 137
The retrosynthetic step7 that was favoured within 137 is at the oxygen carbon bond 
either side o f the ether. Disconnection at this point yields an equivalent o f 
nucleophilic alcohol 139 and an equivalent o f electrophilic 138 containing a leaving 
group at the y carbon. The synthetic step required to bring these two molecules 
together to form 137 would be a Williamson ether coupling reaction. To ensure the 
synthesis was scalable and repeatable 138 and 139 were further retrosynthesised to
140 and 141 amino acids aspartic acid and methionine. Starting from the chiral pool 
o f reagents eliminates the need for asymmetric creation o f chiral centres, which can 
be both expensive and difficult to scale up successfully. It was important that the 
amino acids used contained the correct number o f carbon atoms in the side chain. 
Making up for a deficit or excess would require extra steps and reactions that could 
damage the integrity o f the chiral center. It was also imperative that the side chains 
contained functional groups that were synthetically malleable to allow for alcohol and 
leaving group formation.
2.2.1 Synthesis of the Nucleophile
It was anticipated that aspartic acid would yield the easiest route to the alcohol. It 
already contains an oxygenated functional group in the correct position. Reduction of 
protected aspartic acid would therefore yield 139. The synthetic problem encountered 
with aspartic acid is that it contains two acid groups practically equivalent in 
reactivity. A review o f the literature showed that it is possible to preferentially protect 
the P acid. This was not ideal as having the a  acid preferentially protected it would be 
possible to reduce the other acid to the alcohol with treatment with /so-butyl 
chloroformate and NaBH4 . If both were protected it seemingly adds an extra step as 
the p acid would have to be deprotected. The lack o f methods preferentially 
protecting at the a  acid meant methods had to be found that would give orthogonal 
groups at each ester.
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A widely used method for aspartic acid differentiation is complexation o f  the a  acid 
and amine to a metal. The p acid can then be protected and the metal decomplexed to 
yield the protected amino acid. The most common elements used to perform this are 
copper and boron.
Boroxazolidones8,9 are synthesised by reaction of the amino acid with alkyl boranes
O Q
such as BPI13 and BBU3 . These species are then decomplexed with strong acid. A 
milder method uses copper chelation, this reaction has been more comprehensively 
studied10,11,12. Using this chemistry it was hypothesised that chelation o f the a  amino 
acid to the copper would allow for protection o f the p acid with benzyl bromide. The 
presence o f a benzyl ester deprotected by hydrogenation would allow for acid or base 
labile groups to be present at the a  acid which would not be affected by the removal 
conditions to yield a p acid.
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HoN
Cu2+
■Cu
142
N(CH3 ) 2
h2n^ +
N(CH 3 ) 2
143
47%
n 2 \
OBz
144
145
a) CuC03, H2 0 , 70°C to rt, 24 h b) TMG, DMF, H2 0 , rt. 3 h c) benzyl 
bromide, DMF, H2 0 , rt, 20 h d) EDTA, NaHC03, H2 0 , rt, 3 h
Scheme 29: Synthesis o f p benzyl ester aspartic acid 145
After dissolving C11CO3 in water at 70°C (Scheme 29), aspartic acid 140 was added 
and the solution was stirred for two days. The isolated bright blue solid 142 was then 
dried. The counterion was changed from Cu (II) to two equivalents o f TMG. The 
literature encouraged this step as 143 was found to give far better yields in the 
following benzyl alkylation reaction than 142. Addition o f benzyl bromide to 143
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yielded 144 as a light blue powder after isolation, which was again dried. 
Decomplexation o f the copper from the aspartic acid benzyl ester was achieved using 
EDTA. Isolation o f  145 occurred by rapid crystallisation from a cold acetone:H20 
solution. This synthesis yielded 145 in 47% yield over 3 steps and the material 
produced was not in need o f further purification. Taking into account the cheap and 
readily available starting materials 47% was an acceptable yield for the first step o f a 
synthesis. The length o f the pathway to a simple material was long and took some 
time to perfect and perform. Upon searching for new routes to differentiate the acids a 
synthesis involving just one step to pure material was discovered.
60%
H2 N Y  H3 N+
o  c r  o
140 146
a) SOCI2 , MeOH, -10°C to rt, 20 min
Schem e 30: Synthesis o f p methyl ester aspartic acid 146
Following well precedented procedures methyl esterification o f the P acid was 
achieved by treatment o f a solution o f aspartic acid in methanol with thionyl chloride 
at -10°C in 60% yield13 (Scheme 30). After warming to room temperature and adding 
cold ether, a solid was formed. This material was isolated by filtration and after two 
crystallizations was pure by melting point and NMR. This method although not high 
yielding uses cheap reagents and produces 146 pure within two hours. After
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performing this reaction several times on a large 30 g scale it was found to be both 
scalable and repeatable.
We then sought a pathway that made use o f this step as a means o f differentiation to 
yield protected homoserine derivatives. A five step scheme to 150 (Scheme 31) was 
identified14 and work commenced to test its feasibility.
BocHN'
d um -  ^ O t-B u  60% .Ot-Bu 98% /Ot-Bu
BocHN y  Boc2 N ^ Y  Boc2N
O O O
148 149 150
a) SOCI2, MeOH, -10°C to rt, 20 min b) (Boc)2 0 , Na2 C 0 3, THF/H20  (2:1), rt, 
48 h c) teuOH, DCC, DMAP, CH2 CI2, 0°Cto rt, 48 h d) (Boc)2 0 , DMAP, 
MeCN, rt, 24 h e) DIBAL, THF, -45°C, 1 h.
Scheme 31: Synthesis o f protected homoserine 150
After selective p-esterification, protection o f the amine with Boc anhydride and 
subsequent esterification o f the free carboxyl group with 'butanol, DCC and DMAP 
yielded protected aspartic acid derivative 148. The amine was then protected with a 
further Boc group. This was initially performed by refluxing 148 in THF for two 
hours with sodium hydride and Boc anhydride. These conditions are very harsh and it
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was thought that they may cause racemisation o f the amino acid so a milder method 
was found. Using 4 equivalents o f Boc anhydride with catalytic DMAP in acetonitrile 
at room temperature it was possible to add the second Boc group in 24 hours15. These 
conditions were slower and less atom efficient but did not risk racemisation o f the 
amino acid. Following the literature, reduction of 149 with DIBAL in Et20 gave two 
major products, the aldehyde and the desired product, alcohol 150. Optimisations of 
the reaction involved changing the temperature, time, solvent, dilution and rate of 
addition o f the DIBAL. Yields of 98% were realised using dilute THF solutions with 
a very slow dropwise addition at -45°C16. If the reaction was not very carefully 
judged, increasing amounts of aldehyde and 150 minus a Boc group were formed. 
Recently purchased DIBAL was also found to be important to ensure the fidelity of 
the protecting groups.
The importance o f the di-Boc amine protecting group was studied. Reactions o f 148 
with DIBAL yielded a very dirty reaction. No purification was attempted as the TLC 
analysis performed showed the presence o f over eight separate compounds with no 
clear major spot. It appears that an acidic proton in the molecule does not allow for a 
clean reduction with DIBAL. The presence o f the two Boc protecting groups does 
not complicate further steps as they can removed together with standard deprotection 
conditions17. It is thought that the selectivity observed in this reduction is primarily 
due to steric interactions between the wo-butyl groups o f DIBAL and the lbutyl group 
of the a-carboxyl ester, although the susceptibility o f methyl esters to DIBAL
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reduction over larger esters may also have helped in the discrimination o f the two 
esters.
With a successful synthesis o f nucleophile 150 completed attention was turned to 
making electrophile 138.
2.3.1 Electrophile Synthesis 1 -  Tosvl Homoserine
Published syntheses o f amino acid molecules containing a leaving group at the y 
position have often used radical decarboxylative halogenation18,19,20,2 *.
HO"
152
c h i 3
AIBNDCC, DMAP
R'HN'RnHN'
O O
OH
OR‘
R'HN'
O
151 153 154
Scheme 32: Synthesis o f iodide 154 by decarboxylative halogenation
Protected glutamic acid 151 is coupled to hydroxylamine 152 using DCC (Scheme
32). The intermediate Barton ester 153 is then subjected to either reflux temperatures, 
light or a chemical radical initiator such as AIBN to encourage homolytic bond 
cleavage. This is followed by decarboxylation to give a primary carbon based radical 
which is quenched with CHI3 to give the primary iodide 154. To synthesise starting
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glutamic acid 151 requires acid differentiation and a multi step synthesis. The yields 
reported within the literature for the final step are varied and generally below 50%20. 
We decided early on to eliminate this route due to these low yields. Also there were 
concerns that the harshness o f conditions might affect the integrity o f the chiral centre 
and the claim that the product was very difficult to purify22.
X
HX
RHN1
O
155
Scheme 33: Synthesis of iodide 156 by homoserine lactone ring opening
Another reaction used for synthesising derivatives such as 138 involves regioselective 
ring opening o f homoserine lactone 155 with either HC123, HBr24 or HI25 (Scheme
33). The reaction using HI has been shown to racemize the chiral centre during the 
idodination but HC1 and HBr are reported to give enantiopure products. The reaction 
was not attempted because o f reasons such as the difficulty in making homoserine 
lactone26, possible racemization during the ring opening reaction due to the harsh 
conditions and the requirement o f amine protecting groups that are resilient to <pH 1.
A synthesis that appeared to suit requirements was found which over 5 steps
'■yn
produced tosylated homoserine derivative 161 (Scheme 34) . The only change to the 
published route was the protecting groups used. The paper had used a Boc and benzyl 
ester for the amine and acid protection respectively whereas we chose to use aloe and 
an allyl ester.
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H2I
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AlocHN
OAII 6%
OTs
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OAII
a) Mel, H2 0/MeOH (10:1), rt, 24 h b) K2 C 0 3, H2 0 , reflux, 4 h c) allyl 
chloroformate, Na2 C0 3 , dioxane:H20  (1:1), rt, 24 h d) allyl bromide, DMF, rt, 48 h
e) p-TsCI, Et3 N, CH2 CI2, rt, 3 h
Schem e 34: Synthesis o f protected tosyl homoserine 161
L-Methionine was reacted with methyl iodide to form sulfonium salt 157. Subsequent 
nucleophilic displacement o f the sulfine by a hydroxide ion, by refluxing 157 in water 
with potassium carbonate, yielded unprotected homoserine 158, liberating dimethyl 
sulfide. By TLC this step produced three separate products all approximately equal in 
intensity. Due to 158 being extremely polar no chromagraphic separation was 
attempted. Protection o f the amine with allyl chloroformate and reaction o f the 
subsequent sodium salt o f the acid with allyl bromide gave 160. Alcohol 160 was 
then protected and activated with tosyl chloride to give 161 before purification was 
attempted. After work up the isolated brown oil consisted o f over 20 spots by TLC.
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After two very slow gradient elutions o f flash column chromatography 161 was 
obtained pure as a red brown oil in only 6% yield over 5 steps.
The synthesis was repeated but there was no improvement o f the yield. It was 
hypothesised that the low yield may be due to the early step where three spots of 
equal intensity are observed by TLC. Unprotected homoserine is known to
78 7Qlactonise ’ and common side reactions o f Sn2 displacements are eliminations so it 
is possible that a combination o f 158, 162 and 163 were produced, though no spectral 
evidence was obtained.
OH
158 162 163
Figure 21: Possible products from sulfonium salt displacement reaction, homoserine 158, 
hom oserine lactone 162 and vinyl glycine 163
With three separate products created during the conversion o f 157 to homoserine a 
low yield was experienced from an early stage in the route. The molecule was also 
able to lactonise throughout the synthesis and this too would contribute to the low 
yields observed. Another drawback o f this synthesis is the lack o f purification after 
each step. Due to the polar nature and the constant lactonisation it was felt that 
purification would only reduce the yields further. This though produces a very
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difficult and slow chromatographic isolation o f 161. The low yields and the problems 
associated with the synthesis drove us to search for a new route to electrophile 138.
To circumvent the alcohol group being free for long amounts o f time a pathway was 
attempted repeating the synthesis but changing the order o f the steps. By first 
protecting methionine we envisaged that we could then perform the displacement as 
the last step and minimise the amount o f lactonisation (Scheme 35).
OAII65% AlocHN
O
OH
H2 N'
O
OH
AlocHN
O
141 164 165
OH
OAIIOAII AlocHNAlocHN'
OO
166 160
a) Allyl chloroformate, Na2 C0 3 , THF:H2 0  (1:1), rt, 24 h b) i) K2 CO3 , MeOH 
ii) allyl bromide, DMF, rt, 48 h c) Mel, H2 0:MeOH (10:1) d) K2 C 0 3, H2 0 ,
reflux, 4 h
Schem e 35: Synthesis towards protected homoserine 160
Protection o f methionine as its allyl carbamate and allyl ester was performed as 
before to give 165. After sulfonium salt formation it was subjected to the same
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conditions as in Scheme 6. The TLC after two hours showed the products to be very 
polar. Increasing the polarity o f the TLC solvent system with AcOH showed a 
complex mixture o f over six spots. It was reasoned that among other reactions 
saponification o f the allyl ester had occurred. The reaction was then performed at a 
lower temperature and over extended times but there appeared to be very little 
reaction. It seems likely that the reaction requires reflux temperatures to proceed in 
the allyl ester and sulfine displacement. We therefore attempted new pathways.
2.3.2 Electrophile Synthesis II - Halide Displacement of Sulfonium Salts
OAII
AlocHN
O
OAII
AlocHN
O
165 167
a ) M el, N a l, (C H 3)2C O
Scheme 36: Synthesis towards protected iodide 167
As discussed, the formation o f sulfonium salts from sulfides creates good leaving 
groups for nucleophilic attack. A literature search revealed that these groups could 
also be displaced by halide ions30,31. This reaction was appealing as it would give a 
direct route to 167 from 165 and there would be no risk o f saponification (Scheme 
36). Sulfonium salt was prepared in situ and reacted with sodium iodide in acetone. 
The reaction showed only starting material after 24 hours at room temperature. It was
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then refluxed for a further two hours and after this time TLC, using three different 
solvent systems to ensure they were the same spot, showed only starting material 165.
The reaction was performed over a range o f temperatures and concentrations but 
results showed no indication o f the iodide 167. A one pot sealed tube reaction, where 
the nucleophile was added with the alkyl iodide and protected methionine, also 
yielded no desired products.
Most o f the literature reactions being followed had used phenyl or benzyl sulfides as 
the starting material32,33,34. This was then reacted to form the sulfonium salt with 
methyl iodide or methyl bromide. From the lack o f positive results presented here it 
can be concluded that the presence o f the aryl group creates a more susceptible centre 
for halogen attack. Attempts were then made to get around this problem by increasing 
the temperature o f the reactions. Using solvents with high boiling points it was hoped 
that the activation point o f the reaction could be reached using just alkyl substituents. 
The solvents chosen were toluene and diglyme which boil at 111°C and 160°C 
respectively. It appeared at the high temperatures that the allyl carbamate protecting 
group was unstable.
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a
CbzHN
OH
64%
b
CbzHN OAII
O O O
141 168 169
a) Benzyl chloroformate, THF:H20  (1:1), Na2 C 03, 0°C to rt, 24 h b) i) K2 C 0 3, MeOH
ii) allyl bromide, DMF, rt, 24 h
Scheme 37: Synthesis o f protected m ethionine 169
169 was therefore synthesised containing a benzyl carbamate (Scheme 37). No 
problems were found with this molecule when it was heated to reflux in diglyme. 
Unfortunately no positive results were obtained using sodium iodide or lithium 
bromide with preformed sulfonium salt or with in situ addition o f methyl iodide.
The decision was then made to change the type o f alkyl halide added. By changing 
the source from methyl iodide to the more electron rich allyl bromide and benzyl 
bromide it was anticipated that there would be an increase in the reactivity o f the 
sulfine as a leaving group. Conditions were varied but there appeared to be no effect 
using toluene. However bromide 173 was observed by electrospray mass
CbzHN CbzHN
O O
169 170
Scheme 38: Synthesis o f towards protected iodide 170
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spectrometry when diglyme was used with allyl bromide (Scheme 39). Unfortunately 
after removal of diglyme in vacuo only starting sulfide 169 and 172 were observed.
Scheme 39 shows the proposed mechanism for the synthesis o f 172. Formation of 
bromide 173 occurs with concurrent formation o f high boiling allyl methyl sulfide 
(b.p. 91-93°C). The high temperatures required to remove diglyme in vacuo would 
also encourage nucleophilic attack o f the bromide by the unsymmetrical sulfide. Once 
sulfonium salt 171 has been reformed either the methyl or the allyl group can be lost 
to reform the sulfide with loss o f the respective alkyl bromide. The higher boiling 
temperatures o f the electron rich alkyl halides which initially aids the formation of 
bromide 173 finally inhibits its isolation. Other techniques o f removing diglyme such 
as ice-ether extractions were not attempted as the high boiling sulfide would remain 
in the same layer as the iodo alanine and the same result would be reached. Research 
of this route ceased at this point as a more promising synthesis o f the target bridged 
ether amino acid was found.
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Scheme 39: Synthesis o f bromide 173 and m echanism of formation o f 172
2.3.3 Electrophile Synthesis III - Reduction of Aspartic Acid
Aloc(Boc)N
Reduce lodinate
Alcx;(Boc)Nt
.OAII
Aloc(Boc)N
Scheme 40: Planned synthesis o f iodide 176
The methodology used to create nucleophile 150 had worked well. Revision o f this 
synthesis was planned but this time using orthogonal groups (Scheme 40), replacing
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the Boc and *butyl groups with Aloe and Allyl to give 174. The molecule would still 
require a second carbamate to stop the secondary amine interfering with the 
reduction. The Boc group was chosen again as there was methodology to put it on and 
literature evidence suggested it could be removed without removal o f the Aloe 
group17. It was anticipated that the presence o f two reasonably bulky carbamates and 
an allyl ester would create a crowded a  center therefore hindering reduction. The use 
o f the bulky reducing agent would also encourage site specific reduction o f the 
sterically small (3 methyl ester. To encourage selectivity in the reduction the 
temperature was lowered to further emphasise the steric difference. The free alcohol 
produced from this route could then be turned into an electrophile for ether synthesis 
by mesylation and subsequent iodination.
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AlocHN'AlocHN'
Aloc(Boc)NAloc(Boc)N'
a) SO CI2 , MeOH, -10°C to rt b) allyl chloroformate, Na2 CC>3 , 
THF:H20  (1:1), rt, 24 h c) i) N aH C 03, MeOH ii) allyl 
bromide, DMF, rt, 24 h d) (Boc)20 , DMAP, MeCN, rt, 24 h e) 
DIBAL, CH2CI2, -78°C, 1 h
Schem e 41: Synthesis o f protected hom oserine 175
Aspartic acid was again reacted in methanol with thionyl chloride to yield 146 
(Scheme 41). Protection o f the amine was achieved with allyl chloroformate and 
Na2CC>3 in THF and H2O. The sodium carboxylate salt was then protected with allyl 
bromide in DMF to give 178. The Boc group was then added as the second carbamate 
using the same conditions as before. Reaction o f 174 with DIBAL yielded a large 
mixture o f products by TLC when first attempted in CH2CI2 at -7 8 °C. After some trial 
reactions optimum dilutions and addition rates were achieved. The resultant TLC 
showed five products. Isolation of the major three spots by flash chromatography
84
followed by TLC showed that one spot rapidly lost purity and became two spots after 
the column. This occurred too quickly to obtain a good NMR. The other spots 
isolated were a mixture o f deprotected and direduction products. The main spot was 
hypothesised to be alcohol 175 but was rapidly lactonising. The yield after 
chromatography was very poor and therefore trapping o f the alcohol as the tosylate or 
mesylate would not have produced an appreciable amount o f material.
Work performed in parallel to this also indicated that the presence o f the free y 
alcohol resulted in lactonisation.
H,N
O
HN
Ph
179
OH
O
180
o  o
HN
Ph
181
O'
182
a) Benzaldehyde dimethyl acetal, pTsOH, 1,1,1-trichloroethane, reflux,
18 h b) ethyl chloroformate, Et3 N, THF, -5°C, 1 h c) NaBH4, EtOH, rt, 4 h
Schem e 42: Synthesis o f oxazolidine protected homoserine 182
Reaction o f aspartic acid with benzaldehyde under Dean-Stark conditions (Scheme
42) gave a mixture o f two products believed to be 179 and p acid regioisomer 18035
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This protecting group was chosen as it can be deprotected with base and is therefore 
orthogonal to those used on the potential coupling partner 150. The two molecules 
were isolated by acidic work up. Their similar Rf values and high polarity led to the 
delaying o f purification until after the reduction to the less polar 182. The mixture 
was therefore subjected to mixed anhydride formation with ethyl chloroformate 
followed by sodium borohydride reduction36. Alcohol 182 was never isolated as the 
molecules produced were not stable and decomposed on work up, on standing or 
during attempts at flash column chromatography.
aioc(B oc)n^ N ^ AI1
Aloc(Boc)N Xq  
183 184
Scheme 43: Synthesis o f homoserine lactone 184 from homoserine 175
From these experiments and literature precedent there was no doubt that if  the y 
alcohol was free and unless the a  carboxylate group was protected as a lbutyl ester 
lactonisation would occur (Scheme 43)37. These groups are well known to be resilient 
to attack by nucleophiles.
The planned synthesis requires that there must be orthogonal protecting groups 
present in 138 therefore this protecting group could not be used again on both the 
nucleophile and electrophile. If the lbutyl ester were used and then the y position 
converted to an electrophile such as an iodide, subsequent attempted protecting group
Aloc(Boc)N
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exchange would surely result in failure as the molecule would lactonise with the acid 
acting as nucleophile (Scheme 44).
| Acidic I ^
lodination ^  Deprotecton /  j
A lo c (B o c )N ^ V 0 t-Bu A lo c (B o c )N ^ Y 0 t-Bu ReProtec‘ton AlocHN< Y ° Na
0 0 o
175 176 185
O
Aloc(Boc)Nf
184
Scheme 44: Synthesis o f homoserine lactone 184 by carboxylic acid attack of terminal iodide 185
The planned synthesis o f the electrophile then had to be changed to ensure that there 
was no way in which lactonisation could occur.
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2.3.4 Electrophile Synthesis IV - Reduction and Oxidation of Aspartic Acid
The reactions outlined in Scheme 45 show one way o f eliminating the problem of 
lactonisation. Reducing both the acid groups o f a protected aspartic acid species gives 
diol 186 where there is no electrophilic carbonyl onto which the y alcohol can 
lactonise. The alcohols can be differentiated by oxazolidine formation via reaction 
utilising Dean-Stark apparatus with an aldehyde. Using anisaldehyde would give a 
wide variety o f options for steps later in the synthesis as there are many deprotection
i n
procedures for this group . Electrophilic derivativization o f the free alcohol as the 
mesylate would produce an adequate partner for Williamson ether coupling with 150. 
Oxazolidine deprotection would then lead to possibly the most problematic step o f the 
scheme, oxidation o f the alcohol back up to the acid. This would have to be 
performed in the presence o f many sensitive protective groups but it was anticipated
n 1 \ C c t a r i f i / ,' o f i n n r\u OH
4)Oxazolidine
formation
5)Mesylation
6 ) 150
2)Aloc Protection
3)Reduction
AlocNAlocHN'
PMB
140 186 187
OtBu
AlocN'
NHBoc
7)Oxazolidine deprotection
8 )Oxidation
9)Allyl protection NHAIoc
NHBoc
BuOK^O
O
188 189
Scheme 45: Planned synthesis o f protected ether bridged bis-amino acid 189
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that using methods such as H 5IO6/C1O 338, TPAP/NMO39 or Ca(OCl)2/HOAc40 we 
could effect this transformation.
+H 3 N
OH
r
69% A lo c H N ^ V 0 ^ ^  7 1  % AlocHN1
OH
140 190 1 9 1  186
a) SOCI2, EtOH, 0°C to rt, 3 h b) allyl chloroformate, Na2 C 03, MeCN:H20  (1:2), rt, 24 h c)
NaBH4, LiBr, diglyme, rt, 4 h
Scheme 46: Synthesis o f Aloe protected diol 186
Diesterification o f aspartic acid 140 (Scheme 46) with thionyl chloride in ethanol 
gives 190. The reaction in methanol to give the dimethyl ester o f aspartic acid was 
also performed. However this was a very low yielding reaction as there was a strong 
preference for the mono ester. Pushing the reaction towards completion required 
excessive amounts o f thionyl chloride and long reaction times. It was therefore 
decided that the synthesis should be performed using the ethyl ester. Protection of the 
amine as the allyl carbamate was achieved to give 191 in good yield over two steps. 
Literature methods for the reduction o f this molecule used sodium borohydride in 
ethanol41,42. Following this precedent attempts were made to reduce the ester. After 
many reactions to optimise the very poor yields experienced the conditions were 
changed. Using the powerful reductant LiBH4 formed in situ by premixing NaBH4 
and LiBr in diglyme43, the diol 186 was produced in 3.5 hours giving a good yield 
after flash column chromatography. Unfortunately all attempts at oxazolidine 
formation o f 186 with anisaldehyde failed, as it was highly insoluble in non protic
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solvents and therefore all Dean-Stark reactions performed using toluene, benzene and 
1,1,1-trichloroethane failed. Changing the dilution and adding excess reagent made 
no difference to the reaction.
At this point continuation o f this scheme was stopped. Even with further attempts at 
performing the Dean-Stark reaction it was unlikely that a high yielding reaction 
would occur due to the poor solubility o f 186. Encountering such problems early on 
in the synthesis with more uncertain steps to follow, such as the oxidation, a new 
route to the electrophile was found.
2.3.5 Electrophile Synthesis V - Hemithioacetal Formation of Methionine
Literature precedent showed that thioethers could be reacted with NCS to form a- 
chloro sulfides44 193 (Scheme 47).
R R R
192 193 194
Scheme 47: a-Chlorination o f a sulfide and displacem ent by a nucleophile
These highly reactive species provided good coupling partners for alcohol attack and 
hemithioacetal formation45. Using this chemistry it was envisaged that a protected
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methionine species could be made to react with alcohol 150 and form hemithioacetal 
196 (Scheme 48). Cleavage o f the carbon sulfur bond would yield target ether 197.
1) NCS activation 
 ^
2) OH
195
BOC2N*
,Ot-Bu
t-BuO
NB0 C2 
O
196
3) C-S Bond Cleavage
Ot-Bu
197
Scheme 48: Planned synthesis o f protected ether bridged bis-am ino acid 197
The reaction of sulfides with NCS46 to form a-chlorosulfides is richly precedented in 
the literature44,47,48. The reaction has been shown to work in natural product synthesis 
and also in amino acid chemistry. It can be carried out with a range o f reagents such 
as sulfuryl chloride49, thionyl chloride49, trichloroisocyanuric acid (Chloreal)50, 
iodobenzene51 dichloride and benzenesulfenyl chloride52, but NCS is by far the 
mildest.
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Scheme 49: M echanism of a-chlorination reaction with sulfides
Scheme 49 shows the mechanism o f the reaction. Chlorination o f the sulfur to form a 
sulfonium salt (199) occurs by nucleophilic attack o f the chlorine atom by the sulfur 
lone pair. The succinimide counter ion then deprotonates a  to the sulfide which 
results in loss o f a chloride ion. The positively charged sulfide is then neutralized by 
attack o f the chloride ion a to the sulfide (200). The product 193 is generally 
considered to be unstable and often used straight away without purification. By using 
NCS and carbon tetrachloride as solvent crude purification can be achieved as 
succinimide is not soluble and can be filtered off. a-Chlorosulfides are potent 
electrophiles and react with a range o f nucleophilic reagents such as sulfides, 
alcohols, Grignard reagents and silyl enol ethers44.
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195
O O
t-BuO
(30%)
196
NHBoc 
O
O O
202
a) Phthalic Anhydride, DMF, microwave, 4 mins b) i) NaHC0 3 , MeOH ii) allyl bromide, 
DMF, 48 h c) NCS, CCI4, rt, 2 h d) 150, AgOTf, DMAP, CH2 CI2, -40°C to -25°C
Scheme 50: Synthesis o f protected hemithio acetal bridged bis-amino acid 196
Scheme 50 shows the synthesis o f hemithioacetal 196. Protection o f methionine as 
the phthalimide using microwave irradiation in DMF followed by allyl ester 
formation yielded 195. a-Chlorosulfide formation was then performed by the action 
of NCS in carbon tetrachloride. After 30 minutes the solution was filtered and the 
solvent removed. The residual oil was taken up in CH2CI2 and dripped slowly into a 
solution o f alcohol 150, silver triflate, DMAP and CH2CI2 at -45  °C53,54. Silver triflate
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was used as it is well known to increase the activity o f alkyl halides in nucleophilic 
reactions55. The literature protocol being followed had used the virtually non 
nucleophilic bulky base DTBP. In this initial trial reaction DMAP was used as it was 
the only dry amine base available at the time. The poor final 30% yield o f 196 was 
hypothesised to be due to the use o f DMAP and highlighted the advantages o f using 
more bulky and less nucleophilic bases, as the a-chlorosulfide formed is a potent 
electrophile and therefore quite capable o f reacting with DMAP. The yield although 
poor was acceptable for an unoptimized reaction at this stage. During the course of 
the reaction one o f the two Boc protecting groups was removed. It was hypothesised 
that this was caused by the Lewis acidic reagent AgOTf. This occurrence made little 
difference to the planned scheme as the presence o f two Boc groups was no longer 
required.
To study the potentially challenging step o f carbon sulfur bond cleavage a model 
hemithioacetal was synthesised, as alcohol 150 (and therefore 196) was an expensive 
resource.
94
195 202
203
SMe
OEt
204
(60%) (35%)
a) NCS, CH2 CI2, rt, 1 h b) EtOH, 2,6-lutidine, rt, 24 h
Schem e 51: Synthesis of model hemithioacetal 203
Reaction o f previously protected methionine 195 with NCS in CH2CI2 at room 
temperature for 30 min produced the a-chlorosulfide 202 (Scheme 51) which was not 
isolated. Addition o f 2,6-lutidine and a vast excess o f ethanol gave a final yield of 
60% for 203. Though low yielding the reaction used cheap materials that could be 
scaled up to 15 g and synthesised in 2 days. Reactions performed with DMAP and 
K2CO3 gave yields o f 30% and 45% respectively highlighting the importance of the 
base used in the reaction. The final hemithioacetal and foul smelling by-product, 
tentatively assigned to be 204 by NMR and mass spectrometry, had very close Rf 
values and therefore the separation o f the two compounds required a minimum of 
three slowly eluted columns. Similar work conducted on methionine has been
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attempted before using different protecting groups and methanol instead o f ethanol as 
the nucleophile56.
There are many documented methods and reagents for the cleavage o f carbon-sulfur 
bonds57, Raney nickel58, radical desulfurization59’60, oxidation61, nickel boride62, 
zinc/ammonium chloride63, samarium iodide64 and novel nickel complexes65,66. There 
are also papers regarding cleavage o f carbon-sulfur bonds in hemithioacetals67. 
Unfortunately many o f the literature methods were performed on simple alkyl 
sulfides where very harsh conditions could tolerated. Molecule 196 contained 5 
protecting groups and 2 chiral centres and was susceptible to side reactions with 
acids, bases, nucleophiles and transition metals amongst other reagents. It was 
therefore important to cast aside the more brutal methods and choose those that 
appeared mildest.
203
Raney Ni
205
Scheme 52: Attem pted cleavage o f the C-S bond o f 203 using Raney Ni
The first method attempted was cleavage using Raney Ni (Scheme 52). This 
represented a cheap and well precedented method for sulfur extrusion though it 
appeared to not have been attempted on hemithioacetals before. Problems were
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encountered initially when weighing the material. When developing methodology it is 
fundamental to know how much o f each reagent is used. This is difficult using Raney 
Ni as it must be kept wet due to its pyrophoric nature at all times and is therefore 
weighed out as a suspension. The density o f Raney Ni within the suspension is not 
known and therefore the equivalents cannot be accurately measured. It was therefore 
attempted to perform the same steps each time it was weighed to minimize 
discrepancies in equivalents. The small volume being used made it very difficult to 
work out the amount of Raney Ni contained within a certain volume by weight minus 
the weight o f the water due to the accuracy o f the scales at low masses.
Reports in the literature for desulfurisation using the same grade o f Raney nickel vary 
wildly with respect to time, temperature, solvents and equivalents58. Table 2 (page 
100) shows the range o f conditions that were attempted using this reagent. Reactions 
were carried out and then passed through a plug o f silica to remove any nickel 
residues. Solvent evaporation followed by NMR showed that none o f the experiments 
carried out yielded anything resembling the target model ether. Reactions generally 
returned starting material but in the longer reactions left for a number o f days at 
reflux complex decomposition had taken place. The results were surprising 
considering the generality o f the reaction in the literature but as it did not work in this 
system a second method was chosen.
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Scheme 53: Attem pted cleavage of the C-S bond of 206 using radical desulfurisation
Radical desulfurizations are typically performed with tributyl tin hydride in the 
presence o f a radical initiator such as AIBN68. There is a degree o f argument over this 
reaction in the literature, some claim it does not work for the less reactive methyl
69 70 1 1sulfides and others claim it does ’ . Under the reductive radical conditions it was 
believed that the unsaturated allyl ester may react. Methyl ester 206 was therefore 
synthesised. The methyl group could be saponified upon completion o f the reaction 
and replaced with an allyl ester, it is also orthogonal to the protecting groups o f 150. 
Following literature procedures the reaction was attempted over a range o f different 
conditions. The number o f equivalents o f both hydride and initiator were varied. The 
solvent, toluene, was degassed using the ffeeze-thaw method72 with both argon and 
nitrogen. The temperature and time o f reaction was also varied. After an extensive list 
of parameters were tried (Table 2) there only ever remained starting hemithioacetal
206. It was concluded that radical desulfurisation was ineffective for 206.
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Scheme 54: M echanism  of attempted cleavage of the C-S bond o f 206 using NCS and Et3SiH
Scheme 54 shows the proposed mechanism for the next method attempted. Using an 
electrophilic halide source it was proposed that upon formation o f the sulfonium salt 
anchimeric assistance from the oxygen would form the oxonium ion 210. This would 
then be reduced by a hydride source such as EtsSiH or NaBlU to yield the ether 211. 
The reaction performed was based on the mechanism o f DMTSF desulfurisations73,74. 
Reactions were performed using NBS and NCS in parallel. H alf an equivalent of 
either reagent was used in each reaction as the initially formed methanesulfenyl 
chloride goes on to chlorinate a second equivalent o f hemithioacetal. Reactions were 
carried out in CH2CI2 and although temperature, concentration, timing o f addition of 
reagents and equivalents was varied no desired ether was obtained. The major 
products from these reactions were starting hemithioacetal 208 and aldehyde 213 
(Scheme 64). The reactions were carried out in dry solvents and under an argon 
atmosphere so aldehyde 213 is generated in the absence o f water.
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Scheme 55: Postulated mechanism explaining formation o f aldehyde 213
Scheme 55 shows our postulated mechanism to explain this. Formation o f the chloro 
sulfonium salt 209, followed by deprotonation o f the ethyl ether by the succinimide 
counter ion leads to a cascade which results in formation o f succinimide, ethene and 
aldehyde 213. The presence o f starting material can be attributed to incomplete 
reaction after NCS addition. To minimize the amount o f aldehyde produced and 
increase the likelihood o f ether formation a source o f acidic protons was introduced. 
Reactions were carried out in CHfeCb^butanol mixtures but starting material and 
aldehyde were still present. The acidity o f the solution was then increased by the use 
of acetic acid as the lone solvent (Scheme 56).
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Scheme 56: M echanism of attempted cleavage of the C-S bond o f 206 using NCS, Et3SiH and
AcOH
After addition o f NCS for thirty minutes at room temperature, triethylsilane was 
added and the solution refluxed for 2 hours. After work up and purification ether 207 
was isolated in good yield. Upon repeating this reaction using identical conditions 
only starting sulfide 206 and aldehyde 213 were isolated. Varying all the conditions 
and using newer reagents also did not help and the ether was never again isolated 
using these conditions (Table 2).
PhthNPhthN’
206 217 207
a) MCPBA, CH2 CI2, 0°C, 2 h b) BF3 .OMe2l Et3 SiH, CH2 CI2, -45°C, 1 h
Scheme 57: Synthesis o f ether 207 using M CPBA and BF 3  dimethyl etherate
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Scheme 57 shows the final attempt to cleave the carbon-sulfur bond. The reaction had 
little literature precedent61 but what had been performed was in delicate natural 
product molecules and we therefore considered the conditions mild enough for 196. 
The reaction involved oxidation o f the sulfur and subsequent addition o f a Lewis acid. 
The presence o f the Lewis acid cleaves the sulfur carbon bond. Following the 
literature MCPBA was used as oxidant. This step proceeded well producing two spots 
presumed to be the sulfoxide and sulfone which was confirmed by mass 
spectrometry. Certain literature sources had claimed the oxidation o f hemithioacetals 
led to decomposition products but this was not observed67. Boron trifluoride dimethyl 
ether was then added to the reaction as the Lewis acid. Upon purification a small 
yield o f the ether 207 was isolated. Crude isolation o f the two products (217) as an 
oil, and removal o f any traces o f the MCPBA or water that might hamper the effect o f 
the Lewis acid was then performed, subsequent reaction with boron trifluoride gave 
ether 207, isolated in 35% yield. Attempts to optimise the reaction were performed, 
however no yield greater than the first attempt was achieved.
Table 2: List o f conditions attempted in cleaving the C-S bond from  hemithio acetals 203 and 206
R eagen ts So lven ts T em perature Time G as Yield
1 R a n e y  Ni A c e t o n e  / EtOFI rt to reflux 0 .5 h  - 7 d a y s Ar / H2 / N2 0
2 n B u 3S n H ,  AIBN T o lu e n e Reflux 0 . 2 5 h  - 1 d a y s Ar / H2 / N2 0
3 1) N C S ,  2)  N a B H 4 DCM / g lym e rt to Reflux 0 . 2 5 h  - 2 d a y s Ar 0
4 1) N C S ,  2)  E t3SiH DCM rt to Reflux 0 .2 5 h  - 3 d a y s Ar 0
5 1) N B S,  2) N a B H 4 DCM / g ly m e rt to Reflux 0 .2 5 h  - 2 d a y s Ar 0
6 1) N C S ,  2)  Et3SiH DCM & 'BuOH rt to Reflux 0 . 2 5 h  - 2 d a y s Ar 0
7 1) N C S ,  2)  Et3SiH DCM & 'BuOH Reflux 0 .2 5 h  - 2 d a y s Ar 0
8 1) N C S ,  2) EtaSiH AcO H rt to Reflux 0 . 2 5 h  - 2 d a y s Ar 0
9 M C PB A , B F 3. O M e 2 DCM 0°C 2h Ar < 10%
10 1) M CPB A , 2)  B F 3.O M e 2 DCM 0°C 2h Ar 3 6%
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Considering this result, the suitability of the pathway was called into question. The 
low yields observed in the coupling and sulfur cleavage steps were clearly increasing 
the cost o f the synthesis as a large amount of starting material was required to make
207. Also upon repetition the yields o f the reactions were highly variable. No 
standard could be reached and the success o f the reaction appeared to be due to 
minute untraceable factors. This made the possibility o f a scale up using this 
chemistry extremely risky. Other attempts towards electrophile 138 were therefore 
tried.
2.3.6 Electrophile Synthesis VI -  Successful Iodide Synthesis
A paper came to our attention which claimed that the problem o f lactonisation 
inherent to homoserine could be prevented using a protecting group orthogonal to 
'butyl75. Using the base labile Fm group Grieco and co-workers were able to 
synthesise stable protected derivatives o f homoserine. Fm groups are often thought o f 
as the ester variety o f the Fmoc group as they are both removed with piperidine in 
approximately the same time. The literature pathway went on to derivatise the alcohol 
as an iodide and this too was stable. Scheme 58 shows the planned route to iodide 221 
and ether 222.
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1) Amine Protection
2) Anhydride Formation
OH
220
RHN
5) Reduction
6 ) Mesylation
7) lodination
HO. 219
4) Crystallization
R-,HN
8 ) Ether Bond Fomation 
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B0 C2 N Ot-Bu
Ot-Bu
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Scheme 58: Planned synthesis o f protected ether bridged bis-amino acid 222
The literature source initially protected aspartic acid as the Boc derivative. As an 
orthogonal strategy was needed, we envisaged that this could be changed to an allyl 
carbamate. The diacid would then be dehydrated to anhydride 218 and opened with 
Fm alcohol 219 to give a mixture of a  and p protected esters. Recrystallisation to 
yield 220 and subsequent active ester reduction would provide protected homoserine. 
The primary iodide could then be made by mesylation followed by iodide
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displacement. It was envisaged that coupling o f alcohol 150 and iodide 221 would 
form ether 222.
OH
OH
OH
OH
AlocHN
O O
140 223
AlocHN
224
O
OH
AlocHN" Y ° Fm AlocHN 
O
225
OFm
OH
O
226
a) Allyl chloroformate, Na2 C 0 3) H2 0, rt, 24 h b) Ac2 0, THF, reflux, 4 h c) 219, 'Pr2 EtN, THF, rt,
24 h
Scheme 59: Synthesis o f protected aspartic acid regioisomers 225 and 226
Aspartic acid was protected as its allyl carbamate 223 (Scheme 59) and then 
dehydrated by heating the acids in THF with A c2Oie to give 224. After addition of 
219, 225 and 226 were isolated as a waxy solid, attempted recrystalisation o f the two 
regioisomers failed. No attempt was made at isolating a DCHA salt o f 225 and 227 as 
the Fm would be deprotected under the conditions required to form the molecule. 
Failure also occurred when trying to purify the mixture by flash column 
chromatography as the two compounds coeluted. Although it was hypothesised that 
the two regioisomers contained acids that would have differing properties due to their 
electronic and steric environments no separation was possible. The strategy therefore
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had to be changed as the allyl carbamate did not allow for isolation and purification 
o f the a  Fm ester 225.
1) Boc Protection
BocHN'2) Anhydride Formation
227
219
HO.
4) Crystallization
BocHN
5) Deprotection
6 ) Aloe Protection
AlocHN
Scheme 60: Planned synthesis o f protected aspartic acid 225
Scheme 60 shows the revised route to 225. Deprotection o f the Boc and reprotection 
as the Aloe carbmate was to be performed once the desired a  Fm ester was isolated. 
This scheme also requires a change of reagent when performing the cyclisation as the 
presence of AcOH found within AC2O would very likely deprotect the Boc group, so
77DCC was planned to be used instead.
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OHh2i BocHN
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75% BocHN
229
BocHN'
227
HoN
96% AlocHN 73% AlocHN
OFm
AlocHN
a) (Boc)20, Na2 C 0 3, H2 0 , 0°C to rt, 24h b) DIC, 'Pr2 EtN, THF, rt, 4h c) 219, 
'Pr2 EtN, THF, rt, 24 h d) TFA:CH2 CI2  (1:1), Et3 SiH, 0°C, 2.5h e) allyl chloroformate, 
NaHC03, THF:H20  (1:1), 0C, 2h f)'butyl chloroformate, 'Pr2 EtN, CH2 CI2, rt, 1 hr 
then MeOH, NaBH4, -78°C 2.5 h g) MsCI, Et3 N, CH2 CI2, rt, 2.5 h
Scheme 61: Synthesis of aspartic acid derived m esylate 232
Upon protection o f aspartic acid with (Boc^O 229 was cyclised with DCC and 
opened with Fm alcohol (Scheme 61). The reaction produced a very fine brown solid 
which was resistant to dissolving in EtOAc. After extensive heating a clear brown 
solution was obtained. Upon addition o f a small quantity o f hexane, a fine brown 
suspension started to appear. The solid was isolated and found to be a mixture of
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DCU and unwanted side reaction material. Repeating the crystallisation gave a small 
amount o f pure 228 and after 5 more cycles of recrystallisation a reasonable yield of 
32% was achieved. Due to the very lengthy and problematic purification procedure 
using DCC it was decided to attempt the dehydration using a different carbodiimide. 
Using DIC it was possible to isolate the mixture o f regioisomers as a pink crystalline 
material that was far easier to recrystallise. After a further four recrystallisations, 228 
was isolated in excellent 75% yield. This reaction was found to be highly robust when 
scaled up to 15 g and repeated. The Boc group o f 228 was then deprotected with TFA 
in CH2CI2 and amino acid 230 was rapidly crystallised with cold Et20 and hexane. 
NMR spectroscopy o f this crude material showed that there had been a small amount 
of transesterification within the molecule producing the p Fm ester. After 
optimisation it was possible to stop this happening by increasing the TFA 
concentration and therefore shortening the length o f the reaction. Upon reprotection 
of the amine with allyl chloroformate and purification it became clear that a small 
degree of transesterification had again occurred. Optimisation o f the conditions by 
reducing reaction times and lowering the temperature gave pure 225. This was then 
reacted with zso-butyl chloroformate and NMM to yield a mixed anhydride. The 
protonated NMM present as a solid in the dichloromethane was initially filtered off 
but it was found that this step could be omitted and there was no loss o f yield. 
Lowering the temperature to -78°C NaBFLj was then added followed by dropwise 
addition o f MeOH. It was important to maintain the low temperature as reactions 
performed above this suffered from many side reactions and low yields. After work 
up homoserine 231 was rapidly purified by flash column chromatography. A small
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amount o f lactonisation could be observed by TLC after 231 had been in a standing 
solution at room temperature for 2 hours. As an oil it was stable in the freezer 
indefinitely. Mesylation o f 231 was then performed which occurred in good yield and 
gave 232. Purification was not attempted on this molecule as only one spot by TLC 
was observed.
99% AlocHN 99% AlocHN'
O O o
234 232 233
a) LiBr, THF, reflux, 2 h b) Nal, THF, reflux, 2 h
Scheme 62: Synthesis of protected iodide 233 and bromide 234 from mesylate 232
Mesylate 232 was reacted with Nal in refluxing THF to give iodide 233 (Scheme 62) 
This reaction again was very clean and produced a single spot by TLC. The iodide 
was stable at room temperature in solution or as a yellow powder. It was decided that 
bromide 234 should also be made so mesylate 232 was refluxed in THF with LiBr. 
The reaction was again very clean yielding only one spot by TLC. The reason the 
bromide was synthesised too was because these are sometimes found to give cleaner 
etherification reactions over iodides as they are less prone to elimination reactions. 
Producing the two primary halides it was felt that any attempted ether coupling 
methodology could be more rigorously probed.
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Scheme 63: Attempted synthesis o f orthogonally protected ether bridged bis-amino acid 235
using iodide 233 and alcohol 150
With the previously planned molecules 233 and 150 synthesised the stage of 
attempting to couple the two together had been reached (Scheme 63). After reviewing 
the literature for etherification reactions a standard Williamson ether coupling via a 
sodium alkoxide was not chosen to be performed first. This was because although 
alcohol 150 was stable to lactonisation, if it was deprotonated it was likely to ring
78close. It was therefore decided to attempt a silver salt mediated etherification . These 
reactions are often used in natural product syntheses when harsher conditions must be 
avoided79,80. It is most commonly performed with AgOTf81 and Ag20 82,83,84. 
Reactions with Ag20 generally require high temperatures and/or long reactions 
times85, whereas those with AgOTf are often performed at low temperatures and are 
complete in under an hour86. Typically a bulky amine base such as DTBP is used in 
the reactions. This is a very expensive reagent so the cheaper 2,6-lutidine was used 
which is a hindered base but a slightly more nuclophilic one43.
The two molecules 233 and 150 were dissolved in CH2CI2 and the temperature 
lowered to -78°C. 2,6-Lutidine was then added followed by AgOTf. After 10 minutes 
the TLC showed many products (without a main intense spot), and starting alcohol
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150. When reaction times were shortened or dilutions increased it was clear that the 
many side reactions were occurring faster than any etherification. Attention was 
therefore turned to performing the reaction with bromide 234 (Scheme 64).
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Scheme 64: Attempted synthesis of orthogonally protected ether bridged bis-amino acid 235
using bromide 234 and alcohol 150
The reaction was stirred for one hour at -78°C but no reaction was observed to be 
occurring by TLC so it was very slowly warmed to room temperature. After being at 
this temperature for 10 minutes the TLC showed again a multitude o f products and 
starting alcohol 150. Attempts to optimise the reaction by changing the temperature, 
dilution, solvent and length o f reaction time it became apparent that no etherification 
was occurring. From the results experienced it appeared that the alcohol 150 was 
stable to the reaction conditions but the primary halides were reacting with the 
reagent or with themselves. Hypothesising it may be a problem with the reactive 
AgOTf the salt was changed to Ag20. Reactions using this reagent also resulted in a 
lack o f formation o f an ether bond. Even when heating the reaction to 40°C in the 
presence Ag20  very little happened. Further reactions were attempted using 
Ag2C0387 and A gN 0388 but no indication that an ether had been formed could be 
found. Table 3 shows the reactions performed.
I l l
Table 3: List of conditions attempted form ether from alcohol 150, iodide 233 and bromide 234
Electrophile Base Solvent Used Silver Salt Time/hrs Temperature Yield of 106
Iodide 2,6-Lutidine CH2CI2/ M eN02/TH F AgOTf 0.1 -78°C 0
Bromide 2,6-Lutidine CH2CI2 / M eN 02 / THF AgOTf 0.1 -78°C to 0°C 0
Iodide 2,6-Lutidine CH2CI2/ M eN02/ THF Ag20 0.1 to 120 rt & 50°C 0
Bromide 2,6-Lutidine CH2CI2/ M eN02/ THF Ag20 6 to 120 rt & 50°C 0
Iodide 2,6-Lutidine CH2CI2 / M eN02 / THF AgN03 0.1 to 120 rt & 50°C 0
Bromide 2,6-Lutidine CH2CI2/M e N 0 2/TH F AgN03 6 to 120 rt & 50°C 0
Iodide N/A CH2CI2 / M eN02 / THF Ag2C 0 3 1 to 120 rt & 50°C 0
Bromide N/A CH2CI2/ M eN02/ THF Ag2C 0 3 1 to 120 rt & 50°C 0
Next a classical Williamson ether coupling with NaH was performed. Although there 
are competing reactions such as lactonisation and Fm deprotection it was felt that by 
adding the NaH at low temperature to a solution o f 150 and 233 the etherification 
would be favoured. The reaction was performed at -78°C in CH2CI2 after 20 minutes 
it was quenched with AcOH and warmed to room temperature. The resultant TLC 
consisted o f many spots and a small amount o f starting iodide, there was no sign of 
the alcohol 150. Other variations attempted such as using the bromide and changing 
the solvent had no effect. A reaction run with just alcohol 150 and NaH in THF 
showed only decomposition products after 10 minutes at -78°C, highlighting the 
unstable nature o f the alkoxide formed. A similar reaction to this was tried which
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used KF fused onto Celite as the etherification reagent . The reaction involved 
microwave irradiation and the iodide 233 and alcohol 150 in a very concentrated 
solution o f DMF. It was hypothesised that as the reaction involved no extremes o f pH 
the starting molecules may withstand the conditions. After testing various conditions 
such as dilution, length o f time in the microwave and equivalents o f KF-Celite the
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reaction did not work The products isolated included 150 minus a Boc group and 
starting iodide. No positive result was achieved with bromide 234 either.
A relatively new method then came to our attention, reductive etherification o f silyl 
protected alcohols and aldehydes90,91,92,93. This reaction has seen considerable interest 
in recent years as there are limited methods for mild etherifications. The reaction has 
been performed by a variety o f reagents such as FeCb94,95, CuOTf06, B(C6Hs)397, and 
BiBr398,99. It is believed that the reaction proceeds by formation o f an oxonium ion 
which is then quenched by a hydride source. There has been much debate over the 
catalytic cycle and reactive species of the etherification98,90,100.
Before the etherification reaction could be performed the starting materials had to be 
synthesised. Silylation o f alcohol 150 with TBDMSC1101 was favoured as test 
reactions with 231 showed that the presence o f imidazole deprotected the Ofm group 
over the course o f the reaction.
OH OTBDMS
Ot-Bu
O
Ot-Bu
O
150 236
a) TBDMSCI, DMF, imidazole, rt, 18 h
Scheme 65: Synthesis o f TBDMS protected homoserine silyl ether 236
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Silylation occurred in a concentrated solution o f 150 (Scheme 65) in DMF at room 
temperature overnight. Purification by flash column chromatography gave an 
excellent yield o f 98% for TBDMS ether 236.
OH O
OFmAlocHN
O
52% OFm
AlocHN
O
231 237
a) Oxalyl Chloride, DMSO, CH2CI2, -78°C, 0.5 
h then 231, Et3N,to 0°C, 2 h
Scheme 66: Synthesis o f aspartate semi-aldehyde 237
To synthesise the desired aldehyde 237, a Swem reaction was used102,103. Oxalyl 
chloride was cooled to -7 8 °C in CH2CI2 and DMSO was added dropwise (Scheme
66). After 30 minutes alcohol 231 dissolved in CH2CI2 was added dropwise. After 
another 30 minutes EtaN was added and the reaction was warmed to 0°C. Post work 
up, it became clear that there were two major products from the reaction. The side 
product produced in large quantity is produced if  the reaction becomes too warm. 
Unfortunately no way o f stopping this unwanted side reaction was found however 
slow the addition, or low the temperature was. This gave a poor yield o f 53%.
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o  OTBDMS
Ot-Bu
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Ot-Bu
AlocHN
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237 236 235
a) BiBr3, Et3SiH, MeCN, rt, 48h
Scheme 67: Attem pted synthesis o f orthogonally protected ether bridged bis-amino acid 235
using silyl ether 236 and aldehyde 237
Silyl ether 236 was dissolved in MeCN and stirred at room temperature (Scheme
6 7 ) io° g t3sj]_[ was tjien added followed by BiBr3. Upon addition o f the catalyst the 
reaction went a dark black grey colour. Aldehyde 237 was then dripped into the 
reaction and the mixture was stirred for 48 hours. The final TLC showed at least 7 
products had been made but there was one spot which was both UV active and 
stained with ninhydrin, indicative o f the Fm group and Boc amine being present.
Isolation o f this spot gave a product with an NMR which showed a missing Boc 
group and a proton missing adjacent to the ether linkage. At first it was believed that 
the compound was 238 (Scheme 68). By mass spectrometry it appeared that the 
oxonium salt 239 was seen, with elimination o f Br" in the spectrometer. However 
attempts to quench the bromide with Et3SiH, or NaBH4 with a Lewis acid, were 
unsuccessful.
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NHAIoc Br Br
FmO
Ot-Bu
BocHN
O
OAlocHN NHBoc
FmO
t-BuO
239
Scheme 68: Postulated products from silyl ether 236 and aldehyde 237
Previous reports on a-halo ethers indicated that they are extremely reactive and would 
rapidly react with water to form hemi acetals104. After reassessing the spectra 
obtained it was eventually worked out that the correct final structure was not 238, but 
240 (Figure 22).
NBoc
OFm
AlocHN'
O
240
Figure 22: Product of reductive etherification reaction, hemiaminal 240
It was hypothesised that the formation o f 240 would occur during the coupling step. 
The small amount o f HBr produced within the reaction would deprotect the Boc 
group and this would leave a highly nucleophilic nitrogen anion which could attack 
the oxonium salt reportedly formed during the coupling (Scheme 69).
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NHBoc
Br ?  J  
AlocHN
OFm
O
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OFm
AlocHN
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241 240
Scheme 69: Postulated mechanism of silyl ether 236 and aldehyde 237
Reactions performed containing K2CO3 to try and stop excessive HBr production 
returned starting materials 237 and 236. This is understandable as the acid is believed 
to be the catalytic species and by removing this we see no reaction.
117
2.4 Summary
After successfully making target synthons 150 and 233 no way was found o f coupling 
them together. Many reactions and attempts to optimise all o f the silver, bismuth and 
classical Williamson ether coupling reactions had been performed but an ether was 
never successfully synthesised. The lactonisation that occurs when an alkoxide forms 
from alcohol 150 is understandable. This molecule is ideally set up to perform this 
reaction but is stopped by the presence o f the bulky lbutyl group. The increase in 
reactivity that occurs when the alkoxide forms must be greater than the effect of the 
steric repulsion and lactonisation occurs, even at low temperatures.
Reductive etherification gave good yields, unfortunately o f the wrong material. After 
working out what the final product formed was we attempted to stop its formation and 
encourage ether formation by addition o f base. From the postulated mechanism 
though it can be seen why this would leave just starting materials.
The failure o f any o f the silver salt chemistry to work is however surprising. The 
reactions carried out have much literature precedent. Although the less hindered base 
2,6-lutidine was used instead o f DTBP reactions were expected to occur but in less 
than excellent yields. One explanation could be that the iodide and bromide reacts 
with itself before any coupling occurs when AgOTf is used. This though does not 
explain the lack o f success achieved using Ag2 0 . With the failure o f any positive
118
results experienced attempting to couple alcohol and halide we changed our approach 
and ended the work on etherifications.
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3.0 Synthesis of Protected Homolanthionine
NH2
242
Figure 23: Product of reductive etherification reaction, hemiaminal 240
Homolanthionine 242 is a one sulfur mimic of a disulfide bridge. Instead o f 
containing a two sulphur bridge it contains a thioether and is therefore not readily 
cleaved under physiological conditions. These properties have made it an attractive 
candidate for stabilisation o f small bioactive peptides. To date two groups have 
performed syntheses of a peptide containing a homolanthionine bridge105,75. The two 
syntheses both installed the bridge as a post synthetic modification o f the peptide and 
potentially therefore limit the amino acids residues that can be used in the sequence. 
We planned to synthesise an orthogonally protected homolanthionine and incorporate 
it into the peptide in the same way as Scheme 43.
SH
O O
F m o c H N ^ Y 0 t"Bu + TrtHN ' Y ° AI1 90% *  t - B u O ^ ^ " S ^ - ^ O A I I
O O NHFmoc NHTrt
119 118 120
a) Cs2 C 03, DMF, rt, 2.5 h 
Scheme 70: Synthesis of protected lanthionine 120
120
Work within the group to make lanthionine 120 by coupling cysteine 119 with 
iodoalanine 118 has been shown to work in very good 90% yield (Scheme 70)4.
Using the same reaction conditions iodide 233 was reacted with cysteine 119 in DMF 
with CS2CO3 (Scheme 71). After optimisation of time and dilution a reliable 64% 
yield o f 122 could be achieved upon increasing the reaction to a 5 g scale. The 
success in performing this reaction highlights the increased nucleophilicity of 
sulphur over oxygen. Whereas none of the etherifications worked this reaction was 
completed with an ionic base at room temperature.
SH
a
Ot-Bu
FmocHN^ ' Y ° t"Bu A lo c H N * )^ 0  Fm 64% Fm0 ^  ^  "NHFmoc
O O NHAIoc
119 233 243
a) Cs2C 03, DMF, rt, 2.5 h
Schem e 71: Synthesis o f protected homolanthionine 243
The synthesised sulfide contained protecting groups that had to be changed to the 
ideal set o f 127, a free acid, Fmoc carbamate, allyl carbamate and an allyl ester 
(Scheme 72). To achieve this a series o f protecting group exchanges were performed
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O ^ O t-B u  (V  .Ot-Bu
1 a .  Q V  b
S II Q I
^  NHFmoc HO'/^ / X n /  580//°’2
NHAIoc 2 4 3  NHAIoc 244
NHAIoc
O ^ O t-B u  n  O ^ O t-B u
- J U
NHBoc 72% AIIO^ ^ S'^ / ^NH Boc  
245 NHAIoc 246
o ^ o h  e 0  c y O H
S^ N H 2  53% AIIO/ ^ ^ v % /S ' ^ >*NHFmoc 
NHAIoc 247 NHAIoc ^
a) Piperidine, DMF, rt, 2.5 h b) NaHC03, THF:H20  (1:1), (Boc)2 0 , rt. 24 h c) i) 
Cs2 C 0 3, MeOH i) allyl bromide, DMF, rt, 24 h d) TFA, Et3 SiH, CH2 CI2, 0°C to 
rt, 3.5 h e) Fmoc chloroformate, NaHC03, THF:H20  (1:1), 0°C to rt, 2.5 h
Scheme 72: Synthesis of homolanthionine 248 for peptide synthesis
Firstly both the Fm and Fmoc groups were removed by treatment o f 243 with 
piperidine at room temperature. The primary amine was then Boc protected to ensure 
that it did not react with the ester made in the next step. The free acid was esterified 
with allyl bromide to furnish fully protected homolanthionine 246. The Boc and lbutyl 
groups were then removed with TFA and the primary amine protected as an Fmoc 
carbamate 248 in a disappointing 53% yield. The entire pathway o f protecting group 
exchange involving 5 steps was performed in a good overall yield o f 22%. Each step 
o f this route was painstakingly optimised as 250 mg of 248 was the minimum mass 
required for peptide synthesis. After scaling the reaction up three times enough 
material was obtained to make a peptide.
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The peptide that was chosen to be synthesised was an analogue o f a Bowman Birk 
inhibitor106,107,108,109. These are naturally-occurring serine protease inhibitors 
containing a nine-residue p turn constrained by a disulfide loop which is responsible 
for their inhibitory activity. To increase the stability of the native peptide mimics 
have been created containing saturated and non saturated carba side chains o f varying 
lengths, although no one has produced a homolanthionine derivative (249, Figure
Peptide synthesis was then begun towards molecule 249. A preloaded tyrosine 
chlorotrityl Sieber resin was used to install the first residue into the peptide sequence 
(Scheme 73). All peptide synthesis was carried out using a SYRO peptide 
synthesizer. The first step involved deprotection of the Fmoc group from the resin 
bound tyrosine. A Kaiser test was then performed which confirmed that an amine was 
present. The free acid o f protected homolanthionine 248 was then activated with 
PyAOP, HOAt and DIEA and coupled with the amine o f the tyrosine residue. The 
mixture was reacted for 1 hour with a fast vortex o f the solution occurring every 2  
minutes for 20 seconds. The resin was then washed with several portions o f DMF and 
CH2CI2 before a Kaiser test was again performed. This showed a negative result for 
the presence o f an amine so the synthesis was continued by deprotection o f the Fmoc
S
W X  W  F W  I W  
249
P W  X W
- t q n - { t } - c o o h
Figure 24: Target peptide 249 containing an ether bridged side-chain
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protecting group. After a positive result from the Kaiser test the amine was then 
coupled to the HBTU/DIEA activated acid of a glutamine residue. The synthesis was 
then automated using standard Fmoc SPPS protocols until 252 was arrived at. With 
the Fmoc group still present on the amine of the tyrosine both allylic protecting 
species were deprotected with a cocktail o f Pd(PPh3)4, DMF, CHCI3 , NMM, AcOH in 
the absence o f light and under nitrogen. After the solution had been reacting for 2 
hours with a 1 minute vortex every 3 minutes the resin was washed with a solution of 
DIEA in DMF and then DMF containing diethyl dithiocarbamate to ensure all allylic 
species were quenched and removed from the reaction vessel. The Kaiser test at this 
stage showed only a partial positive result, being a light red as apposed to the dark 
purple we had encountered for previous positive results. Regardless o f this we 
continued with the synthesis and cleaved the Fmoc group from the resin bound 
tyrosine at the end of the linear chain. The Kaiser test at this point was firmly 
positive. The peptide was then cyclised using PyOAP, HOAt and DIEA to give 254.
A similarly unconvincing Kaiser test was then observed but the synthesis was 
resumed and the final amino acid serine coupled to the free amine and the Fmoc 
removed. The resin was then treated with a cocktail o f TFA, ethanedithiol, Et3SiH 
and water to cleave the peptide from the solid phase and remove all side chain 
protecting groups to give 249.
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a) PyAOP, HOAt, DIEA, DMF b) i) piperidine, DMF ii) 
Fmoc SPPS c) i) Pd(PPh3)4, DMF, CHCI3, NMM, AcOH ii) 
piperidine, DMF d) PyAOP, HOAt, DIEA, DMF e) i) Fmoc- 
SerCOteiO-COOH, HBTU, DIEA, DMF ii) piperidine, DMF 
iii) TFA, ethanedithiol, Et3 SiH, H20
Scheme 73: Attempted synthesis o f peptide 249 by SPPS
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The cleavage cocktail was then diluted with ether and cooled to -23°C in the freezer. 
This caused the peptide to precipitate out as a white solid. The solid was isolated by 
centrifugation and freeze dried from water to give 15 mg ( 1 0  % yield) o f crude 
m aterial.
The solid was dissolved in water and subjected to preparative reverse phase HPLC. 
The graph created from this contained a series of at least 5 very broad peaks and a 
rising base line. This indicated that the material was not very soluble in the solvent 
system o f water MeCN being used. Mass spectrometry o f samples from the major 
peaks indicated that there was peptide sized material present but nothing matching the 
mass o f 249. These same samples were then subjected to NMR and the lack of 
solubility was confirmed. None o f the material readily dissolved in D2O giving very 
poor broad peaks. None o f the NMR spectrographs showed presence o f peptide 249. 
This was confirmed by comparison of the spectrographs obtained with those o f the 
natural peptide SCTFSIPPQST synthesised in parallel to 249. The only sample that 
looked like it contained most o f the amino acids expected to be in 249 gave two peaks 
by mass spectrometry 12 and 13 mass units higher than the expected mass. The NMR 
spectrograph o f this material showed the presence o f allylic material. Postulating that 
the Pd(PPh3)4 used to cleave the allylic groups may not have been fully active, as it 
was from a old batch we decided to repeat the synthesis.
Upon repetition o f the synthesis the same results were encountered. The main peak by 
HPLC gave the same 12 to 13 mass unit increase by mass spectrometry and the NMR
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contained allylic signals. Although a newly ordered batch o f Pd(PPh3)4 had been used 
this time the result was the same. The quality of the Pd(PPh3)4  was later found to be 
very poor as it did not deprotect allylic protecting groups on a different peptide after 
many hours o f reacting. This was unfortunate as there was no more protected 
homolanthionine 248 to try another peptide synthesis.
The low yields o f both peptide syntheses produced very little material for 
spectroscopy. The lack o f solubility in D2O and poor NMR spectrum meant that 
working out what the mystery structure was not possible. The small increase in mass 
of 1 2  and 13 units meant that it was not a simple case o f an allylic group still being 
present either as a protecting group or attached to a nearby nucleophilic amino acid 
side chain. After calculating many masses accounting for deletion sequences and the 
presence o f a variety o f protecting groups attached and removed nothing similar to 
the observed mass could be found.
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3.1 Summary
Synthesis o f protected homolanthionine was achieved coupling iodide 233 with a 
cysteine derivative. The protecting groups were then manipulated to make the 
molecule ready for SPPS. A peptide was synthesised as a mimic o f the Bowman-Birk 
inhibitor. After cleavage o f the peptide from the solid phase and purification by 
HPLC nothing resembling target peptide 249 was observed by NMR or mass 
spectrometry. The closest material resembling 249 contained allylic spcecies by NMR 
and had a mass o f 12 and 13 units higher than expected. After much deliberation no 
conclusion could be reached over what this moiety was.
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4.0 Conclusion
After many failed routes to an ether it can be concluded that making this molecule 
from simple chiral pool substrates is not easy. The lack o f many ether bridged amino 
acids reported in the literature highlights the difficulty in creating these species. 
Although target molecules alcohol and iodide were obtained no ether could be 
synthesised. This therefore also highlights the scarcity o f mild etherification methods 
in the literature. Beyond the Williamson ether coupling and the emerging reductive 
etherification there does not appear to be any robust preparations for making alkyl 
ethers.
The two orthogonal pathways to stable protected homoserine molecules are however 
very useful as shown in the homolanthionine work. Iodides o f either molecule can be 
made easily and reacted with cysteine to give homolanthionine. Further derivatisation 
of these molecules would be interesting to investigate a whole series o f sulfur, 
nitrogen and carbon bridged bis amino acids.
Although peptide synthesis was undertaken no peptide was obtained. The reasons for 
this could be either the poor state o f the Pd(PPh3)4 or the large size o f the ring closure 
reaction. This nine amino acid ring closure is the largest that has been attempted in 
the group; most have consisted o f a maximum of five residues between the bridged 
bis amino acids. Without full characterisation o f the final peptide-like species it is 
very hard to know which o f the two were to blame for the failure.
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5.0 Future Work
The lack o f simple reactions to yield ether means that more challenging synthetic 
pathways should be attempted. Using asymmetric synthesis it should be possible to 
install the two stereocentres o f a bis amino acid in much the same way as 25 (Scheme 
3) but starting from a symmetrical ether rather than an alkyl chain (Scheme 83).
COOH
EtO^  .
EtO
Auxiliary coupling
O o
AEtO, ,N
N OEt
Amination of oxazolidinone
FmocHN
OEt
Removal of auxiliaries
NH2  FmocHN
AIIO 
AlocHN
Protecting group manipulation 
O
OH 
FmocHN
Scheme 74: Planned synthesis o f orthogonally protected ether bridged bis-am ino acid using
asymmetric chemistry
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Further work towards homolanthionine 248 containing peptides and the identification 
of why the peptide synthesis did not work should be performed (Figure 25). Having 
two stable homoserine molecules means that orthogonally protected bis amino acids 
such as 255, 256, and 257 should be easy to prepare. Changing the heteroatom from 
sulfur to nitrogen could also give interesting results.
NHFmocNHFmoc
NHAIocNHAIoc
NHFmoc NHAIoc NHFmoc NHAIoc
256 257
Figure 25: Future target molecules to attempt synthesis of, protected homolanthionines 248 and
255 and bridged sulfide 256 and amine 257
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6.0 Experimental
All *H NMR spectra were recorded on a Bruker 300 MHz NM R machine. 13C NMR 
were recorded on a Bruker 75 MHz NMR machine. Low resolution mass 
spectrographs were recorded on a Quattro LC electrospray mass spectrometer. HRMS 
were recorded on a VG ZAB 2SE. IR spectrographs were recorded on a Shimadzu 
8700. Optical rotations were recorded using a Optical Activity AA-100 digital 
polarimeter using the sodium-D line. Melting points were recorded using a Reichert 
hot stage apparatus and are given uncorrected.
Unless otherwise noted, solvents used were reagent grade and used without 
purification. The solvents THF, CH2CI2 , toluene and MeCN were dried using solvent 
drying columns. 2,6-Lutidine, diglyme, piperidine, TMG, 'P^EtN, Et3N and NMM 
were dried by distillation from CaH2 under argon and stored over molecular sieves. 
EtOH and MeOH were distilled from Z n /f  under an argon atmosphere and used 
immediately. Acetone was distilled from activated molecular sieves onto activated 
molecular sieves and used immediately. DMF was purchased dry from Aldrich and 
stored over molecular sieves. CCI4 and methanesulfonyl chloride were distilled from 
P2O5.
Flash column chromatography was performed using silica 60 obtained from BDH. 
TLC was performed using 0.25 mm thick layer Merck 60 F254. Visualisation o f the
140
spots on TLC plates was achieved using UV, phosphomolybdic acid, anisaldehyde, 
potassium permanganate, vanillin, ninhydrin, bromocresol green or iodine stains.
L-Aspartic acid copper (II) complex copper II salt octahvdrate (142)1
A suspension o f Q1CO3 (2.0 g, 16.2 mmol, 1.1 eq) in H2O (230 ml) was heated to 
70°C and stirred until all the solid CuCCh had dissolved. To this a solution o f L- 
aspartic acid (2.0 g, 15.0 mmol) in H2O (85 ml) was added dropwise over 1 hour. The 
resulting mixture was allowed to cool to room temperature and was stirred for a 
further 48 hours. The mixture was then suction filtered to isolate the desired solid. 
This was washed with H2O (3 x 20 ml), EtOH (3 x 20 ml) and EtO Ac (3 x 20 ml). 
The solid 142 was then dried in a vacuum oven 80°C / 14 mmHg for 48 hours and 
used crude in following reactions.
Aspartic acid 4-benzvl ester copper (II) complex (144)1
O
142
141
Bn
P
<
OBn
144
To a solution o f finely powdered 143 (0.77 g, 1.99 mol) prepared above and aspartic 
acid (0.52 g, 3.98 mmol) in DMF (5.0ml) and H2O (0.6 ml) stirred at room 
temperature was added TMG (1.0 ml, 7.96 mmol) over 30 minutes. After 2 hours 
further DMF (5.0ml) was added. To this mixture was added benzyl bromide (0.95 ml, 
7.96 mol) and the solution stirred for 24 hours at room temperature before dilution 
with acetone (30 ml). The resultant mixture was stirred for 3 hours and then suction 
filtered. The isolated solid was washed with acetone (3 x 20 ml) and dried under 
vacuum in the presence o f P2O5 for 72 hours and used crude in following reactions.
L-Aspartic acid B -benzyl ester (14511
To a solution o f NaFICCb (900 mg) in H2O (13.0 ml) was added EDTA (2.0 g) and 
the mixture stirred at room temperature for 1 hour. To this was added 144 (2.0 g) in
O
145
142
one portion and the resulting suspension was shaken vigorously for 20 minutes, 
before being left to stir for 3 hours at room temperature. After dilution with acetone 
(10 ml) and cooling to 10°C the suspension was suction filtered. The collection flask 
was changed and the resulting solid was washed with H2O (20 ml). Removal of the 
solvent in vacuo yielded white solid 145 (445 mg, 46.9%). Identical by *H NMR and 
13C NMR to lit.2
Rf = 0.62 (silica gel, 50% "BuOH, 25% AcOH, 25% H20 )  
m.pt. = 216-218°C [lit m.pt. = 218°-219° C]2
[a]D21 = +5.15° (0.012M in H20 )  [lit [a]D20 = +6.9° (c = 0.89 in H20 )]2
*H NMR (300 MHz, DMSO -d6) 5 7.35 (5H, m, Ar), 5.07 (2H, s, C/fcFh), 3.48 (1H, 
m, C H a), 2.88 (1H, dd, J = 7.6Hz, CH//[3), 2.58 (1H, dd, J = 5.2, 16.8 Hz, Ci/H  P), 
2.47 (2H, s, NH 2)
13C NMR (75 MHz, DMSO-</6) 6 175.2 (CO Acid), 172.5 (CO Ester), 142.1 (Cq Ar), 
128.9 (C-H Ar), 127.4 (C-H Ar), 127.1 (C-H Ar), 73.1 (CH2 CO OC//2C6H5), 55.3 
(CH a), 36.9 (CH2 (3)
143
L-Aspartic acid B-methvl ester (14613
OMe
•OH
146
A solution o f L-aspartic acid (2.0 g, 15.0 mmol) in dry MeOH (10.0 ml) at -10°C was 
treated with dropwise addition of SOCI2 (1.2ml, 16.8 mmol, 1.1 eq) over 10 minutes. 
After 20 minutes at -10°C the mixture was warmed to room temperature and stirred 
for a further 25 minutes. Upon addition o f Et20 (50 ml) white crystals appeared. After 
cooling to 0°C and vigorous shaking the solid was removed by suction filtration. The 
resulting residue was recrystalised twice from Et2 0 /MeOH with addition o f a few 
drops o f IN  HC1 to yield pure white solid 146 (1.65 g, 60%). Identical by *H NMR 
and 13C NMR to lit.3
Rf = 0.51 (silica gel, 50% nBuOH, 25% AcOH, 25% H20 )  
rn.pt. = 189-191 °C dec [lit. m.pt. = 193°C]3
!H NMR (300 MHz, D20 )  5 4.17 (1H, t , J=  5.7 Hz, C H a ), 3.64 (3H, s, COOCH3), 
3.11 (2H, d, J =  5.6 Hz,C H 2P)
144
I3C NMR (75 MHz, D20 )  8 172.1 (CO Acid), 169.8 (CO Ester), 54.5 (CH a), 49.7 
(OCH3), 34.2 (CH2 fi)
A -a-B oc-L-aspartic acid B-methvl ester (147)
A solution o f 146 (24.0 g, 0.131 mol) in THF (200 ml) and H2O (100 ml) at 0°C was 
treated with Na2CC>3 (13.8 g, 0.131 mol, 1 eq). After effervescence o f CO2 , further 
Na2CC>3 (13.8 g, 0.131 mol, 1 eq) was added, followed by careful addition o f (Boc^O 
(31.5 g, 0.144 mol, 1.1 eq). The mixture was warmed to room temperature and stirred 
for 48 hours, before removal o f THF in vacuo. The resulting mixture was poured onto 
ice/water and extracted with Et20 (100 ml) to remove non-acidic impurities. The 
aqueous layer was then acidified to pH 2.0 with 0.1M HC1 and extracted with diethyl 
ether (3 x 150 ml). The combined ether extracts were washed with saturated brine and 
dried (NaSO,*). The solvent was removed in vacuo to yield 147 as an oil which was 
used crude in the following step.
OMe
BocHN
O
147
145
TV-g-Boc-L-aspartic acid B-methvl ester ^ utvl ester (148)4
OMe
•Ot-Bu
BocHN'
148
To a solution o f crude 147 (0.131 mol) in dry CH2CI2 (250 ml) at 0°C was added 
DM A P(1.20 g, 9.83 mmol, 0.07 eq) followed by lBuOH (13.0 ml, 0.144 mol, 1.1 eq) 
and DCC (32.3 g, 0.157 mol, 1.2 eq). The mixture was warmed to room temperature 
and stirred for 48 hours, before being filtered and washed with CH2CI2 (80 ml) to 
remove DCU. The resulting solution was washed with saturated aqueous NaHCC>3 (3 
x 150 ml), saturated brine (2 x 150 ml), dried (Na2SC>4) and concentrated in vacuo. 
The residual oil was purified by flash column chromatography (silica gel, 5% EtO Ac 
in CH2CI2) to provide 148 as a solid (28.1 g, 71%).
Rf = 0.55 (silica gel, 5% EtO Ac in CH2CI2)
m.pt. = 65°-69°C
[a]D22: -39.1° (c = 0.012M in CH2C12)
IR vmax; 3435 (N-H), 2923 (C-H), 1751, 1728 (O O )
146
'H  NMR (300 MHz, CDCI3) 8  5.40 (1H, br m, NH), 4.41 (1H, br m, CH a ) ,  3.59 (3H, 
s, OCH 3), 2.88 (1H, dd, / =  16.5, 4.5 Hz, C /ffl p), 2.71 (1H, dd, J =  16.5, 5.0 Hz, 
CUH  P), 1.43 (9H, s, N C O O C ( C 1.41 (9H, s, NCOOC(CH 3)})
13C NMR (75 MHz, CDCI3) 5 171.6 (CO 'Butyl), 170.3 (CO Methyl), 158.3 (CO 
Boc), 82.7 (OCOC(CH 3)3), 80.2 (NCOOC(CH3)3), 52.1 (CH a), 51.0 (OCH3), 37.4 
(CH2 p), 28.7 (CH3 ' OCOC(CH 3)3), 28.2 (NCOOC(CH3)3)
HRMS C |4H26N06calcd. for [M + H]+ 304.17600 found 304.17712. 
TV-g-DiBoc-L-aspartic acid B-methvI ester 'butvl ester (149I5
To a solution o f 148 (200 mg, 0.660 mmol) in dry MeCN (5.0 ml) was added DMAP 
(16 mg, 0.132 mmol, 0.2 eq) and (Boc^O  (576 mg, 2.64 mmol, 4 eq). After stirring 
for 24 hours at room temperature the solvent was removed in vacuo. The residual oil 
was taken up in EtOAc (35 ml) and washed with 0.01M KHSO4 (2 x 35 ml),
O
149
147
saturated aqueous NaHCC>3 ( 2 x 3 5  ml), saturated brine ( 3 x 3 5  ml), dried (Na2SC>4) 
and concentrated in vacuo. The residual oil was purified by flash column 
chromatography (silica gel, 20% Et2 0  in hexane) to provide yellow solid 149 (160 
mg, 60%). Identical by 'H  NMR, l3C NMR and IR to lit .4
Rf = 0.45 (silica gel, 20% Et2 0  in hexane)
m.pt. = 63 - 6 6 " C [lit. m.pt. = 64"- 6 6 °C] 4
[a ]D19: -72.1" (c = 0.012M in CH2C12) [lit. [a ]D25: -13.0" (c = 2.01 in CH2C12) ] 4
IR vmax (Nujol, cm"1) = 2952, 2922, (C-H), 1741 (C =0)
‘H NMR (300 MHz, CDC13) 8  5.33 (1H, dd, ./=  7.2, 6.4 Hz, CH  a ), 3.69 (3H, s, 
C O O C ft), 3.21 ( l H , d d , / =  16.5,7.2 HzCt fHP) ,  2.67 (1H, dd, J =  16.5, 6.3 Hz 
C R H  p), 1.50 (18H, s, 2 x NCOOC(Ctf3)3), 1.43 (9H, s, OCOC(CHs)})
13C NMR (75 MHz, CDC13) 8  171.4 (CO 'Bu), 168.7 (CO Me), 152.0 (CO Boc), 83.2 
(OCOC(CH3)3), 82.0 (NCOOC(CH3)3), 55.6 (CH a), 51.9 (COOCH3), 35.5 (CH2 /?),
28.0 (OCOC(CH3)3), 27.9 (NCOOC(CH3)3)
ES+ C i8H 33N 0 7Nam/z [M + Na]+ 426, [M -  Boc + Na] 326.
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HRMS Ci9H 33N 0 8Nacalcd. for [M + Na]+ 426.21038 found 426.20902. 
7V-a-Di-t.Boc-L-Homoserine t.-butvl ester (150)4
•OtBu
150
To a solution o f 149 (100 mg, 0.248 mmol) in dry CH2CI2 (8.0 ml) at -78°C was 
added DIBAL (1.0 M solution in toluene, 520 jlxI ,  0.521 mmol, 2.1 eq) slowly over 8  
minutes. The reaction mixture was stirred for 1 hour before being quenched with 
acetone (5.0 ml) and then H2O (1.0 ml), allowed to warm to room temperature, dried 
(Na2SC>4) and filtered through Celite. The solvent was removed in vacuo and the 
residual oil purified by flash column chromatography (silica gel, 20% EtOAc in 
hexane) to yield a thick colorless oil 150 (91 mg, 98%). Identical by !H NMR, 13C 
NMR and IR to lit .4
Rf = 0.30 (silica gel, 20% EtOAc in hexane)
149
[a]D22: -23.3“ (c = 0.010M in CH2C12) [lit. [a ]D25: -13.0“ (c =  2 . 0 1  in CH2C12) ] 4
IR vmax (neat, cm '1) = 3543 (O-H), 2979, 2935, (C-H), 1789, 1747 (C =0)
'H  NMR (300 MHz, CDC13) 8  4.90 (1H, dd, J =  9 .5 ,4 .9  Hz, CH a ) ,  3.68 (2H, m,
CHZ y), 2.30 ( 1 H, m, CH 2  p), 1.95 ( 1 H, m, CH 2 p), 1.46 (18H, s, 2  x N C O O C (C ft)3), 
1.39 (9H, s, OCOC(CHi)i)
l3C NMR (CDC13, 75 MHz) 5 170.9 (CO 'Bu), 153.0 (CO Boc), 83.6 (Cq ‘Bu), 81.9 
(Cq Boc), 59.8 (CH2 y), 56.9 (CH a), 32.9 (CH2 fi), 28.4 (OCOC(CH3)3), 28.3 
(NCOOC(CH3)3)
ES+ C i8H33N 0 7Na m/z [M + N a f  398.
HRMS C |8H 33N 0 7Na calcd. for [M+Na]+ 398.21546 found 398.21600. 
jV-g-Aloc-L-Homoserine allvl ester tosvlate 11611
150
SM
H2N’^ y t
O
141
/
h 2 n * ' ' y '
o
158
.OH O'Na
AlocHN’
159
-OAII
AlocHN’
160
OTs
.OAII
AlocHN’
161
A solution o f L-methionine (2.0 g, 13.4 mmol) in H2O (131 ml) and MeOH (26.0 ml) 
was stirred at -10°C and was then treated with Mel (2.5 ml, 40.2 mmol, 3 eq). The 
reaction mixture was warmed to room temperature and stirred for 24 hours. The 
solvent was then concentrated in vacuo, until approximately 50 ml remained. To this 
was added NaHCC>3 (1.13 g, 13.4 mmol, 1 eq), the resulting solution was heated at 
reflux for 4 hours. The solution was cooled to room temperature and 158 was used 
unpurified in the next reaction.
A solution o f crude 158 (13.4 mmol) in H2O (50.0 ml) was cooled to 0°C and 
NaHCC>3 (4.50 g, 53.6 mmol, 4 eq) was added. This was followed by dropwise 
addition o f a solution o f allyl chloroformate (2 . 8  ml, 26.8 mmol, 2  eq) in dioxane 
(50.0 ml) over a period o f 10 minutes. The resulting mixture was stirred at 5°C for 48
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hours. The solvents were then removed in vacuo and the crude solid 159 was used in 
the next reaction without purification.
To a solution o f crude 159 (13.4 mmol) in DMF (40.0 ml) was added allyl bromide 
(0.57 ml, 13.5 mmol, 1.01 eq). The resulting mixture was stirred for 60 hours at room 
temperature before the solvent was removed in vacuo. The residual oil was dissolved 
in CH2CI2 (50 ml), washed with saturated aqueous NaHCC>3 (3 x 50 ml), dried 
(MgSC>4) and concentrated in vacuo. The crude oil 160 was taken into the next step 
without purification.
Crude 160 (13.4 mmol), was dissolved in dry CH2CI2 (35.0 ml) at 0°C and tosyl 
chloride (3.07 g, 16.0 mmol, 2 eq) was added. Dry Et3N (6.0 ml) was then added and 
the mixture was stirred for 3 hours at room temperature. The solution was then 
washed with 0.05M aqueous citric acid (3 x 50 ml), aqueous saturated NaHCC>3 (3 x 
100 ml), dried (Na2SC>4) and evaporated to give a colorless oil. This was purified by 
flash column chromatography (silica gel, 80% CH2CI2 in hexane) to isolate a 
collection o f spots. Further purification by flash column chromatography (silica gel, 
40% EtOAc in hexane) provided pure brown oil 161 (585 mg, 6 %).
Rf = 0.5 (silica gel, 40% EtOAc in hexane)
[a]20D = -15.1" (c = 0.015M in CH2C12)
152
IR vmax (neat, cm '1) = 3327 (N-H), 2972, 2947 (C-H), 1647 (O C ) ,  1596 (C=C, Ar)
*H NMR (300 MHz,CDC13) 5 7.63 (2H, d, J =  8.3 Hz, CH  Ar), 7.20 (2H, d, J =  8.1 
Hz, CH  Ar), 5.7-5 . 8  (2H, m, 2  x CH2C//=CH2), 5.1-5.2 (4H, m, 2 x CH2CH=Ci/2),
4.5 (4H, m, 4H, 2 x C //2CH=CH2), 4.49 (1H, m, CH  a ), 3.97 (2H, t, J = 5.8 Hz, CH2 
y), 2.30 (3H, s, CH 3Ai), 2.01-2.15 (2H, m, CH2 (3).
13C NMR (75 MHz , CDC13) 5 171.3 (CO Allyl) 156.8 (CO Alloc), 145.3 (CH3CAr),
133.1 (S 0 2 CAr), 132.8 (CH2 CH=CH2), 131.7 (CH2CH=CH2), 130.3 (CH Ar), 128.4 
(CH Ar), 119.6 (CH2CH=CH2), 118.3 (CH2CH=CH2), 6 6 . 8  (CH2CH=CH2), 66.4 
(CH2CH=CH2), 53.8 (CH2 y), 51.4 (CH a), 31.8 (CH2 P), 22.0 (CH3Ar)
ES+ C i8H23N 0 7S m/z [M + Na]+ 420.
HRMS C i8H23N 0 7SNa calcd. for [M+Na]+ 420.10929 found 420.10797.
A -g-Aloc-L-M ethionine allvl ester (1651
.OH
151
AlocHN' YO
164
OAII
AlocHN’
165
153
To a stirred solution o f L-methionine (5.0 g, 33.5 mmol) and Na2C0 3  (3.55 g, 33.5 
mmol, 1 eq) in THFiKbO (1:1, 30.0 ml) at 0°C was added allyl chloroformate (3.6ml,
33.5 mmol, 1 eq) drop wise over 20 minutes. After slow warming to room temperature 
the mixture was stirred for 24 hours. The solution was then acidified to pH 2 with 1M 
HC1 at 0°C and extracted with EtOAc (5 x 50 ml), dried (Na2S0 4 ) and the solvent 
removed in vacuo. The remaining white solid 164 was used without further 
purification
To a solution o f 164 (7.90 g, 33.5 mmol) in dry MeOH (20.0 ml) was added K2CO3 
(4.62 g, 33.5 mmol, 1 eq). After 5 minutes of agitation the solution was concentrated 
in vacuo to yield a white solid which was subsequently taken up in dry DMF ( 8  ml). 
To this was added allyl bromide (2.83 ml, 33.5 mmol, 1 eq) and the mixture was 
stirred overnight at room temperature under an Argon atmosphere. The solvent was 
removed in vacuo and the residual solid taken up in CH2CI2 , washed with saturated 
aqueous NaHCC>3 (3 x 100 ml), saturated brine (3 x 100 ml) and dried (Na2S0 4 ). 
Upon solvent evaporation the residual oil was purified by flash column 
chromatography (silica gel, 30% EtOAc in Hexane) to provide clear yellow oil 165 
(3.24 g, 65%) over two steps.
Rf = 0.50 (silica gel, 20% EtOAc in Hexane)
[ot]20D = +98.0° (c = 0.015 M in CH2C12)
IR Vmax (neat, cm '1) = 3357 (N-H), 2950, 2900 (C-H), 1751 (C =0), 1647 (C=C)
154
*H NMR (300 MHz, CDC13) 5 5.87 (2H, m, CH2Ctf=CH2), 5.53 (1H, br s, NH), 5.2 
(4H, m, CH2CH=GH2), 4.59 (2H, d, 5.7 Hz, C //2CH=CH2), 4.52 (2H, d, J =  5.7 
Hz, C i/2CH=CH2), 4.44 (1H, br. m, C / /a ) ,  2.50 (2H, t, 7.5 Hz, CH 2 y), 2.13 (1H, 
m, CH3 P), 2.05 (3H, s, SC //3), 1.97 ( 1 H, m, CH 3 p)
13C NM R (75 MHz, CDCI3) 5 171.7 (CO Allyl), 155.8 (CO Alloc), 132.6 
(CH2 CH=CH2), 131.5 (CH2CH=CH2), 119.0 (CH2CH=CH2), 117.8 (CH2CH=CH2),
66.1 (OCOCH2CH=CH2) 65.8 (CH2CH=CH2), 53.2 (CH a), 31.9 (CH2 P), 29.9 (CH2 
7 ), 15.4 (SCH3)
HRMS Ci2H20NO4S calcd. for [M+H]+ 274.1113 found 274.1153. 
A-g-Cbz-L-M ethionine allyl ester (169)
CbzHN'CbzHN'
O O O  
151 168 169
To a stirred solution o f L-methionine (10.0 g, 67.0 mmol) and Na2C0 3  (10.6 g, 0.10 
mol, 1.5 eq) in THF:H20  (1:1, 30.0 ml) at 0°C was added benzyl chloroformate (11.5 
ml, 80.4 mmol, 1.2 eq) dropwise over 20 minutes. After slow warming to room
155
temperature the mixture was stirred for 24 hours. The solution was then acidified to 
pH 2.5 with 0.01 M HC1 at 0°C and extracted with EtOAc (5 x 50 ml), dried 
(Na2 S0 4 ) and the solvent removed in vacuo. The remaining solid 168 was used 
without further purification
To a solution o f 168 (19.0 g, 67.2 mmol) in dry MeOH (30.0 ml) was added K2CO3 
(9.28 g, 67.2 mmol, 1 eq). After 5 minutes of agitation the solution was concentrated 
in vacuo to yield a white solid which was subsequently taken up in dry DMF (15 ml). 
To this was added allyl bromide (5.69 ml, 67.2 mmol, 1 eq) and the mixture was 
stirred overnight at room temperature under an argon atmosphere. The solvent was 
removed in vacuo and the residual solid taken up in CH2CI2 , washed with saturated 
aqueous NaHCC>3 (3 x 100 ml), saturated brine (3 x 100 ml) and dried (Na2SC>4). 
Upon solvent evaporation the residual oil was purified by flash column 
chromatography (silica gel, 30% EtOAc in hexane) to provide 169 as a clear yellow 
oil (13.9 g, 64%) over two steps.
Rf = 0.50 (silica gel, 20% EtOAc in Hexane)
[a]20D = +79.7" (c = 0.013 M in CH2C12)
IR vmax (neat, cm '1) = 3342 (N-H), 2947, 2918 (C-H), 1728 (C=0), 1662 (C=C), 1525 
(C=C, Ar)
156
*H NMR (300 MHz, CDCI3) 8  7.29 (5H, m, CH  Ar) 5.90 (1H, m, CH2C//=CH2), 5.33 
(3H, m, NJ/, CH2CH=CH 2), 5.23 (2H, s, NCOOCtf2Ar), 4.63 (2H, m, C //2CH=CH2), 
4.48 (1H, br m, CH  a ) , 2.52 (2H, t, J =  6.3 Hz, CH2 y), 2.15 (1H, m, C //H  P), 2.06 
(3H, s, SC //3), 2.02 (1H, m, CH//(3)
13C NMR (75 MHz , CDCI3) 5 171.4 (CO Allyl), 155.8 (CO Cbz), 136.5 (Cq Ar Cbz),
131.6 (CH2 CH=CH2), 128.4 (CH Ar), 128.0 (CH Ar), 127.9 (CH A r), 118.7 
(CH2CH=CH2), 67.0 (CH2CH=CH2) 65.9 (COOCH2Ar), 53.5 (CH a), 32.2 (CH2 p),
30.0 (CH2 y), 15.3 (SCH3)
HRMS Ci6H22N 0 4S calcd. for [M+H]+ 324.26950 found 324.27119.
A-g-Aloc-L-Aspartic acid B-methyl ester allyl ester (178)
O
OMe 
OH
Cl O 
146
To a stirred solution o f acid 146 (800 mg, 4.37 mmol) and NaHC0 3  (1.83 g, 21.9 
mmol, 5 eq) in THF:H20  (1:1, 10.0 ml) at 0°C was added allyl chloroformate (510 (il,
OMe
AlocHN'
OH
177
OMe
OAII
AlocHN
178
157
4.81 mmol, 1.1 eq) dropwise over 5 minutes. The solution was slowly warmed to 
room temperature and after 24 hours was complete by TLC. The THF was removed 
in vacuo and the resulting aqueous solution was acidified to pH 2 with KHSO4 and 
washed with EtOAc (5 x 50 ml). The organic layer was then washed with brine (3 x 
50 ml), dried (Na2S0 4 ) and evaporated to give thick colourless oil 177 which was 
used without any further purification.
Rf= 0.9 (silica gel, n-butanol:acetic acid:water, 2:1:1)
Acid 177 (1.01 g, 4.37 mmol) was dissolved in dry MeOH (10.0 ml) and NaHC0 3  
(403 mg, 4.81 mmol, 1.1 eq) was added. After 5 minutes o f agitation the solution was 
concentrated in vacuo to yield a white solid which was subsequently taken up in dry 
DMF (3.0 ml). To this was added allyl bromide (407 pi, 4.81 mmol, 1.1 eq) and the 
mixture was stirred overnight at room temperature under an argon atmosphere. The 
solution was then diluted with CH2CI2 ( 1 0 0  ml) and washed with saturated aqueous 
NaHCC>3 (3 x 100 ml). The aqueous layer was then extracted with CH2CI2 (3 x 50 ml) 
before the organic layer was washed with brine (3 x 50 ml), dried (Na2SC>4) and 
concentrated in vacuo to yield a clear colourless oil. This was purified by flash 
column chromatography (silica gel, 10% EtOAc, 10% CH2CI2 , 80% hexane) to yield 
clear yellow oil 178 (890 mg, 55% over two steps).
Rf = 0.64 (silica gel, 40% EtOAc in Hexane)
158
[ cc] 19d  = +72.4° (0.016M in CH2C12)
IR vmax (neat, cm '1) = 3356 (N-H), 2952 (C-H), 1732, 1739 (C =0), 1647 (C=C)
*H NMR (300 MHz, CDC13) 5 5.96 - 5.84 (2H, m, CH2C//=CH 2), 5.83 (1H, br s,
NH), 5.34 - 5.18 (4H, m, 2  x CH2CH =C//2), 4.64 - 4.63 (m, 5H, 2 x C //2CH=CH2, 
C H a),  3.67 (3H, s, OC//3), 3.0 (1H, dd, J =  16.9, 4.7 Hz, CHH  P), 2.8 (1H, dd, J =  
16.9, 4.7 Hz, C H i/p )
13C NMR (75 MHz , CDC13) 6  171.1 (CO Allyl) 170.3 (CO Methyl), 155.8 (CO 
Alloc), 132.5 (CH2CH=CH2), 131.5 (CH2CH=CH2), 118.8 (CH2CH=CH2), 117.8 
(CH2CH=CH2), 66.3 (CH2CH=CH2), 65.9 (CH2CH=CH2), 52.0 (COOCH3), 50.5 (CH 
a), 36.5 (CH2 p)
HRMS Ci2H i8N 0 6 calcd. for [M+H]+ 272.11341 found 272.11262.
A-g-Boc-Aloc-L-Aspartic acid B-methvl ester allvl ester (17415
OMe
•OAII
Aloc(Boc)N'
174
159
To a solution o f 178 (100 mg, 0.369 mmol) in dry MeCN (5.0 ml) was added DMAP 
(45mg, 0.0738 mmol, 0.02 eq) and (Boc^O  (323 mg, 1.48 mmol, 4 eq). After stirring 
for 24 hours at room temperature the solvent was removed in vacuo. The residual oil 
was taken up in CH 2CI2 (30 ml) and washed with 1M KHSC>4 ( 3  x 50 ml), saturated 
aqueous NaHCC>3 (3 x 50ml), saturated brine (3 x 50 ml), dried (Na2S0 4 ) and 
concentrated in vacuo. The residual oil was purified by flash column 
chromatography (silica gel, 20% EtOAc, 10% CH2CI2 , 70% hexane) to provide 174 
clear yellow oil (134 mg, 98%).
Rf = 0.45 (silica gel, 40% EtOAc in Hexane)
[<x] 19d  = -62.4” (c = 0.014M in CH2C12)
IR vmax (neat, cm '1) = 2981, 2952 (C-H), 1747 (C=0), 1649 (C=C)
'H NMR (300 MHz, CDC13) 8  5.85 (2H, m, 2 x CH2C//=CH 2), 5.49 (1H, t, J  = 7.0, 
CH  a ), 5.29 -  5.18 (4H, m, 2  x CH2CH=C3/2), 4.69 -  4.67 (4H, m, 2  x 
C/72CH=CH2), 3.66 (3H, s, OC//3), 3.24 (1H, dd, J =  16.5, 7.0 Hz, CHH P), 2.75 (1H, 
dd, 7=16 . 5 ,  7.0 Hz, C H //p )
13C NMR (75 MHz, CDCI3) 8  170.9 (CO Allyl), 169.1 (CO Methyl), 153.3 
(NC(O)O), 150.9 (CONC(O)O), 131.4 (CH2CH=CH2), 131.3 (CH2 CH=CH2), 118.9
160
(CH2CH=CH2), 118.6 (CH2CH=CH2), 84.1 (C(CH3)3), 67.9 (CH2CH=CH2), 66.2 
(CH2CH=CH2), 55.2 (CH a), 50.9 (COOCH3), 35.4 (CH2 p), 27.9 (C(CH3)3)
HRMS Ci7H26N 0 8 calcd. for [M+H]+ 372.16583 found 372.16448.
iV-a-Aloc-L-Aspartic acid di-ethvl ester (191)
To a solution o f L-aspartic acid (5.0 g, 37.6 mmol) in dry EtOH (20.0 ml) was added 
SOCl2 (10.9 ml, 15.2 mmol, 0.4 eq) dropwise over a period o f 30 minutes at 0°C. The 
mixture was warmed to room temperature and stirred for 2  hours, before being 
basified to pH 5.0 by slow addition of saturated aqueous N aH C 0 3 and H20 . Removal 
of the solvent in vacuo yielded crude solid 190 which was used unpurified in the next 
reaction . 7
AlocHN'
O
140
O
191190
ES+ C8H i5N 0 4Na m/z [M + Na]+ 212.
HRMS C 8H i6N 0 4 calcd. for [M+H]+ 190.10793 found 190.10812.
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To a solution o f crude 190 (37.6 mmol) in MeCN (35.0 ml) and H2O (70.0 ml) was 
added Na2C0 3  (3.99 g, 37.6 mmol, 1 eq) and allyl chloroformate (3.99 ml, 37.6 
mmol, 1 eq). The mixture was stirred at room temperature for 24 hours before the 
solvents were removed in vacuo. The residual oil was dissolved in CH2CI2 (50 ml). 
The organic layer was then washed with saturated aqueous citric acid (2 x 50 ml), 
saturated aqueous NaHCC>3 (2 x 50 ml), saturated brine (2 x 50 ml), dried (Na2S0 4 ) 
and concentrated in vacuo. The residual oil was purified by flash column 
chromatography (silica gel, 6 % EtOAc in CH2CI2) to yield clear colourless oil 191 
(7.1 g, 69.3%) over two steps.
Rf = 0.45 (silica gel, 5% EtOAc in CH2CI2);
[a]20D = +65.7" (c = 0.025 M in CH2C12)
IR vmax (neat, cm '1) = 3358 (N-H), 2984, 2941 (C-H), 1732 (C=0), 1647 (C=C)
'H  NMR (300 MHz, CDCI3) 5 5.91 (1H, m, CH2C//=CH 2), 5.83 (2H, d , J =  5.5 Hz, 
NH), 5.25 (2H, m, CH2CH=C/72), 4.57 (3H, m, C //2CH=CH2, CH  a ) , 4.14 (4H, m, 2 
x CH2 CH3), 2.95 (1H, dd, J =  17.0, 4.6Hz, CHU |3), 2.78 (1H, dd, J =  17.0, 4.7 Hz, 
C H //P), 1.22 (6 H, m, CH2CH,)
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13C NMR (75 MHz, CDCI3) 8  170.7 (2 x CO Ethyl), 155.8 (CO Aloe), 132.6 
(NCOCH2CH=CH2), 117.8 (NCOCH2CH=CH2), 65.9 (NCOCH2CH=CH2), 
61.8(CH2CH3), 61.0 (CH2CH3), 50.4 (CH a), 36.7 (CH2 (3), 14.0 (2 x CH2 CH3)
HRMS C i2H20NO6 calcd. for [M+H]+ 274.12906 found 274.12841.
2 -(SV f [(allvloxvcarbonyll a mi no]-1 ,4-butanedioI (186)
AlocHN’
OH
186
To a solution o f NaBH4 (280 mg, 7.40 mmol, 2 eq) in dry diglyme (10.0 ml) was 
added LiBr (643 mg, 7.40 mmol, 2 eq) and the milky solution stirred for 0.5 hours. 
Diester 191 (1.0 g, 3.66 mmol) dissolved in dry diglyme (10.0 ml) was then added 
dropwise over 10 minutes. The resulting mixture was stirred at room temperature for
3.5 hours. The reaction was quenched with acetone (5.0 ml) followed by H 2O (5.0 ml) 
and the solvent removed in vacuo to give a oil which was purified by flash column 
chromatography (silica gel, 10% MeOH in CHCI3) to give clear colourless oil 186 
(994 mg, 71%).8
Rf = 0.15 (silica gel, 4% MeOH in CH2C12)
163
[a]20D = -72.3" (0.041 M in CH2C12)
IR Vmax (neat, cm '1) = 3606 (O-H), 3346 (N-H), 3009, 2977, (C-H), 1760 (C=0), 
1651 (C=C)
'H NMR (300 MHz, CDC13) 6  5.89 (1H, m, CH2Cff=CH2), 5.78 (1H, br. d, J  = 8.3 
Hz, NH) 5.26 (2H, m, CH2CH=C/72), 4.55 (2H, d, J =  5.6 Hz, Cff2CH=CH2), 3.85 
(1H, br m, CH  a), 3.68 (4H, m, C /f2OH), 1.81 (1H, m, C //2CH2OH),1.67 (1H, m, 
CJ72CH2OH)
l3C NMR (75 MHz, CDClj) 5 158.7 (CO Alloc), 133.2 (CH2CH=CH2), 117.6 
(CH2CH=CH2), 66.1 (CH2CH=CH2), 64.3 (NCHCH2OH), 58.3 (CH2 CH2OH), 50.3 
(NCH), 33.4 (CH2CH2OH)
ES+ C 8H 15N06Li m/z [M + Li]+ 196, [M + Na]+212.
HRMS C8H i6N 0 4 calcd. for [M+H]+ 190.10793 found 190.10778. 
A^-g-Phthalvl-L-methionine allvl ester (195)
164
141 201
To a solution o f L-methionine (1.0 g, 6.70 mmol) in dry DMF (20.0ml) was added 
phthalic anhydride (0.99 g, 6.70 mmol, 1 eq). The flask was then heated in a 600 W 
commercial kitchen microwave on full power for 2 0  seconds with subsequent stirring. 
This was repeated until there was no more solid phthalic anhydride remaining. The 
solvent was removed in vacuo and crude yellow oil 2 0 1  was used without further 
purification.
Acid 201 (1.86 g, 6.67 mmol) was dissolved in dry MeOH (5.0 ml) and NaHC0 3  
(617 mg, 7.33 mmol, 1.1 eq) was added. After 5 minutes o f  agitation the solution was 
concentrated in vacuo to yield a white solid which was subsequently taken up in dry 
DMF (3.0 ml). To this was added allyl bromide (564 pi, 7.33 mmol, 1.1 eq) and the 
mixture was stirred overnight at room temperature under an argon atmosphere. The 
solution was then diluted with CH2CI2 ( 1 0 0  ml) and washed with saturated aqueous 
NaHC0 3  (3 x 1 0 0  ml). The aqueous layer was then extracted with CH2CI2 (3 x 50 ml) 
before the organic layer was washed with brine (3 x 50 ml), dried (Na2S0 4 ) and 
concentrated in vacuo to yield a clear colourless oil. This was purified by flash 
column chromatography (silica gel, 30% EtOAc in hexane) to yield clear yellow oil 
195 (1.32 g, 62% over two steps).
165
Rf = 0.45 (silica gel, 30% EtOAc in hexane)
[<x ] 20d  = 26.1" (c = 0 .0 1 1 M in CH2C12)
IR v max(neat, cm '1) = 2918 (C-H), 1716 (C=0), 1647 (C=C), 1525 (C=C, Ar)
'H  NMR (300 MHz, CDClj) 8  7.84 (2H, m  CH Ar),  7.75 (2H, m, CH  Ar), 5.88 -  5.79 
(1H, m, CH2C //=CH 2), 5.28 -  5.09 (3H, m, CH2CH=C7/2, CH a ) ,  4.62 (2H, m, 
Cff2CH=CH2), 2.60 -  2.20 (4H, br m, CH2 P, CH2 y), 2.06 (3H, s, SCHi)
13C NMR (75 MHz, CDClj) 8  168.8 (CO Allyl), 167.6 (CO Phthalyl), 134.3 (Cq Ar),
131.8 (CH Ar), 131.4 (CH2 CH=CH2), 123.6 (CH Ar), 118.7 (CH2CH=CH2), 66.4 
(CH2CH=CH2), 51.0 (CH a ) , 30.9 (CH2 P), 28.0 (CH2 y), 15.4 (SCH3)
HRMS C ,6H i8N 0 4S calcd. for [M+H]+ 320.09565 found 320.09518.
A'-a-Phthalvl-L-methionine methyl ester 1258)9
Me
•OMe
258
166
To a solution of 201 (17.0 mmol) in dry MeOH (25.0 ml) was added K2CO3 (2.35 g,
17.0 mmol, 1 eq). After 5 minutes o f agitation the solution was concentrated in vacuo 
to yield a yellow solid which was subsequently taken up in dry DMF (4.0 ml). To this 
was added methyl iodide (1.1 ml, 17.0 mmol, 1 eq) and the mixture was stirred 
overnight at room temperature under an argon atmosphere. The solvent was removed 
in vacuo and the residual solid taken up in CH2CI2 , washed with saturated aqueous 
NaHCOs (3 x 100 ml), saturated brine (3 x 100 ml) and dried (Na2SC>4). Upon solvent 
evaporation the residual oil was purified by flash column chromatography (silica gel, 
30% EtOAc in hexane) to provide 258 as a thick clear yellow oil (3.24 g, 65%) over 
two steps.
Rf = 0.45 (silica gel, 30% EtOAc in hexane)
[a]20D = -60.1” (c = 0.028 M in CH2C12)
IR vmax(neat, cm '1) = 2916 (C-H), 1776, 1716(C =0), 1612(C=C ,A r)
'H  NMR (300 MHz, CDCI3) 8  7.84 (2H, m, CH  Ar), 7.72 (2H, m, CH A r),  5.07 (1H, 
CH  a), 3.71 (3H, s, O C //3), 2 .5 7 -2 .2 8  (4H, brm,  CII2 p, CH2  y), 2.04 (3H, s, SCH,)
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13C NMR (75 MHz, CDC13) 5 169.6 (CO Methyl), 167.6 (CO Phthalyl), 134.3 (Cq. 
Ar), 131.8 (CH Ar), 123.6 (CH Ar), 52.9 (OCH3), 50.8 (CH a ) , 30.8 (CH2 P), 28.0 
(CH2 y), 15.3 (SCH3)
HRMS C l4H |5N 0 4S calcd. for [M]+ 293.07218 found 293.07240.
4-(5r)-(3-tert-Butoxvcarbonvl-3-tert-butoxvcarbonvlamino-propoxv)-2-(S)-(l,3- 
dioxo-l,3-dihvdro-isoindol-2-vD-4-methvlsiilfanvl-butvric acid allyl ester (196)10
\
S
Ot-Bu
BocHN
O
196
To a stirred solution o f 195 (175 mg, 0.597 mmol) in CH2CI2 (0.6 ml) at room 
temperature was added NCS (80 mg, 0.597 mmol, 1 eq). After 20 minutes the 
reaction was cooled to -78°C and added to a premixed solution o f 150 (336 mg, 0.896 
mmol, 1.5 eq), A gOTf (257 mg, 0.716 mmol, 1.2 eq) and 2,6-lutidine (43 pi, 0.597 
mmol, 1 eq) in CH2CI2 (0.6 ml) at -78°C. The mixture was stirred at this temperature 
for 2  hours before being slowly warmed to room temperature and diluted with CH2CI2 
(50 ml). This was subsequently filtered through silica gel and concentrated in vacuo. 
The residual oil yielded was purified by flash column chromatography (silica gel, 
30% EtOAc in hexane) to provide clear yellow oil 196 (153 mg, 37%).
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Rf = 0.20 (silica gel, 30% EtOAc in hexane)
IR vmax (neat, c m 1) = 2979, 2910 (C-H), 1764 (C=0), 1649 (C=C), 1630 (C=C, Ar) 
Diastereoisomer I
!H NMR (300 MHz, CDCI3) 6  7.86 (2H, m, CH  Ar), 7.74 (2H, m, CH  Ar), 5.85 (1H, 
m, CH2C //=CH 2), 5.28 -  5.18 (4H, m, CH2CH=CH 2, P th N C //a , BocNH), 4.64 (2H, 
m, C //2CH=CH2), 4.45 (2H, m, C//(SMe)OCH2, B ocN H C //a), 3.80 (1H, m, 
OCH2 CH2 ), 3.26 (1H, m, O C //2CH2), 2.80 -  2.50 (2H, br. m, C //2CH(SMe)), 2.02 
(4H, br. s, SC //3, OCH2CH 2), 1.67 (1H, m, OCH2CH2), 1.47 (9H, s, CH3 Boc), 1.44 
(9H, s, CH3 lBu)
Diastereoisomer II
'H  NMR (300 MHz, CDC13) 5 7.86 (2H, m, CH  Ar), 7.74 (2H, m, CH  Ar), 5.85 (1H, 
m, CH2C //=CH 2), 5.28 -  5.18 (4H, m, CH2CH=C//2, P th N C //a , BocN//), 4.64 (2H, 
m, C //2CH=CH2), 4.45 (1H, m, B ocN H C //a), 4.22 (1H, m, C//(SM e)OCH2), 3.80 
(1H, m, OCH 2CU 2), 3.26 (1H, m, O C //2CH2), 2.80 -  2.50 (2H, br. m, C //2CH(SMe)),
2.02 (4H, br. s, SCH,, OCH 2C //2), 1.67 (1H, m, OCH2C //2), 1.47 (9H, s, CH, Boc), 
1.44 (9H, s, CH, ‘Bu)
ESMS m/z C29H4oN20 9SNa m/z [M -  Boc + Na]+615.
169
(Not enough material for further spectroscopy)
2-(5,)-(l,3-Dioxo-l,3-dihvdro-isoindol-2-vD-4-ethoxv-4-methvlsulfanvl-butvric 
acid allyl ester (203)
To a solution o f 195 (100 mg, 0.313 mmol) in CH2CI2 (5.0 ml) was added NCS (46 
mg, 0.344 mmol, 1.1 eq) and the mixture was stirred for 1 hour in the dark under an 
argon atmosphere. To this was added EtOH (10.0 ml) and the solution was stirred 
overnight. The reaction was then washed with saturated brine (3 x 50 ml), dried 
(Na2SC>4) and concentrated in vacuo. The resulting colourless oil was purified by a 
series of gradient eluted flash column chromatography runs (silica gel, 1% to 5% 
EtOAc, 29% to 25% CH2CI2 in hexane) to provide 203 as a thick clear yellow oil and 
a mixture o f inseparable diastereoisomers ( 6 8  mg, 60%).
Rf = 0.40 (silica gel, 20% EtOAc in hexane).
203
[a]20D = -46.0" (c = 0.018 M in CH2C12)
170
IR vmax (neat, c m 1) = 2976, 2925 (C-H), 1778, 1716 (C =0), 1663 (C=C), 1601 (C=C, 
At)
Diastereoisomer I
*H NMR (300 MHz, CDC13) 5 7.78 (2H, m, CH  Ar), 7.71 (2H, m, CH  Ar), 5.80 (1H, 
m, CH2C / / C H 2), 5.24 -  5.14 (3H, m, CH2CH=C//2, C/7 a), 4.61 (2H, d, J =  5.4 Hz, 
CH2 CU=CU2), 4.25 (1H, dd, J  = 9.8, 3.2 Hz, C//(SMe)OEt), 3.71 (1H, m, 
O C //2CH3), 3.23 (1H, m, OC/72CH3), 2.68 (2H, m, CH2 (3), 1.96 (3H, s, SCH3), 0.87 
(3H, t, J  = 7.0 Hz, OCH2C //3)
13C NMR (75 M H z ,  C D C I 3 )  5 168.8 ( C O  Allyl), 167.5 ( C O  Phthalyl), 134.0 (Cq Ar),
131.4 ( C H  Ar), 131.3 ( C H 2 C H = C H 2) ,  123.6 ( C H  Ar), 118.8 ( C H 2C H = C H 2) ,  80.9 
( C H ( S M e ) O E t ) ,  66.7 ( C H 2C H = C H 2) ,  63.5 ( O C H 2 C H 3)  49.6 ( C H  a), 34.8 ( C H 2 P),
14.6 ( O C H 2 C H 3 ) ,  9.3 ( S C H 3)
Diastereoisomer II
'H  NMR (300 MHz, CDClj) 6  7.78 (2H, m, CH  Ax), 7.71 (2H, m, C H A r), 5.80 (1H, 
m, CH2C//=CH 2), 5.24 -  5.14 (3H, m, CH2CH=Cff2, C H a ),  4.61 (2H, d, J =  5.4 Hz, 
C7/2CH=CH2), 4.59 (1H, t , J =  6.9Hz, CH(SMe)OEt), 3.71 (1H, m, O C //2CH3), 3.23 
(1H, m, O C //2CH3), 2.68 (2H, m, CH2 P), 1.98 (3H, s, SCH 3), 1.13 (3H, t, J =  7.0 Hz, 
OCH2C //3)
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I3C NMR (75 MHz, CDCI3) 5 168.8 (CO Allyl), 167.5 (CO Phthalyl), 134.0 (Cq Ar),
131.4 (CH Ar), 131.3 (CH2 CH=CH2), 123.6 (CH Ar), 118.8 (CH2CH=CH2), 82.9 
(CH(SMe)OEt), 66.7 (CH2CH=CH2), 63.9 (OCH2CH3) 50.2 (CH a), 35.1 (CH2 P),
14.8 (OCH2 CH3), 9.4 (SCH3)
HRMS C i8H21N 0 4SNa calcd. for [M + H]+ 386.10377 found 386.10304.
2-(SV(l,3-Dioxo-l,3-dihvdro-isoindol-2-vl)-4-ethoxv-4-methvIsulfanvl-butvric 
acid methyl ester (206)
Me
•OMe
206
To a solution o f 258 (100 mg, 0.341 mmol) in CH2CI2 (5 ml) was added NCS (50 mg, 
0.380 mmol, 1.1 eq) and the mixture was stirred for 1 hour in the dark under an argon 
atmosphere. To this was added EtOH (10 ml) and the solution was stirred overnight. 
The reaction was then washed with saturated brine (3 x 50 ml), dried (Na2SC>4) and 
concentrated in vacuo. The resulting colourless oil was purified by a series o f gradient 
eluted flash column chromatography runs (silica gel, 1% to 5% EtOAc, 29% to 25% 
CH2CI2 in hexane) to provide 206 as an oil and a mixture o f inseparable 
diastereoisomers (62%, 71mg).
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Rf = 0.40 (silica gel, 20% EtOAc in hexane)
[a]20D = -20.5° (c = 0.018 M in CH2C12)
IR vmax (neat, cm '1) = 2976, 2925 (C-H), 1778, 1716 (C=0), 1612 (C=C, Ar) 
Diastereoisomer I
NMR (300 MHz, CDCI3) 5 7.87 (2H, m, CH  Ar), 7.74 (2H, m, CH  Ar), 5.12 (1H, 
C H a), 4.50 (1H, t, J =  6.7 Hz, C//(SMe)OEt), 3.74 (4H, m, OCH3, OCH2 CU3), 3.25 
(1H, m, O C //2CH3), 2.70 -  2.40 (2H, m, CH 2 P), 2.03 (3H, s, SC //3), 1.18 (3H, t, J=
7.0 Hz, OCH2C //3)
13C NMR (75 M H z ,  C D C I 3 )  5 169.6 ( C O  Methyl), 167.5 ( C O  Phthalyl), 134.3 (Cq 
Ar), 131.8 ( C H  Ar), 123.6 ( C H  Ar), 82.9 ( C H ( S M e ) O E t ) ,  63.8 ( O C H 2C H 3) ,  52.9 
( O C H 3 ) ,  50.0 ( C H  a ), 35.1 ( C H 2 p), 14.7 ( O C H 2C H 3) ,  9.4 ( S C H 3)
Diastereoisomer II
*H NMR (300 MHz, CDC13) 5 7.87 (2H, m, CH  Ar), 7.74 (2H, m, CH  Ar), 5.12 (1H, 
CH  a ), 4.27 (1H, dd, J  = 9.9, 3.7 Hz, C//(SMe)OEt), 3.74 (4H, m, OCH3, OCH2 CU3), 
3.25 (1H, m, O C //2CH3), 2.70 -  2.40 (2H, m, CH2 P), 2.05 (3H, s, SCH3), 0.91 (3H, t, 
. /=  7.0 Hz, OCH 2C //3)
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13C NMR (75 MHz, CDCI3) 8  169.6 (CO Methyl), 167.5 (CO Phthalyl), 134.3 (Cq 
Ar), 131.8 (CH Ar), 123.6 (CH Ar), 80.9 (CH(SMe)OEt), 63.5 (OOfcCHj), 52.9 
(OCH3), 49.4 (CH a ) , 34.9 (CH2 (3), 14.6 (OCH2 CH3), 9.3 (SCH3)
HRMS C i6H20NO5S calcd. for [M + H]+ 338.10621 found 338.10675.
2-6S,)-(1.3-Dioxo-l,3-dihvdro-isoindol-2-vD-4-ethoxv-butvric acid methyl ester 
(207)
•OMe
207
To a stirred solution o f 206 (64 mg, 0.189 mmol) in CH2CI2 (3 ml) at 0°C was added 
MCPBA (72mg, 0.416 mmol 2.2 eq). After 1 hour Et3SiH (150 pi, 0.945 mmol) and 
BF3 .0 Me2 (17 pi, 0.189 mmol, 1 eq) were added dropwise. After a further 1 hour the 
reaction was diluted with CH2CI2 (50 ml) and warmed to room temperature before 
being filtered through celite. The filtrate was washed with 0.01 M aqueous K H S O 4  (3 
x 50 ml), saturated brine (3 x 50 ml), dried (Na2SC>4) and concentrated in vacuo. The 
residual oil was purified by flash column chromatography (silica gel, 20% EtOAc in 
hexane) to yield clear colourless oil 207 (17 mg, 30%).11
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Rf = 0.35 (silica gel, 20% EtOAc in hexane)
[a]20D = 52.5" (c = 0.027 M in CH2C12)
IR (Too small an amount o f material for reliable spectrograph)
*H NMR (300 MHz,CDC13) 5 7.87 (2H, m, CH  Ar), 7.75 (2H, m, CH  Ar), 5.10 (1H, 
dd, J =  10.6, 4.7 Hz, C H a ),  3.73 (3H, s, OCH 3), 3.50 (1H, m, CH2 y), 3.35 (3H, m, 
O C //2CH3 , CH2 y), 2.46 (2H, m, CH2 P), 0.976 (3H, t , J =  6.9 Hz, OCH2C //3)
13C NMR (75 MHz, CDC13) 5 169.2 (CO Methyl), 165.2 (CO Phthalyl), 134.7 (Cq 
Ar), 134.1 (CH Ar), 123.5 (CH Ar), 67.1 (OCH2CH3), 66.3 (OCH2CH2), 52.8 (CH a),
49.8 (OCH3), 28.9 (CH2 P), 14.3 (SCH3)
ES+ C i5H i7N 0 5Na m/z [M + Na]+ 314.
HRMS C i5H i8N 0 5 calcd for [M + H]+292.11078, found 292.11042.
A-a-t.-Boc-L-Aspartic acid fluorenvlmethvl ester (228)12
175
oA .
h2n ^ Y "
o
140
OH
OH
BocHN
AOH
OH
BocHN
O
229
A  AcOHOFm
O
228
To a stirred solution o f L-aspartic acid (20.0 g, 0.150 mol) and Na2CC>3 (47.7 g, 0.450 
mol, 3 eq) in H 2O (1.0 1) at 0°C was added (Boc^O (32.8 g, 0.150 mol, 1 eq) over 20 
minutes. After slow warming to room temperature the reaction was stirred for 24 
hours. The mixture was then cooled to 0°C and acidified to pH 2.0 with 0.05 M 
KHSO4 before being extracted with EtOAc ( 5  x 150 ml). The organic layer was then 
washed with brine (3 x 200 ml), dried (Na2CC>3) and concentrated in vacuo to give a 
clear colourless oil 229 which was used in the next step without further purification.
To a stirred solution o f 229 (10.0 g, 0.0429 mol) in dry THF (175 ml) under an argon 
atmosphere was added DIC (7.32 ml, 0.0473 mol, 1.1 eq) dropwise over 20 minutes. 
After 4 hours the reaction mixture was filtered through a dry sinter funnel and 
concentrated to approximately 100ml in vacuo. To the solution was added 9- 
fluorenylmethanol (9.28 g, 0.0473 mol, 1.1 eq) in one portion and then 'Pr2EtN (4.1 
ml, 0.0452 mol, 1.05 eq) dropwise over 20 minutes. The reaction was then stirred for 
24 hours under argon before being diluted with toluene (50 ml) and quenched with 
AcOH (5 ml). The solution was concentrated in vacuo until approximately 10 ml 
remained and was then diluted with EtOAc (100 ml), washed with 0.05M KHSO4 (3 
x 100ml), saturated brine (3 x 100 ml), dried (Na2SC>4) and the solvent evaporated in
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vacuo. After 24 hours drying on a high vacuum line a pink solid remained which was 
subsequently dissolved in a minimum amount o f  hot EtOAc and recrystallized by 
addition o f hexane. The filtered solid was then washed twice with cold ethyl acetate 
to give 228. The filtrate was concentrated in vacuo and recrystallised another four 
times to give solid 228 (13.2 g, 75%). Identical by 'H  NMR to lit. 12
Rf = 0.1 to 0.3 (silica gel, 50% EtOAc in hexane)
m.pt. = 138° to 142°C [lit. m.pt. = 156‘C]13
[a]20D = +19.1° (0.011 M in MeOH)
IR Vmax (Nujol, c m 1) =  3290 (N-H), 2952, 2922 (C-H), 1737 (0 = 0 ), 1504 (C=C, Ar)
‘H NMR (300 MHz, CDCI3/DMSO) 8  7.45 (2H, m, CH Ar), 7.26 (2H, m, C //A r), 
7.10 (4H, m, CH  Ar), 5.74 (1H, br. d, J  = 9.0 Hz, N //), 4.30 (1H, m, CH a ) ,  4.02 (2H, 
d, / =  6.4 Hz, CO OC//2CHAr), 3.98 (1H, d, J = 1 2  Hz,COOCH2C//Ar), 2.66 (1H, 
dd, J  = 17.2, 5.2 Hz, CH R  (1) 2.43 (1H, m, C H // p), 1.11 (9H, s, NCOOC(C//3)3)
13C NMR (75 MHz, CDCl3/DMSO) 8  171.8 (CO OFm), 171.3 (CO Acid), 155.3 (CO
Boc), 143.4 (Cq. Ar), 140.9 (Cq. Ar), 127.7 (CH Ar), 127.1 (CH Ar), 125.0 (CH Ar),
119.8 (CH Ar), 82.5 (NCOOC(CH3)3), 67.3 (COOCH2CHAr), 49.9 (CH a), 46.4
(COOCH2 CHAr), 42.7 (CH2 P), 28.2 (NCOOC(CH3)3)
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HRMS C23H25N06Na calcd. For [M+Na]+ 434.15795 found 434.15697. 
A-g-Aloc -L -A spartic acid fluorenvlm ethvl ester (225)
O
OH
^OFrri
BocHN AlocHN'
-OFm
O
228
O
225
To a solution o f CH2Cl2 :TFA (1:1, 5.0 ml) at 0°C was added 228 (200 mg, 0.486 
mmol). The mixture was stirred at this temperature for 2.5 hours before being poured 
into ether (300 ml) and cooled to -23 °C in the freezer overnight. After this time a 
solid precipitate was formed which was isolated by filtration. The filtrate was diluted 
with hexane (100 ml) and again cooled to -23°C in the freezer overnight to produce 
more solid. The solid was isolated by filtration and this process was performed once 
more to yield amino acid 230 which was used crude in the following reaction.
To a solution o f amine 230 (270 mg, 0.657 mmol) and NaHCC>3 (330 mg, 3.94 mmol, 
6  eq) in H2 0 :THF (1:1, 16 ml) being stirred at 0°C was added allyl chlorofomate (67 
pi, 0.723 mmol, 1.1 eq). After 2 hours the reaction was quenched by careful addition 
o f 0.05M KHSO4 (20ml) and diluted with EtOAc (50 ml). The organic layer was 
washed with 0.05M aqueous KHSO4 (3 x 40 ml), saturated brine (3 x 40 ml), dried
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(Na2SC>4) and the solvent removed in vacuo to give a thick oil. Purification with flash 
column chromatography (silica gel, 1% AcOH, 50% EtOAc in hexane) provided a 
cloudy pink crystalline glass 225 (249 mg, 96%).
Rf= 0.1 to 0.3 (silica gel, 50% EtOAc in hexane)
m.pt. - 6 8 °C
[a]20D = -16.7" (0.015 M in MeOH)
IR  Vmax (Nujol, cm '1) = 3305 (N-H), 2952, 2922 (C-H), 1747 (C=0), 1645 
(C=C), 1506 (C=C, Ar)
‘H NMR (300 MHz,CDC13) 6  7.73 (2H, d, J =  7.5 Hz, CH  Ar), 7.53 (2H, t, 7 =  6 . 6  
Hz, CH  Ar), 7.38 (2H, m, CH A t ) ,  7.28 (2H, m, CH  Ar), 5.89 (2H, m, NH, 
CH2CH=CH2), 5.35 -  5.2 (2H, m, CH2CH=CH2), 4.68 (1H, m, C H a), 4.66 (2H, m, 
CH2CH=CH2), 4.54 (2H, m, COOCH2CHAr), 4.22 (1H, t, J =  6.3 Hz 
COOCH2CHAr), 2.89 (1H, dd, J =  17.7, 4.5 Hz, CHH p), 2.71 (1H, dd, J = 17.7, 4.5 
Hz, CHHP)
13C NMR (75M MHz, CDCI3/DMSO) 8  175.7 (CO OFm), 170.7 (CO Acid), 156.0 
(CO Aloe), 143.4 (Cq. Ar), 141.3 (Cq. Ar), 132.4 (CH2CH=CH2), 127.9 (CH Ar),
127.2 (CH Ar), 124.9 (CH Ar), 120.0 (CH Ar), 118.2 (CH2CH=CH2), 67.7
179
(COOOfcCHAr), 66.2 (CH 2CH=CH2), 50.2 (CH a), 46.7 (COOCH2 CHAr), 36.3
( c h 2 p)
ES+ C22H2 ,N 0 6Na m/z [M + Na]+ 418
HRMS C22H22N 0 6 calcd. for [M+H]+ 396.14471 found 396.14642.
-/V-g-Aloc -L-Homoserine fluorenylmethvl ester (231)
To a stirred solution o f 225 (1.7 g, 4.30 mmol) in dry CH2CI2 (10.0 ml) was added 
isobutyl chloroformate (614 ju.1, 4.73 mmol, 1.1 eq) dropwise over 5 minutes and then 
N-methylmorpholine (373 pi, 4.30 mmol, 1 eq). The reaction was stirred under argon 
at room temperature for 30 minutes and then cooled to -78°C before NaBfLi (325 mg, 
8 . 6  mmol, 2 eq) was added in one portion followed by dropwise addition o f MeOH 
(10.0 ml) over 10 minutes. After 1.5 hours the reaction was quenched by addition of 
AcOH (3.0 ml) and stirred for 30 minutes at -7 8 °C before warming to room 
temperature and dilution with toluene (40 ml). The solvent was removed in vacuo
AlocHN'
O
231
180
with the water bath not exceeding 30°C to give a thick oil. This was taken up by 
EtOAc (50 ml) and washed with 0.1 M HC1 (3 x 50 ml), saturated brine (3 x 50 ml), 
dried (Na2S0 4 ) and the solvent evaporated in vacuo to yield a viscous oil. This was 
purified by flash column chromatography (silica gel, 40% EtOAc in hexane) to give 
clear colourless oil 231 (1.3 g, 73%).
Rf = 0.25 (silica gel, 50% EtOAc in hexane)
[a]2°D = -84.7” (0.012 M in CH2C12)
IR Vmax (neat, cm*1) = 3419 (N-H), 2899 (C-H), 1758 (C=0), 1683 (O C ) , 1576(C=C, 
Ar)
'H  NMR (300 MHz, CDCI3) 5 7.73 (2H, d, J  = 7.5, CH  Ar), 7.57 (2H, m, CH  Ar),
7.36 (2H, m, CH  Ar), 7.30 (2H, m, CH Ar), 5.89 (2H, m, NH, CH 2CH=CH2), 5.37 -  
5.18 (2H, m, CH2CH =C//2), 4.57 -  4.43 (5H, m, CT/2CH=CH2, COOC//2CHAr, CH  
a), 4.21 -  4.09 (1H br m, COOCH2C//Ar), 3.63 (2H, m, CH 2OH) 2.03 (1H, m, CH 2 
p), 1.69 (2 H, m, CH2  P)
l3C NMR (75 M H z, CDCI3) 6  172.5 (CO OFm), 156.6 (CO Aloe), 143.6 (Cq. Ar),
141.3 (Cq. Ar), 132.5 (CH2CH=CH2), 127.9 (CH Ar), 127.2 (CH Ar), 125.0 (CH Ar),
120.1 (CH Ar), 118.0 (CH2CH=CH2), 67.1 (COOCH2CHAr), 66.0 (CH2CH=CH2), 
58.5 (CH2, y), 51.7 (CH a), 46.8 (COOCH2CHAr), 34.9 (CH2 P)
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HRMS C22H23NC>5Na calcd. For [M+Na]+ 404.14738 found 404.14640.
N-g-Aloc -L-Aspartic acid fluorenvlmethvl ester mesylate (2321
-OFm
AlocHN’
232
To a stirred solution o f 231 (2.70 g, 7.08 mmol) in dry CH2CI2 (54.0 ml) under argon 
was added methanesulfonyl chloride (1.4 ml, 17.7 mmol, 2.5 eq) and then N- 
methylmorpholine (1.7 ml, 17.2 mmol, 2.4 eq). After 2.5 hours at room temperature 
the reaction was quenched with 0.1 M aqueous KHSO4 (20 ml). The organic layer 
was washed with 0.1M aqueous KHSO4 (3 x 50 ml), saturated aqueous NaHCC>3 (3 x 
50 ml), brine (3 x 50 ml), dried (Na2S0 4 ) and the solvent concentrated in vacuo. The 
resultant oil 232 was used without any further purification.
Rf = 0.25 (silica gel, 40% EtOAc in hexane)
4-lodo-2-6Sr)-alIvloxvcarbonvlamino-butvric acid fluoren-9-vlmethvl ester (2331
182
,OFm
AlocHNTnr
O
233
To a stirred solution o f 232 (500 mg, 0.956 mmol) in dry THF (50.0 ml) under argon 
was added N al (780 mg, 3.82 mmol, 4 eq). The reaction was heated to 70°C and after 
2 hours the solvent was removed in vacuo. The remaining solid was taken up in 
CFEC^EtO A c (50:3, 53.0 ml) and washed with 0.1M aqueous Na2S2 0 3  (3 x 50 ml), 
saturated brine:H20  (1:6, v:v, 3 x 50 ml), dried (T^SCU) and the solvent removed in 
vacuo. The resultant yellow solid 233 (465 mg, 99%) was used without further 
purification.
Rf = 0.55 (silica gel, 30% EtOAc in hexane)
m.pt. = 112°C
[<x ] I8d  = -39.6' (c = 0.0092 M in CH2C12)
IR vma* (Nujol, cm '1) = 3312 (N-H), 2922, 2952 (C-H), 1737 (C=0), 1693 (C=C), 
1537 (C=C, Ar)
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'H  NMR (300 MHz,CDC13) 5 7.77 (2H, d, J =  l.A, C H  Ar), 7.57 (2H, m, CH  Ar),
7.39 (2H, m, C tf Ar), 7.34 (2H, m, CH  Ar), 5.89 (1H, m, CH2C77=CH2), 5.3 -  5.2 
(2H, m, N7/, CH2C H = 0 7 2), 4.57 (4H, m, C //2CH=CH2, COOC772CHAr), 4.39 (1H, 
m, CH a ), 4.21 (1H, m, C 0 0 C H 2O7Ar), 3.00 (2H, m, CH2 I), 2.24 (1H, br m, CH2 p),
2.04 (1H, br m, CH2  P)
13C NMR (75 MHz, CDCI3) 6  171.2 (CO OFm), 155.8 (CO Alloc), 143.4 (Cq. Ar),
141.4 (Cq. Ar), 132.4 (CH2 CH=CH2), 128.7 (CH Ar), 128.0 (CH Ar), 124.9 (CH Ar),
120.2 (CH Ar), 118.1 (CH2CH=CH2), 67.1 (COOCH2CHAr), 66.1 (CH2CH=CH2) 
54.7 (CH a), 46.8 (COOCH2 CHAr), 36.8 (CH2 P), -0.8 (CH2I)
HRMS C22H22N 0 4INa calcd. for [M+Na]+ 514.04912 found 514.04656.
Anal. Calcd. for C22H22N 0 4I (491.319): C, 53.78; H, 4.51; N, 2.85; I, 25.83. Found C, 
54.17; H, 4.64; N, 2.83; I, 25.65.
4-Bromo-2-(»Sr)-allvloxvcarbonvlamino-butvric acid fluoren-9-vlmethvl ester 
a34]
•OFm
AlocHN’
234
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To a stirred solution o f mesylate 232 (500 mg, 0.956 mmol) in dry THF (50.0 ml) 
under argon was added NaBr (393 mg, 3.82 mmol, 4 eq). The reaction was heated to 
70°C and after 2 hours the solvent was removed in vacuo. The remaining solid was 
taken up in C EhC ^EtO A c (50:3, 53 ml) and washed with 0.1M aqueous Na2S2C>3 (3 
x 50 ml) and saturated brineitEO  (1:6, v:v, 3 x 50 ml), dried (Na2S0 4 ) and the 
solvent removed in vacuo. The resultant white solid 234 (419 mg, 99%) was used 
without further purification.
Rf = 0.55 (silica gel, 30% EtOAc in hexane)
m.pt. = 108°C
[a ]20D = -94.9” (0.0071 M in CH2C12)
IR vm2X (Nujol, cm '1) = 3311 (N-H), 2952, 2922 (C-H), 1737 (C=0), 1693 (C=0)
'H  NMR (300 MHz, CDCI3) 5 7.77 (2H, d, J =  7.5 Hz, CH  Ar), 7.55 (2H, m, CH  Ar), 
7.41 (2H, m, CH Ar), 7.34 (2H, m, CH Ar), 5.89 (1H, m, CH2C77=CH2), 5.38 -  5.20 
(3H, br m, NH, CH2C H =C//2), 4.60 (5H, m, CH2CH=CH2, COOCH2CHAr, CH a), 
4.22 (1H, m, COOCH2C//Ar), 3.33 (2H, m, CH2 Br), 2.09 (1H, br m, CH, p), 2.04 
(1H, br m, CH 2 P)
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I3C NMR (75 MHz, CDCI3) 5 171.4 (CO OFm), 155.8 (CO Alloc), 143.0 (Cq. Ar),
141.4 (Cq. Ar), 132.2 (CH 2CH=CH2), 128.7 (CH Ar), 128.0 (CH Ar), 124.9 (CH Ar),
120.2 (CH Ar), 118.4 (CH2CH=CH2), 115.7 (NCOCH2CH=CH2), 67.2 (CH2 
COOCH2CHAr), 66.1 (CH2CH=CH2) 52.7 (CH a), 46.8 (COOCH2 CHAr), 35.5 (CH2 
P), 28.1 (CH2Br)
HRMS C22H22NOsBrNa calcd. for [M+Na]+ 466.06298 found 466.06204.
Anal. Calcd. for C22H22N 0 4Br (443.073): C, 59.47; H, 4.99; N, 3.15; Br, 17.98. 
Found C, 59.73; H, 5.20; N, 3.08; Br, 18.02.
2-(5)-allvIoxvcarbonylam iiio-4-oxo-butvric acid fluoren-9-vlm ethvl ester (237)
■OFm
AlocHN'
237
To a solution o f oxalyl chloride (233 pi, 2.76 mmol, 1.5 eq) in dry DCM (0.50 ml) at 
-78°C was added dropwise DMSO (145 pi, 2.76 mmol, 1.5 eq). The resulting 
solution was stirred for 30 minutes at this temperature before 231 (700 mg, 1.84
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mmol) disolved in DCM (2.0 ml) was added dropwise over 10 minutes. After 30 
minutes Et3N (1.28 ml, 9.2 mmol, 5 eq) was added and the reaction was warmed to 
0°C. After 2 hours the solution was quenched with 0.1M KHSO4 (20 ml) and allowed 
to warm to room temperature. The resulting solution was diluted with DCM (100 ml) 
and the organic layer washed with 0.1M KHSO4 (3 x 75 ml) , dried (NaS04) and 
concentrated in vacuo. The residual oil (650mg) was purified by flash column 
chromatography (silica gel, 30% EtOAc in hexane) to yield dusty brown solid 237 
pure (545 mg, 52%).
Rf = 0.35 (silica gel, 30% EtOAc in hexane) 
m.pt. - - 1 10°C
[a]20D = +63.2" (c = 0.0092 M in CH2C12)
IR vmax (Nujol, cm '1) = 3305 (N-H), 2952, 2922, (C-H), 1737 (C=0), 1645 (C=C), 
1531 (C=C, At)
‘H NMR (300 MHz, CDC13) 5 9.50 (1H, s, C(=0)H), 7.76 (2H, d, J =  7.5, CH  Ar), 
7.54 (2H, m, CH  Ar), 7.41 -  7.25 (4H, m, CH  Ar), 5.89 (1H, m, CH2CH=CH2), 5.61 
(1H, d, J =  8 .6 , N.H), 5.30 -  5.10 (2H, CH2CH=C//2), 4.62 -  4.53 (5H, m, 
C f/2CH=CH2, C O O O /2CHAr, CH  a), 4.23 (1H, t, J  = 6 .1 Hz, COOCH2Cf/Ar), 2.9 
(1H, m, CHi (3)
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I3C NMR (75 MHz, CDC13) 5 199.0 (CO Aldehyde) 170.6 (CO OFm), 155.8 (CO 
Alloc), 143.4 (Cq. Ar), 141.3 (Cq. Ar), 132.4 (NCOCH2 CH=CH2), 127.9 (CH Ar),
127.2 (CH Ar), 124.9 (CH Ar), 120.1 (CH Ar), 118.1 (NCOCH2CH=CH2), 67.3 
(COOCH2CHAr), 66.1 (NCOCH2CH=CH2) 49.0 (CH a), 46.7 (COOCH2 CHAr), 45.7 
(CH2 P)
HRMS C22H2 iNOsNa calcd. for [M+Na]+ 402.13174 found 402.13277. 
iV-a-Di-t.Boc-L-Homoserine t.-butvl ester TBDMS ether (2361
•TBDMS
■Ot-Bu
236
To a solution of 150 (500 mg, 1.33 mmol) in dry DMF (0.5 ml) was added imidazole 
(26 mg, 3.33 mmol, 2.5 eq) and tBuMe2SiCl (260 mg, 1.8 mmol, 1.35 eq). The 
resulting solution was stirred for 18 hours before being diluted with saturated brine 
(20 ml) and ethyl acetate (20 ml). The organic layer was then washed with saturated 
brine (2 x 50 ml), dried (NaS0 4 ) and concentrated in vacuo. The residual oil (0.98 g)
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was purified by flash column chromatography (silica gel, 5% EtOAc, 0.001% Et3N in 
hexane) to yield 236 as a clear colourless oil (640 mg, 98.4%).14
Rf = 0.25 (silica gel, 5% EtOAc in hexane);
[a]20D = + 27.7” (c = 0.022 M in CH2C12)
IR vmax (neat, c m 1) = 2979, 2956 (C-H), 1737 (C=0)
'H  NMR (300 MHz, CDC13) 5 4.90 (1H, dd, J =  8 .6 , 5.3 Hz, C H a ), 3.67 (2H, m,
CH2 P), 2.34 ( 1 H, m, CH 2 y), 2.00 (1H, m, CH 2 y), 1.49 (18H, s, N C O C (073)3), 1.43 
(9H, s, OCOC(Gf/ij)3), 0.87 (9H, s, S i(C //3)2C(Cff3)3), 0.03 (6 H, s, S i(C //3)2C(CH3)3)
13C (75 MHz, CDC13) 6  170.1 (CO ‘Butyl), 152.4 (CO Boc), 82.6 (Cq. ‘Buyl), 81.1
(Cq. Boc), 60.2 (CH2 y), 55.9 (CH a), 33.1 (CH2 P), 28.0 (CH3 *Buyl), 27.9 (CH3
Boc), 26.0 (CH3 Si(CH3)2C(CH3)3), 18.3 (Si(CH3)2C(CH3)3)
(Peaks for Si(CH3)2C(CH3)3 not present on spectrum, expected to be ca. -  6  ppm)
HRMS C24H47N 0 7SiNa calcd. for [M+Na]+ 512.30193 found 512.30246.
2-f2-tert-ButoxvcarbonvIam ino-2"(9H-fluoren-9-vlm ethoxvcarbonvl)-ethvIl-
[1.31oxazinane-3,4-dicarboxvlic acid di-tert-butvl ester (240)
189
NBoc
OFm
AlocHN'
O
240
To a stirred solution o f 236 (56 mg, 0.114 mmol) in MeCN (0.5 ml) at room 
temperature was added EtsSiH (27 pi, 0.171 mmol, 1.5 eq.). After 5 minutes BiBr3 
(34.0 mg, 0.076 mmol, 0.67 eq.) was added. 237 (65 mg, 0.171 mmol, 1.5 eq.) 
dissolved in MeCN (0.5ml) was then added and the solution stirred for 24 hours. The 
reaction was diluted with EtOAc 50 ml which was then washed with Na2C0 3  (2 x 50 
ml), dried (NaS0 4 ) and concentrated in vacuo. The residual oil was purified by flash 
column chromatography (silica gel, 20% EtOAc in hexane) to yield clear colourless 
oil 240 pure (50.2 mg, 69.1%).15
R f = 0.17 (silica gel, 20% EtOAc in hexane)
[a]20D = + 1 1 .2 ° (c = 0 . 0 1 0  M in CH2C12)
'H  NMR (300 MHz, CDC13) 8  7.85 (2H, m, CH  Ar), 7.60 (2H, d, J  = 7.1, CH  Ar),
7.37 (2H, m, CH  Ar), 7.26 (2H, m, CH  Ar), 5.92 (1H, m, CH2Ctf=CH2) 5.87 (1H, m, 
N.H), 5.44 (1H, m, AlocNHCHCH2C//(0)NBoc) 5.28 -  5.18 (2H, m, CH2CH=C//2), 
4.71 (1H, br. s, 'BuOOCC/TNBoc), 4.58 -  4.48 (5H, m, CH2 CU=CH2,
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COOCff2CHAr, AlocNHCf/CH 2CH(0)NBoc), 4.29 (1H, br m, COOCH2C//Ar), 3.75 
(2H, *Bu00CCHCH 2C # 20 ) , 2.25 - 2.20 (2H, m, AlocNHCHCi/2CH(0)NBoc, 
‘B u00C C H C //2CH20 ) , 2.10 -  2.02 (2H, m, AlocNHCHCf/2CH(0)NBoc,
'BuOOCCHC//2CH20 ) , 1.41 (18H, s, NCOC(CH3)3, OCOC(C//3)3)
13C NMR (75 MHz , CDC13) 6  172.1 (CO OFm), 171.4 (CO Al) 156.0 (CO Aloe),
153.4 (CO Boc), 143.6 (Cq. Ar), 141.3 (Cq. Ar), 132.7 (CH2 CH=CH2), 127.8 (CH 
Ar), 127.2 (CH Ar), 125.1 (CH Ar), 120.0 (CH Ar), 117.8 (CH2CH=CH2), 82.0 (Cq 
'Bu), 81.0 (Cq Boc), 67.6 (COOCH2CHAr), 65.8 (CH2CH=CH2), 64.3
(A1ocNHCHCH2CH(0)NBoc), 58.1 ('Bu00CCH CH 2 CH20 ), 51.7 (2 x CH a), 46.9 
(COOCH2CHAr), 34.4 (A1ocNHCHCH2CH(0)NBoc), 34.2 (‘BuOOCCHOfeCTtjO), 
28.3 (OCOC(CH3)3), 27.9 (NCOC(CH3)3)
HRMS C35H44N20 9 Na calcd. for [M+Na]+ 659.29444 found 659.29494. 
3-[CS')-2-fert-Butoxycarbonyl -2-(fluoren-9-
vlm ethoxycarbonvlamino)ethvlsulfanvH-(ty)-(allvloxvcarbonvlamino)butanoic 
acid fluoren-9-yIm ethvl ester (243)16
Ot-Bu
NHFmocFmO'
NHAIoc
243
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To a stirred solution o f thiol 119 (2.20 g, 5.51 mmol) and 233 (2.71 g, 5.51 mmol) in 
dry DMF (10.0 ml) was added CS2CO3 (1.62 g, 4.96 mmol, 1.1 eq). After 2.5 hours at 
room temperature the reaction was diluted with EtOAc (100 ml) and the organic layer 
washed with 0.025 M KHSO4 (50 ml), H2O (6 x 50 ml), dried and the solvent 
evaporated in vacuo. The resultant oil was purified by flash column chromatography 
(silica gel, 5% Et2 0 , in CH2CI2) to give 243 pure (2.7 g, 64%).
Rf = 0.20 (silica gel, 30% EtOAc in hexane)
[a ]20D = +22.0' (0.020 M in CH2C12)
IR vmax(neat, c m 1) = 3415 (N-H), 2901 (C-H), 1 7 3 3 ( 0 0 ) ,  1 6 8 0 ( 0 0 ) ,  1522 (0=C, 
Ar)
‘H NMR (300 MHz, CDCI3) 6  8.04 (4H, d ,J =  7.7 Hz, CH  Ar), 7.77 (4H, m, CH Ax), 
7.59 (4H, m, CH  Ar), 7.43 (4H, m, CH  Ar), 5.93 (2H, m, NT/, CH2C//=CH2), 5.84 
(1H, d, J  = 9.7 Hz, NH), 5.32 -  5.18 (2H, m, CH2CH=C7/2), 4.56 (6 H, m, 
C //2CH=CH2, 2 x CH  a , CH2COOC//2CHAr), 4.96 (2H, m, N CO O CftCH A r), 4.22 
(2H, m, NCOOCH2C//A r & CH2COOCH2CLHAr), 3.00 (2H, b rm , CHC/72S), 2.53 
(2 H, br m, CH2 y), 2.05 ( 1 H, m, C //2CH2S), 2.02 (1H, m, C tf2CH2S), 1.51 (9H, s, 
OCOC(C//3)3)
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13C NMR (75MHz, CDCI3) 5 171.9 (CO OFm), 169.7 (CO O'Bu), 159.9 (CO Fmoc),
155.8 (CO Aloe), 143.9 (Cq Ar Fm), 143.8 (Cq Ar Fmoc), 143.5 (Cq Ar Fm), 143.3 
(Cq Ar Fmoc),132.6 (CH 2CH=CH2) 128.0 (CH Ar Fm), 127.8 (CH Ar Fmoc), 127.3 
(CH Ar Fm), 127.2 (CH Ar Fmoc), 125.0 (CH Ar Fm), 125.2 (CH Ar Fmoc), 120.1 
(CH Ar Fm), 120.0 (CH Ar Fmoc), 117.9 (CH2CH=CH2), 83.0 (OCOC(CH3)3), 67.1 
(CH2COOCH2CHAr & NCOOCH2CHAr), 66.0 (CH2CH=CH2), 54.4 (FmoeNHCH 
a), 53.0 (AllocNHCH a ), 47.2 (CH2COOCH2CHAr), 46.8 (NCOOCH2 CHAr), 34.7 
(CHCH2S), 30.4 (CH2CH2S), 28.6 (CH2 CH2S), 28.1 (OCOC(CH3)3)
HRMS C44H46N20 8SNa calcd. for [M + H]+ 785.28724 found 785.28561.
3-16y>-2 -fert-Butoxvcarbonvl -2-(fert-butoxvcarbonvlI aminolethvlsulfanvll-hy)- 
(allvloxvcarbonvlamino)butanoic acid (245)
O
NHAIoc
S.
HO' X  v  ^  "NHBocHOT X  ^  ^  "NH2
NHAIoc
244  245
To a stirred solution o f 243 (1.20 g, 1.57 mmol) in DMF (10.0 ml) was added 
piperidine (3.0 ml) dropwise over 5 minutes. The reaction was stirred at room 
temperature for 2.5 hours before being quenched with AcOH (5.0 ml) and diluted 
with toluene (100 ml). The solvent was then removed in vacuo and after 24 hours at
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low pressure (0.5 mmHg) the resultant oil 244 was used crude in the following 
reaction.
To a stirred solution o f 244 (1.57 mmol) and NaHCC>3 (317 mg, 3.77 mmol, 2.4 eq) in 
THFiTkO (1:1, 10.0 ml) at 0°C was added B0 C2O (480 mg, 2.20 mmol, 1.4 eq). After 
warming slowly to room temperature the mixture was stirred for 24 hours. The 
reaction was then diluted with EtOAc (100 ml) and quenched by addition o f KHSO4 
(50 ml). The organic layer was then washed with KHSO4 (3 x 50 ml), the collected 
washings were then back extracted with fresh EtOAc (5 x 50 ml) and the combined 
organic extract then washed with saturated brine ( 2 x 5 0  ml). After the solvent was 
dried (Na2S0 4 ) and removed in vacuo the remaining solid was purified by flash 
column chromatography (silica gel, 1 to 10% AcOH, in EtOAc) to give 245 pure (420 
mg, 57.9%) over two steps.
Rf = 0.35 (silica gel, 2% AcOH in EtOAc)
[<x]20D = +5.5“ (0.003 M in CH2C12)
IR vmax (neat, c m 1) = 3440 (N-H), 2919 (C-H), 2890 (COO-H), 1758 (C=0), 1657 
(C=C)
'H  NMR (300 MHz, CDCI3) 8  6.28 (1H, br s N.H), 6.20 (1H, br s, N.H), 5.93 (1H, m, 
CH2C77=CHi), 5.32 -  5.18 (2H, m, CH2CH=C//2), 4.55 (2H, d, J  = 4.7Hz,
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Cff2CH=CH2), 4.54 (2H, m, 2 x CH a), 3.24 (2H, br m, C H O /2S), 2.94 (2H, br m,
CHi -/), 2.34 -  2.26 (2H, m, C //2CH2S), 1.46 (9H, s, OCOC(Ctf3)3), 1.43 (9H, s, 
NCOC(C//3)3)
13C NMR (75 MHz, CDCI3) 5 169.4 (CO O'Bu), 168.9 (CO Acid), 156.2 (CO Boc),
155.5 (CO Alloc), 132.7 (CH2 CH=CH2), 117.9 (CH2CH=CH2), 83.2 (OCOC(CH3)3),
82.8 (NCOC(CH3)3), 65.9 (CH2CH=CH2), 53.2 (BocNHCH a), 50.1 (AllocNHCH 
a), 34.3 (CHCH2S), 30.2 (CH2CH2S), 28.3 (OCOC(CH3)3), 27.9 (NCOOC(CH3)3),
25.0 (CH2 CH2S)
(Unidentifiable by mass spectrometry)
3-riSV2 -tert-Butoxvcarbonvl -2-(fert-butoxvcarbonvlI amino)ethvlsulfanvll-hS)- 
(allvloxvcarbonvlam ino)butanoic acid allvl ester (246)
All NHBoc
NHAIoc
246
To a solution o f 245 (420 mg, 0.909 mmol) in dry MeOH (10.0 ml) was added 
CS2CO3 (148 mg, 0.455 mmol, 0.5 eq). After 5 minutes o f agitation the solution was 
concentrated in vacuo to yield a white solid which was subsequently taken up in dry 
DMF (5.0 ml). To this mixture was added allyl bromide (100 pi, 1.18 mmol, 1.3 eq)
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and the reaction stirred at room temperature under an atmosphere o f argon for 24 
hours. The solution was then diluted with EtOAc (100 ml) and quenched by addition 
of 0.1 M KHSO4 (10 ml). The organic layer was washed with 0.1M KHSO4 (3 x 50 
ml) the collected washings were then back extracted with fresh EtOAc (5 x 50 ml) 
and the combined organic extract then washed with saturated brine (2 x 50 ml). After 
the solvent was dried (Na2 S0 4 ) and removed in vacuo the remaining thick oil was 
purified by flash column chromatography (silica gel, 50% EtOAc, in hexane) to yield 
246 (330 mg, 72.2%).
Rf = 0.20 (silica gel, 50% EtOAc in hexane)
[ oc] 20d  = +17.9° (0 . 0 1 1  M in CH2C12)
IR vmax (neat, cm '1) = 3478 (N-H), 3002 (C-H), 1755 (C=0), 1654 (C=C)
!H NMR (300 MHz,CDC13) 5 5.95 (1H, br s, N/Q, 5.85 (3H, m, 2 x CH2Ctf=CH2,
NH), 5.30 (4H, m, 2  x CH2CH=CH2), 4.61 -  4.41 (6 H, m, 2 x C tf2CH=CH2, 2 x CH  
a), 3.11 (2H, br m, CHC/fcS), 2.81 (2H, br m, CH 2 y), 2.33 ( 1 H, m, C //2CH2S), 2.15 
(1H, m, C //2CH2S), 1.42 (9H, s, OCOC(C//3)3), 1.37 (9H, s, NCOOC(C//3)3)
13C NMR (75 MHz, CDC13) 5 171.0 (CO Allyl), 169.3 (CO OlBu), 156.0 (CO Boc),
153.1 (CO Alloc), 132.5 (CH2 CH=CH2), 131.3 (CH2CH=CH2), 119.2 (CH2CH=CH2),
118.8 (CH2CH=CH2), 83.2 (OCOC(CH3)3), 82.9 (NCOOC(CH3)3), 66.3
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(CH2CH=CH2), 65.9 (CH2CH=CH2), 53.5 (BocNHCH a), 50.4 (AllocNHCH a), 34.1 
(CH2 CH2S), 30.3 (OCOC(CH3)3), 28.2 (NCOOC(CH3)3), 25.6 (CH2CH2S)
(Unidentifiable by mass spectrometry)
3’ [6Sr)-2-Carboxv-2-(fluoren-9-vlmethoxvcarbonvll amino)ethvlsulfanvl1-(5V 
(allvloxvcarbonvlamino)butanoic acid allvl ester (248)
•OH
All NH2
NHAIoc
■OH
All NHFmoc
NHAIoc
2 4 7  248
To a stirred solution o f 246 (330 mg, 0.657 mmol) and Et3SiH (2.0 ml) in CH2C12 (5.0 
ml) at 0°C was added TFA (5.0 ml) dropwise over 15 minutes. The reaction was then 
slowly warmed to room temperature and stirred for 3.5 hours. The solution was then 
diluted with toluene ( 1 0 0  ml) and the solvent removed in vacuo to give a grey solid 
247 used in the next reaction without purification.
To a stirred solution o f 247 (0.661 mmol) and N aH C 03 (275 mg, 3.31 mmol, 0.5 eq) 
in THF:H20  (1:1, 16.0 ml) at 0°C was added Fmoc chloroformate (203 mg, 0.793 
mmol, 1.2 eq). After 2.5 hours stirring at room temperature the reaction was 
quenched by addition o f 0.1 M KHSO4 (50 ml). The aqueous solution was then
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extracted with EtOAc ( 6  x 50 ml) before the organic layer was washed with saturated 
brine (3 x 50 ml), dried (Na2SC>4) and concentrated in vacuo to give a white solid 248 
which was purified by flash column chromatography (silica gel, 1 to 1 0 % AC2O, in 
EtOAc) to yield (199 mg, 53%).
Rf = 0.45 (silica gel, 2% AcOH in EtOAc)
[a]20D = + 1 0 .1 ° (0.010 M in CH2C12)
IR vmax (neat, cm '1) = 3440 (N-H), 2933 (C-H), 2906 (COO-H), 1741 (C=0), 1689 
(O C ), 1520 (C=C, Ar)
NMR (300 MHz, CD3OD) 6  7.77 (2H, d, J=  7.4 Hz, CH  Ar), 7.65 ( 2H, d, J = 7.0 
Hz, CH  Ar), 7.52 (2H, m, CH  Ar), 7.26 (2H, CH  Ar), 5.89 (2H, m, 2 x CU 2 CH=CH2), 
5.35 -  5.22 (4H, m, 2 x CU2 CU=CH2), 4.63 (2H, d, J =  5.6 Hz, N COOC//2CHAr), 
4.51 (2H, m, 2  x CH 2 CU=CU2), 4.50 -  4.35 (4H, br. m, C H a , CH2 CH=CH2, 
NCOOCH2C//Ar), 4.23 (1H, m, C H a), 3.31 (1H, br. m, CH C//2S), 3.19 (1H, br m, 
CH C//2S), 2.90 (2H, br m, CH 2 y), 2.31 (1H, m, C //2CH2S), 2.18 (1H, m, CH2 CH2S)
13C NMR (75 MHz, CDC13) 5 172.0 (COOH), 169.1 (CO Allyl), 157.2 (CO Fmoc),
157.2 (CO Aloe), 143.8 (Cq Ar), 141.2 (Cq Ar), 134.0 (CH2 CH=CH2), 132.9 
(CH2CH=CH2), 128.9 (CH Ar), 128.3 (CH Ar), 126.4 (CH Ar), 121.1 (CH Ar), 119.1 
(CH2CH=CH2), 118.3 (CH2CH=CH2), 68.3 (NCOOCH2CHAr), 67.3 (CH2CH=CH2),
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67.0 (CH2CH=CH2), 54.4 (FmocNHCH a), 49.6 (AllocNHCH a), 48.4 
(NCOOCH2 CHAr), 35.0 (CHCH2S), 30.9 (CH2CH2S), 25.5 (CH2 CH2S)
ES+ C29H32N 0 8SK m/z [M + K]+607.
(Unidentifiable by HRMS)
Peptide Synthesis
Peptide 249 was synthesised on a MultiSynTech Syro Peptide Synthesiser (Model 
MP-60) using Fmoc-Tyr^Bu^NovaSyn TGT resin with a 0.2 mmol/g loading. DMF 
was used as the primary solvent throughout the peptide synthesis. Determination of 
free amines was achieved through a Kaiser test.
Kaiser Test
The resin was washed with CH2C12 to remove all traces o f DMF. A small amount of 
resin was then removed and placed in an Eppendorf vial. Four drops from each Kaiser 
test solution (shown below) were delivered to the vial and the clear yellow mixture 
then heated for 5 minutes at 110°C. A positive test gave a dark purple solution which 
indicated the presence o f primary amines, a negative result produced no colour 
change.
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Solution 1: KCN (2ml, 0.001 M) in pyridine (98ml)
Solution 2: Ninhydrin (5% w/v) in 'butanol 
Solution 3: Phenol (80% v/v) in 'butanol
Svro Protocols
All masses and volumes stated in the pre-programmed MultiSynTech Syro protocols 
are used throughout unless otherwise stated. The peptide synthesiser contains an 
agitation block that holds the 2 ml reaction syringes. These are vessels containing 
frits, the base o f which is connected to a vacuum pump so solutions can be removed 
while the resin remains in the syringe. DMF/piperidine mixes were generated from 
stock solutions o f DMF and piperidine by the peptide synthesizer. Amino acid and 
reagent concentrations were calculated with respect to the amount of starting 
homolanthionine 243 available.
Fmoc Deprotection
Automated Fmoc deprotection was carried out first with piperidine (40% v/v) in DMF 
for 3 minutes (500 pL per syringe), followed by piperidine (20% v/v) in DMF for 10 
minutes (500 pL per syringe) before a series of washing steps with DMF ( 6  x 550 pL 
per syringe). During each deprotection step a fast vortex o f the reaction for 20 
seconds every 1 minute was performed to ensure thorough mixing.
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Automated Amino acid coupling
Amino acid solution in DMF (250 pL per syringe) was transferred from the amino 
acid block on the synthesiser to the reaction syringes, followed by addition of HBTU 
in DMF (250 pL per syringe, 0.4 M). A solution of DIPEA in NMP (100 pL per 
syringe, 1.6 M) was then added to take the total volume to 600 pL and the mixture 
reacted for 40 minutes (fast vortex for 20 seconds every 4 minutes). After this time 
the solution was drained from the syringe and the resin washed with DMF (4 x 550 
pL) before Fmoc deprotection o f the amino acid and washing with DMF ( 6  x 550 
pL).
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Amino Acid MolWeight
[g/mol]
Material
[mg(ml)]
Dissolved 
Volume [ml]
Concentration
[mol/1]
Fmoc-Gln-
(Trt)
610.7 553 2.26 0.40
Fmoc-Pro 337.4 306 2.26 0.40
Fmoc-Pro 337.4 306 2.26 0.40
Fmoc-Ile 353.4 320 2.26 0.40
Fmoc-Ser^Bu) 383.4 347 2.26 0.40
Fmoc-Phe 387.4 351 2.26 0.40
Fmoc-Thr(lBu) 397.5 360 2.26 0.40
Fmoc-Ser(cBu) 383.4 347 2.26 0.40
HBTU/DMF 379.3 1700 11.3 0.40
'Pr2EtN/NMP 129.30 (0.789) 2.83 1.60
Homolanthionine Coupling
3-[(5)-2-Carboxy-2-(fluoren-9-ylmethoxycarbonylamino)ethylsulfanyl]-(5)- 
(allyloxycarbonylamino)butanoic acid allyl ester 248 (257 mg, 0.454 mmol, 4 eq) was 
dissolved in DMF (0.60 ml) and added to a solution o f PyAOP (0.118 g, 0.227 mmol, 
2 eq) and HOAt (0.31 mg, 0.227 mmol, 2 eq) in DMF (1.2 ml). This solution was 
added equally to each syringe (0.36 ml) and the reaction left for 1 hour (vortex 20 
seconds every 2 minutes). The syringes were then drained and any unreacted bis 
amino acid 248 collected and purified.
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Alloc / Allvl deprotection
Deprotection o f both allyl ester and carbamate groups was performed using Pd(PPh3)4  
(0.1725 g, 0.150 mmol, 2 eq., 0.05 M) dissolved in a solution of 
DMF/CHC13/AcOH/NMM (18.5:18.5:2:1 volume, 1.38/1.38/0.15/0.75 ml, total 
volume, 3 ml). This mixture was added to each reaction syringe (500 pJL) and the 
resultant suspension reacted for 2  hours in the dark under nitrogen (vortex 2 0  seconds 
every 2  minutes).
Upon evacuation of the reaction syringe the resin was washed with DMF (2 x 500 pL 
per syringe), 'P^EtN  in DMF (0.5% v/v, 10 ml, 4 x 500 pL per syringe), DMF (4 x 
500 pL per syringe), sodium diethyldithiocarbamate trihydrate in DMF (0.5% w/v, 10 
ml, 4 x 500 pL per syringe) and DMF (4 x 500 pL). All washes were vortexed for 20 
seconds every 1 minute.
Cvclisation
PyAOP (295 mg, 0.567 mmol, 5 eq) and HOAt (77 mg, 0.567 mmol, 5 eq) were 
dissolved in DMF (1.8 ml) and the resultant solution (0.36 ml) added to each syringe. 
'P^E tN  (0.018ml, 5 x 10'4 mol, 10 eq.) was then added to each syringe and the 
reaction was carried out for 1 hour with a fast vortex for 2 0  seconds every 2  minutes.
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Control Peptide -  H^N-SCTFSIPPOST-COQH
Linear control peptide was synthesised containing two cysteine molecules, instead of 
the homolanthionine bridge. This peptide was synthesised by automated methods and 
no Kaiser tests were performed. The control peptide was oxidatively cyclised on resin 
using I2 dissolved in H2O (0.02 M). Cleavage conditions and work up were identical 
for that o f peptide 249.
Synthesis of Peptide 249
Three syringes (2 ml) were loaded with resin (3 x 189 mg) before DMF (1 ml) was 
added and the resin allowed to swell for 30 minutes. After several washings with 
DMF (4 x 500 pL) the Fmoc group o f the resin bound tyrosine was removed followed 
by a Kaiser test. Homolanthionine 248 was then coupled to the free amine and a 
Kaiser test was performed. Subsequent Fmoc deprotection and Kaiser test was 
performed before the peptide synthesis was automated. Fmoc-glutamine(Trt) (0.553 
g, 0.11 mmol, 8  eq) was first to be coupled followed by Fmoc-proline (0.306 g, 0.11 
mmol, 8  eq), Fmoc-proline (0.306 g, 0.11 mmol, 8  eq), Fmoc-isoleucine (0.320 g, 
0.11 mmol, 8  eq), Fmoc-serine-(lBu) (0.347 g, 0.11 mmol, 8  eq), Fmoc-phenylalanine 
(0.351 g, 0.11 mmol, 8  eq) and Fmoc-threonine-^Bu) (0.361 g, 0.11 mmol, 8  eq) The 
Fmoc group o f the threonine residue added was not removed at this time and the allyl
S
p H X h  i Q M  y V co o h
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ester and carbamate deprotected using the previously mentioned Pd(PPh3)4 reagent 
cocktail.
After a Kaiser test the Fmoc group of the terminal serine was deprotected. A further 
Kaiser test was performed before the peptide was cyclised on resin. Another Kaiser 
test confirmed the presence o f the primary amine before the final amino acid, Fmoc- 
serine (0.347 g, 0.11 mmol, 8  eq) was coupled and the Fmoc group removed.
The resin was then washed with CH2CI2 (2 x 1 ml per syringe) and treated with a 
cocktail solution (94% TFA, 2.5% H2O, 2.5% ethanedithiol, 1% triisopropylsilane) 
for 3 hours to cleave the peptide from the resin and remove side-chain protecting 
groups. The solutions were collected and each syringe was washed with TFA (2 x 500 
pL per syringe). These were combined and concentrated in vacuo until a small 
amount of solvent remained in the flask. Cold ether (-23 °C) was then added and 
precipitation o f the peptide was observed. The mixture was cooled in the freezer for 1 
hour before centrifugation (20 minutes at 3500 rpm at 0°C). The supernatant ethereal 
layer was then decanted and the pellet produced by centrifugation resuspended in cold 
ether. The centrifugation procedure was repeated producing a second pellet which 
was dissolved in the minimum volume o f distilled water (5 ml) and freeze-dried over 
night.
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